Loading...
Header Logo
Keywords
Last Name
Institution

IGNACIO IVAN WISTUBA

TitleProfessor
InstitutionMD Anderson
DepartmentTranslational Molecular Pathology
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Francisco-Cruz A, Parra ER, Tetzlaff MT, Wistuba II. Multiplex Immunofluorescence Assays. Methods Mol Biol. 2020; 2055:467-495. PMID: 31502166.
      View in: PubMed
    2. Garmendia I, Pajares MJ, Hermida-Prado F, Ajona D, Bértolo C, Sainz C, Lavín A, Remírez AB, Valencia K, Moreno H, Ferrer I, Behrens C, Cuadrado M, Paz-Ares L, Bustelo XR, Gil-Bazo I, Alameda D, Lecanda F, Calvo A, Felip E, Sánchez-Céspedes M, Wistuba II, Granda-Diaz R, Rodrigo JP, García-Pedrero JM, Pio R, Montuenga LM, Agorreta J. YES1 Drives Lung Cancer Growth and Progression and Predicts Sensitivity to Dasatinib. Am J Respir Crit Care Med. 2019 Oct 01; 200(7):888-899. PMID: 31166114.
      View in: PubMed
    3. Pataer A, Ozpolat B, Shao R, Cashman NR, Plotkin SS, Samuel CE, Lin SH, Kabil NN, Wang J, Majidi M, Fang B, Roth JA, Vaporciyan AA, Wistuba II, Hung MC, Swisher SG. Therapeutic targeting of the PI4K2A/PKR lysosome network is critical for misfolded protein clearance and survival in cancer cells. Oncogene. 2019 Sep 25. PMID: 31554935.
      View in: PubMed
    4. Mitchell KG, Negrao MV, Parra ER, Li J, Zhang J, Dejima H, Vaporciyan AA, Swisher SG, Weissferdt A, Antonoff MB, Cascone T, Roarty E, Wistuba II, Heymach JV, Gibbons DL, Zhang J, Sepesi B. Lymphovascular Invasion Is Associated with Mutational Burden and PD-L1 in Resected Lung Cancer. Ann Thorac Surg. 2019 Sep 21. PMID: 31550464.
      View in: PubMed
    5. Kadara H, Sivakumar S, Jakubek Y, San Lucas FA, Lang W, McDowell T, Weber Z, Behrens C, Davies GE, Kalhor N, Moran C, El-Zein R, Mehran R, Swisher SG, Wang J, Zhang J, Fujimoto J, Fowler J, Heymach JV, Dubinett S, Spira AE, Ehli EA, Wistuba II, Scheet P. Driver Mutations in Normal Airway Epithelium Elucidate Spatiotemporal Resolution of Lung Cancer. Am J Respir Crit Care Med. 2019 Sep 15; 200(6):742-750. PMID: 30896962.
      View in: PubMed
    6. Shi B, Behrens C, Vaghani V, Riquelme EM, Rodriguez-Canales J, Kadara H, Lin H, Lee J, Liu H, Wistuba I, Simon G. Oncogenic enhancer of zeste homolog 2 is an actionable target in patients with non-small cell lung cancer. Cancer Med. 2019 Aug 27. PMID: 31456359.
      View in: PubMed
    7. Mallampati S, Zalles S, Duose DY, Hu PC, Medeiros LJ, Wistuba II, Kopetz S, Luthra R. Development and Application of Duplex Sequencing Strategy for Cell-Free DNA-Based Longitudinal Monitoring of Stage IV Colorectal Cancer. J Mol Diagn. 2019 Aug 08. PMID: 31401123.
      View in: PubMed
    8. Tsao AS, Miao J, Wistuba II, Vogelzang NJ, Heymach JV, Fossella FV, Lu C, Velasco MR, Box-Noriega B, Hueftle JG, Gadgeel S, Redman MW, Gandara DR, Kelly K. Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905). J Clin Oncol. 2019 Oct 01; 37(28):2537-2547. PMID: 31386610.
      View in: PubMed
    9. Lyapichev KA, Piña-Oviedo S, Medeiros LJ, Evans MG, Liu H, Miranda AR, Hunt KK, Clemens MW, Stewart JM, Amin MB, Quesada AE, Chai SM, Di Napoli A, Yoga A, Dave SK, Wistuba II, Wu Y, Bueso-Ramos CE, Schlette EJ, Ferrufino-Schmidt MC, Loghavi S, Khoury JD, Young KH, Miranda RN. A proposal for pathologic processing of breast implant capsules in patients with suspected breast implant anaplastic large cell lymphoma. Mod Pathol. 2019 Aug 05. PMID: 31383966.
      View in: PubMed
    10. Grosu HB, Lu W, Ost DE, Vial MR, Hernandez M, Ghosh N, Noor L, Hasan AM, Bashoura L, Faiz S, Balachandran D, Casal R, Eapen G, Shannon V, Sheshadri A, Tang X, Rahman N, Wistuba II. Pleural Fluid Cytokine Levels at Baseline and Over Time are Associated With Time to IPC Removal: An Exploratory Study. J Bronchology Interv Pulmonol. 2019 Aug 01. PMID: 31373905.
      View in: PubMed
    11. Vence L, Bucktrout SL, Fernandez Curbelo I, Blando J, Smith BM, Mahne AE, Lin JC, Park T, Pascua E, Sai T, Chaparro-Riggers J, Subudhi SK, B Scutti J, Higa MG, Zhao H, Yadav SS, Maitra A, Wistuba II, Allison JP, Sharma P. Characterization and Comparison of GITR Expression in Solid Tumors. Clin Cancer Res. 2019 Jul 29. PMID: 31358539.
      View in: PubMed
    12. Zheng L, Chen Z, Kawakami M, Chen Y, Roszik J, Mustachio LM, Kurie JM, Villalobos P, Lu W, Behrens C, Mino B, Solis LM, Silvester J, Thu KL, Cescon DW, Rodriguez-Canales J, Wistuba II, Mak TW, Liu X, Dmitrovsky E. Tyrosine Threonine Kinase Inhibition Eliminates Lung Cancers by Augmenting Apoptosis and Polyploidy. Mol Cancer Ther. 2019 Oct; 18(10):1775-1786. PMID: 31358662.
      View in: PubMed
    13. Lee HH, Wang YN, Xia W, Chen CH, Rau KM, Ye L, Wei Y, Chou CK, Wang SC, Yan M, Tu CY, Hsia TC, Chiang SF, Chao KSC, Wistuba II, Hsu JL, Hortobagyi GN, Hung MC. Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy. Cancer Cell. 2019 Aug 12; 36(2):168-178.e4. PMID: 31327656.
      View in: PubMed
    14. Hu X, Fujimoto J, Ying L, Fukuoka J, Ashizawa K, Sun W, Reuben A, Chow CW, McGranahan N, Chen R, Hu J, Godoy MC, Tabata K, Kuroda K, Shi L, Li J, Behrens C, Parra ER, Little LD, Gumbs C, Mao X, Song X, Tippen S, Thornton RL, Kadara H, Scheet P, Roarty E, Ostrin EJ, Wang X, Carter BW, Antonoff MB, Zhang J, Vaporciyan AA, Pass H, Swisher SG, Heymach JV, Lee JJ, Wistuba II, Hong WK, Futreal PA, Su D, Zhang J. Multi-region exome sequencing reveals genomic evolution from preneoplasia to lung adenocarcinoma. Nat Commun. 2019 07 05; 10(1):2978. PMID: 31278276.
      View in: PubMed
    15. Acharya S, Yao J, Li P, Zhang C, Lowery FJ, Zhang Q, Guo H, Qu J, Yang F, Wistuba II, Piwnica-Worms H, Sahin AA, Yu D. Sphingosine Kinase 1 Signaling Promotes Metastasis of Triple-Negative Breast Cancer. Cancer Res. 2019 Aug 15; 79(16):4211-4226. PMID: 31239273.
      View in: PubMed
    16. Ruiz-Cordero R, Rao P, Li L, Qi Y, Atherton D, Peng B, Singh RR, Kim TB, Kawakami F, Routbort MJ, Alouch N, Chow CB, Tang X, Lu W, Brimo F, Matin SF, Wood CG, Tannir NM, Wistuba II, Chen K, Wang J, Medeiros LJ, Karam JA, Tamboli P, Sircar K. Hybrid oncocytic/chromophobe renal tumors are molecularly distinct from oncocytoma and chromophobe renal cell carcinoma. Mod Pathol. 2019 Jun 23. PMID: 31231128.
      View in: PubMed
    17. Rimm DL, Han G, Taube JM, Yi ES, Bridge JA, Flieder DB, Homer R, Roden AC, Hirsch FR, Wistuba II, Pusztai L. Reanalysis of the NCCN PD-L1 companion diagnostic assay study for lung cancer in the context of PD-L1 expression findings in triple-negative breast cancer. Breast Cancer Res. 2019 06 13; 21(1):72. PMID: 31196152.
      View in: PubMed
    18. Shi X, Duose DY, Mehrotra M, Harmon MA, Hu P, Wistuba II, Kopetz S, Luthra R. Non-invasive genotyping of metastatic colorectal cancer using circulating cell free DNA. Cancer Genet. 2019 Sep; 237:82-89. PMID: 31447070.
      View in: PubMed
    19. Soundararajan R, Fradette JJ, Konen JM, Moulder S, Zhang X, Gibbons DL, Varadarajan N, Wistuba II, Tripathy D, Bernatchez C, Byers LA, Chang JT, Contreras A, Lim B, Parra ER, Roarty EB, Wang J, Yang F, Barton M, Rosen JM, Mani SA. Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy. Cancers (Basel). 2019 May 24; 11(5). PMID: 31137625.
      View in: PubMed
    20. Mitchell KG, Parra ER, Nelson DB, Zhang J, Wistuba II, Fujimoto J, Roth JA, Antonoff MB. Tumor cellular proliferation is associated with enhanced immune checkpoint expression in stage I non-small cell lung cancer. J Thorac Cardiovasc Surg. 2019 Sep; 158(3):911-919.e6. PMID: 31235357.
      View in: PubMed
    21. Haynes BC, Blidner RA, Cardwell RD, Zeigler R, Gokul S, Thibert JR, Chen L, Fujimoto J, Papadimitrakopoulou VA, Wistuba II, Latham GJ. An Integrated Next-Generation Sequencing System for Analyzing DNA Mutations, Gene Fusions, and RNA Expression in Lung Cancer. Transl Oncol. 2019 Jun; 12(6):836-845. PMID: 30981944.
      View in: PubMed
    22. Curry JL, Reuben A, Szczepaniak-Sloane R, Ning J, Milton DR, Lee CH, Hudgens C, George S, Torres-Cabala C, Johnson D, Subramanya S, Wargo JA, Mudaliar K, Wistuba II, Prieto VG, Diab A, Tetzlaff MT. Gene expression profiling of lichenoid dermatitis immune-related adverse event from immune checkpoint inhibitors reveals increased CD14+ and CD16+ monocytes driving an innate immune response. J Cutan Pathol. 2019 Sep; 46(9):627-636. PMID: 30883858.
      View in: PubMed
    23. Sivakumar S, San Lucas FA, Jakubek YA, McDowell TL, Lang W, Kallsen N, Peyton S, Davies GE, Fukuoka J, Yatabe Y, Zhang J, Futreal PA, Fowler J, Fujimoto J, Ehli EA, Hawk ET, Wistuba II, Kadara H, Scheet P. Genomic landscape of allelic imbalance in premalignant atypical adenomatous hyperplasias of the lung. EBioMedicine. 2019 Apr; 42:296-303. PMID: 30905849.
      View in: PubMed
    24. Peng DH, Kundu ST, Fradette JJ, Diao L, Tong P, Byers LA, Wang J, Canales JR, Villalobos PA, Mino B, Yang Y, Minelli R, Peoples MD, Bristow CA, Heffernan TP, Carugo A, Wistuba II, Gibbons DL. ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanism. Sci Transl Med. 2019 Mar 13; 11(483). PMID: 30867319.
      View in: PubMed
    25. Aung PP, Parra ER, Barua S, Sui D, Ning J, Mino B, Ledesma DA, Curry JL, Nagarajan P, Torres-Cabala CA, Efstathiou E, Hoang AG, Wong MK, Wargo JA, Lazar AJ, Rao A, Prieto VG, Wistuba I, Tetzlaff MT. B7-H3 Expression in Merkel Cell Carcinoma-Associated Endothelial Cells Correlates with Locally Aggressive Primary Tumor Features and Increased Vascular Density. Clin Cancer Res. 2019 Jun 01; 25(11):3455-3467. PMID: 30808776.
      View in: PubMed
    26. Mallampati S, Duose DY, Harmon MA, Mehrotra M, Kanagal-Shamanna R, Zalles S, Wistuba II, Sun X, Luthra R. Rational "Error Elimination" Approach to Evaluating Molecular Barcoded Next-Generation Sequencing Data Identifies Low-Frequency Mutations in Hematologic Malignancies. J Mol Diagn. 2019 May; 21(3):471-482. PMID: 30794984.
      View in: PubMed
    27. Parra ER, Francisco-Cruz A, Wistuba II. State-of-the-Art of Profiling Immune Contexture in the Era of Multiplexed Staining and Digital Analysis to Study Paraffin Tumor Tissues. Cancers (Basel). 2019 Feb 20; 11(2). PMID: 30791580.
      View in: PubMed
    28. Sen T, Rodriguez BL, Chen L, Corte CMD, Morikawa N, Fujimoto J, Cristea S, Nguyen T, Diao L, Li L, Fan Y, Yang Y, Wang J, Glisson BS, Wistuba II, Sage J, Heymach JV, Gibbons DL, Byers LA. Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer. Cancer Discov. 2019 May; 9(5):646-661. PMID: 30777870.
      View in: PubMed
    29. Negrao MV, Lam VK, Reuben A, Rubin ML, Landry LL, Roarty EB, Rinsurongkawong W, Lewis J, Roth JA, Swisher SG, Gibbons DL, Wistuba II, Papadimitrakopoulou V, Glisson BS, Blumenschein GR, Lee JJ, Heymach JV, Zhang J. PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non-Small Cell Lung Cancer. J Thorac Oncol. 2019 Jun; 14(6):1021-1031. PMID: 30780001.
      View in: PubMed
    30. Weissferdt A, Kalhor N, Rodriguez Canales J, Fujimoto J, Wistuba II, Moran CA. Primary Mediastinal Yolk Sac Tumors: An Immunohistochemical Analysis of 14 Cases. Appl Immunohistochem Mol Morphol. 2019 Feb; 27(2):125-133. PMID: 27643524.
      View in: PubMed
    31. Ye W, Hannigan B, Zalles S, Mehrotra M, Barkoh BA, Williams MD, Cabanillas ME, Edeiken-Monroe B, Hu P, Duose D, Wistuba II, Medeiros LJ, Stewart J, Luthra R, Roy-Chowdhuri S. Centrifuged supernatants from FNA provide a liquid biopsy option for clinical next-generation sequencing of thyroid nodules. Cancer Cytopathol. 2019 Mar; 127(3):146-160. PMID: 30620446.
      View in: PubMed
    32. Román M, López I, Guruceaga E, Baraibar I, Ecay M, Collantes M, Nadal E, Vallejo A, Cadenas S, Miguel ME, Jang JH, Martin-Uriz PS, Castro-Labrador L, Vilas-Zornoza A, Lara-Astiaso D, Ponz-Sarvise M, Rolfo C, Santos ES, Raez LE, Taverna S, Behrens C, Weder W, Wistuba II, Vicent S, Gil-Bazo I. Inhibitor of Differentiation-1 Sustains Mutant KRAS-Driven Progression, Maintenance, and Metastasis of Lung Adenocarcinoma via Regulation of a FOSL1 Network. Cancer Res. 2019 02 01; 79(3):625-638. PMID: 30563891.
      View in: PubMed
    33. Martínez-Terroba E, Behrens C, Agorreta J, Monsó E, Millares L, Felip E, Rosell R, Ramirez JL, Remirez A, Torre W, Gil-Bazo I, Idoate MA, de-Torres JP, Pio R, Wistuba II, Pajares MJ, Montuenga LM. 5 protein-based signature for resectable lung squamous cell carcinoma improves the prognostic performance of the TNM staging. Thorax. 2019 04; 74(4):371-379. PMID: 30472670.
      View in: PubMed
    34. Fisher SB, Cote GJ, Bui-Griffith JH, Lu W, Tang X, Hai T, Fisher KE, Williams MD, Wistuba II, Waguespack SG, Dorman CM, Ludwig MS, Graham PH, Perrier ND, Lee JE, Grubbs EG. Genetic characterization of medullary thyroid cancer in childhood survivors of the Chernobyl accident. Surgery. 2019 01; 165(1):58-63. PMID: 30392857.
      View in: PubMed
    35. Wang Z, Cao S, Morris JS, Ahn J, Liu R, Tyekucheva S, Gao F, Li B, Lu W, Tang X, Wistuba II, Bowden M, Mucci L, Loda M, Parmigiani G, Holmes CC, Wang W. Transcriptome Deconvolution of Heterogeneous Tumor Samples with Immune Infiltration. iScience. 2018 Nov 30; 9:451-460. PMID: 30469014.
      View in: PubMed
    36. Caetano MS, Hassane M, Van HT, Bugarin E, Cumpian AM, McDowell CL, Cavazos CG, Zhang H, Deng S, Diao L, Wang J, Evans SE, Behrens C, Wistuba II, Fuqua SAW, Lin H, Stabile LP, Watowich SS, Kadara H, Moghaddam SJ. Sex specific function of epithelial STAT3 signaling in pathogenesis of K-ras mutant lung cancer. Nat Commun. 2018 11 02; 9(1):4589. PMID: 30389925.
      View in: PubMed
    37. Kawakami M, Mustachio LM, Zheng L, Chen Y, Rodriguez-Canales J, Mino B, Kurie JM, Roszik J, Villalobos PA, Thu KL, Silvester J, Cescon DW, Wistuba II, Mak TW, Liu X, Dmitrovsky E. Reply to Oegema et al.: CFI-400945 and Polo-like kinase 4 inhibition. Proc Natl Acad Sci U S A. 2018 11 13; 115(46):E10810-E10811. PMID: 30377273.
      View in: PubMed
    38. Xie Y, Lu W, Wang S, Tang X, Tang H, Zhou Y, Moran C, Behrens C, Roth JA, Zhou Q, Johnson DH, Swisher SG, Heymach JV, Papadimitrakopoulou VA, Xiao G, Minna JD, Wistuba II. Validation of the 12-gene Predictive Signature for Adjuvant Chemotherapy Response in Lung Cancer. Clin Cancer Res. 2019 01 01; 25(1):150-157. PMID: 30287547.
      View in: PubMed
    39. Deribe YL, Sun Y, Terranova C, Khan F, Martinez-Ledesma J, Gay J, Gao G, Mullinax RA, Khor T, Feng N, Lin YH, Wu CC, Reyes C, Peng Q, Robinson F, Inoue A, Kochat V, Liu CG, Asara JM, Moran C, Muller F, Wang J, Fang B, Papadimitrakopoulou V, Wistuba II, Rai K, Marszalek J, Futreal PA. Author Correction: Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer. Nat Med. 2018 Oct; 24(10):1627. PMID: 30104769.
      View in: PubMed
    40. Blumenthal GM, Bunn PA, Chaft JE, McCoach CE, Perez EA, Scagliotti GV, Carbone DP, Aerts HJWL, Aisner DL, Bergh J, Berry DA, Jarkowski A, Botwood N, Cross DAE, Diehn M, Drezner NL, Doebele RC, Blakely CM, Eberhardt WEE, Felip E, Gianni L, Keller SP, Leavey PJ, Malik S, Pignatti F, Prowell TM, Redman MW, Rizvi NA, Rosell R, Rusch V, de Ruysscher D, Schwartz LH, Sridhara R, Stahel RA, Swisher S, Taube JM, Travis WD, Keegan P, Wiens JR, Wistuba II, Wynes MW, Hirsch FR, Kris MG. Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer. J Thorac Oncol. 2018 Dec; 13(12):1818-1831. PMID: 30268698.
      View in: PubMed
    41. Ruder D, Papadimitrakopoulou V, Shien K, Behrens C, Kalhor N, Chen H, Shen L, Lee JJ, Hong WK, Tang X, Girard L, Minna JD, Diao L, Wang J, Mino B, Villalobos P, Rodriguez-Canales J, Hanson NE, Sun J, Miller V, Greenbowe J, Frampton G, Herbst RS, Baladandayuthapani V, Wistuba II, Izzo JG. Concomitant targeting of the mTOR/MAPK pathways: novel therapeutic strategy in subsets of RICTOR/KRAS-altered non-small cell lung cancer. Oncotarget. 2018 Sep 21; 9(74):33995-34008. PMID: 30338041.
      View in: PubMed
    42. Nichols BA, Oswald NW, McMillan EA, McGlynn K, Yan J, Kim MS, Saha J, Mallipeddi PL, LaDuke SA, Villalobos PA, Rodriguez-Canales J, Wistuba II, Posner BA, Davis AJ, Minna JD, MacMillan JB, Whitehurst AW. HORMAD1 Is a Negative Prognostic Indicator in Lung Adenocarcinoma and Specifies Resistance to Oxidative and Genotoxic Stress. Cancer Res. 2018 11 01; 78(21):6196-6208. PMID: 30185546.
      View in: PubMed
    43. Martínez-Terroba E, Ezponda T, Bértolo C, Sainz C, Remírez A, Agorreta J, Garmendia I, Behrens C, Pio R, Wistuba II, Montuenga LM, Pajares MJ. The oncogenic RNA-binding protein SRSF1 regulates LIG1 in non-small cell lung cancer. Lab Invest. 2018 12; 98(12):1562-1574. PMID: 30181552.
      View in: PubMed
    44. Bauer AK, Umer M, Richardson VL, Cumpian AM, Harder AQ, Khosravi N, Azzegagh Z, Hara NM, Ehre C, Mohebnasab M, Caetano MS, Merrick DT, van Bokhoven A, Wistuba II, Kadara H, Dickey BF, Velmurugan K, Mann PR, Lu X, Barón AE, Evans CM, Moghaddam SJ. Requirement for MUC5AC in KRAS-dependent lung carcinogenesis. JCI Insight. 2018 08 09; 3(15). PMID: 30089720.
      View in: PubMed
    45. Chen L, Diao L, Yang Y, Yi X, Rodriguez BL, Li Y, Villalobos PA, Cascone T, Liu X, Tan L, Lorenzi PL, Huang A, Zhao Q, Peng D, Fradette JJ, Peng DH, Ungewiss C, Roybal J, Tong P, Oba J, Skoulidis F, Peng W, Carter BW, Gay CM, Fan Y, Class CA, Zhu J, Rodriguez-Canales J, Kawakami M, Byers LA, Woodman SE, Papadimitrakopoulou VA, Dmitrovsky E, Wang J, Ullrich SE, Wistuba II, Heymach JV, Qin FX, Gibbons DL. CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade. Cancer Discov. 2018 09; 8(9):1156-1175. PMID: 30012853.
      View in: PubMed
    46. Liu Y, Lusk CM, Cho MH, Silverman EK, Qiao D, Zhang R, Scheurer ME, Kheradmand F, Wheeler DA, Tsavachidis S, Armstrong G, Zhu D, Wistuba II, Chow CB, Behrens C, Pikielny CW, Neslund-Dudas C, Pinney SM, Anderson M, Kupert E, Bailey-Wilson J, Gaba C, Mandal D, You M, de Andrade M, Yang P, Field JK, Liloglou T, Davies M, Lissowska J, Swiatkowska B, Zaridze D, Mukeriya A, Janout V, Holcatova I, Mates D, Milosavljevic S, Scelo G, Brennan P, McKay J, Liu G, Hung RJ, Christiani DC, Schwartz AG, Amos CI, Spitz MR. Rare Variants in Known Susceptibility Loci and Their Contribution to Risk of Lung Cancer. J Thorac Oncol. 2018 10; 13(10):1483-1495. PMID: 29981437.
      View in: PubMed
    47. Tan X, Banerjee P, Liu X, Yu J, Gibbons DL, Wu P, Scott KL, Diao L, Zheng X, Wang J, Jalali A, Suraokar M, Fujimoto J, Behrens C, Liu X, Liu CG, Creighton CJ, Wistuba II, Kurie JM. The epithelial-to-mesenchymal transition activator ZEB1 initiates a prometastatic competing endogenous RNA network. J Clin Invest. 2018 07 02; 128(7):3198. PMID: 30108197.
      View in: PubMed
    48. Ballester LY, Glitza Oliva IC, Douse DY, Chen MM, Lan C, Haydu LE, Huse JT, Roy-Chowdhuri S, Luthra R, Wistuba II, Davies MA. Evaluating Circulating Tumor DNA From the Cerebrospinal Fluid of Patients With Melanoma and Leptomeningeal Disease. J Neuropathol Exp Neurol. 2018 07 01; 77(7):628-635. PMID: 29873738.
      View in: PubMed
    49. Martínez-Terroba E, Behrens C, de Miguel FJ, Agorreta J, Monsó E, Millares L, Sainz C, Mesa-Guzman M, Pérez-Gracia JL, Lozano MD, Zulueta JJ, Pio R, Wistuba II, Montuenga LM, Pajares MJ. A novel protein-based prognostic signature improves risk stratification to guide clinical management in early-stage lung adenocarcinoma patients. J Pathol. 2018 08; 245(4):421-432. PMID: 29756233.
      View in: PubMed
    50. Pietanza MC, Waqar SN, Krug LM, Dowlati A, Hann CL, Chiappori A, Owonikoko TK, Woo KM, Cardnell RJ, Fujimoto J, Long L, Diao L, Wang J, Bensman Y, Hurtado B, de Groot P, Sulman EP, Wistuba II, Chen A, Fleisher M, Heymach JV, Kris MG, Rudin CM, Byers LA. Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer. J Clin Oncol. 2018 08 10; 36(23):2386-2394. PMID: 29906251.
      View in: PubMed
    51. Singh A, Ruiz C, Bhalla K, Haley JA, Li QK, Acquaah-Mensah G, Montal E, Sudini KR, Skoulidis F, Wistuba II, Papadimitrakopoulou V, Heymach JV, Boros LG, Gabrielson E, Carretero J, Wong KK, Haley JD, Biswal S, Girnun GD. De novo lipogenesis represents a therapeutic target in mutant Kras non-small cell lung cancer. FASEB J. 2018 Jun 15; fj201800204. PMID: 29906244.
      View in: PubMed
    52. Lissanu Deribe Y, Sun Y, Terranova C, Khan F, Martinez-Ledesma J, Gay J, Gao G, Mullinax RA, Khor T, Feng N, Lin YH, Wu CC, Reyes C, Peng Q, Robinson F, Inoue A, Kochat V, Liu CG, Asara JM, Moran C, Muller F, Wang J, Fang B, Papadimitrakopoulou V, Wistuba II, Rai K, Marszalek J, Futreal PA. Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer. Nat Med. 2018 07; 24(7):1047-1057. PMID: 29892061.
      View in: PubMed
    53. Parra ER, Villalobos P, Behrens C, Jiang M, Pataer A, Swisher SG, William WN, Zhang J, Lee J, Cascone T, Heymach JV, Forget MA, Haymaker C, Bernatchez C, Kalhor N, Weissferdt A, Moran C, Zhang J, Vaporciyan A, Gibbons DL, Sepesi B, Wistuba II. Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches. J Immunother Cancer. 2018 06 06; 6(1):48. PMID: 29871672.
      View in: PubMed
    54. Rolfo C, Mack PC, Scagliotti GV, Baas P, Barlesi F, Bivona TG, Herbst RS, Mok TS, Peled N, Pirker R, Raez LE, Reck M, Riess JW, Sequist LV, Shepherd FA, Sholl LM, Tan DSW, Wakelee HA, Wistuba II, Wynes MW, Carbone DP, Hirsch FR, Gandara DR. Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC. J Thorac Oncol. 2018 09; 13(9):1248-1268. PMID: 29885479.
      View in: PubMed
    55. Skoulidis F, Goldberg ME, Greenawalt DM, Hellmann MD, Awad MM, Gainor JF, Schrock AB, Hartmaier RJ, Trabucco SE, Gay L, Ali SM, Elvin JA, Singal G, Ross JS, Fabrizio D, Szabo PM, Chang H, Sasson A, Srinivasan S, Kirov S, Szustakowski J, Vitazka P, Edwards R, Bufill JA, Sharma N, Ou SI, Peled N, Spigel DR, Rizvi H, Aguilar EJ, Carter BW, Erasmus J, Halpenny DF, Plodkowski AJ, Long NM, Nishino M, Denning WL, Galan-Cobo A, Hamdi H, Hirz T, Tong P, Wang J, Rodriguez-Canales J, Villalobos PA, Parra ER, Kalhor N, Sholl LM, Sauter JL, Jungbluth AA, Mino-Kenudson M, Azimi R, Elamin YY, Zhang J, Leonardi GC, Jiang F, Wong KK, Lee JJ, Papadimitrakopoulou VA, Wistuba II, Miller VA, Frampton GM, Wolchok JD, Shaw AT, Jänne PA, Stephens PJ, Rudin CM, Geese WJ, Albacker LA, Heymach JV. STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. Cancer Discov. 2018 07; 8(7):822-835. PMID: 29773717.
      View in: PubMed
    56. Powell E, Shao J, Picon HM, Bristow C, Ge Z, Peoples M, Robinson F, Jeter-Jones SL, Schlosberg C, Grzeskowiak CL, Yang F, Wu Y, Wistuba I, Moulder SL, Symmans WF, Scott KL, Edwards JR, Liang H, Heffernan TP, Piwnica-Worms H. A functional genomic screen in vivo identifies CEACAM5 as a clinically relevant driver of breast cancer metastasis. NPJ Breast Cancer. 2018; 4:9. PMID: 29736411.
      View in: PubMed
    57. Pataer A, Shao R, Correa AM, Behrens C, Roth JA, Vaporciyan AA, Wistuba II, Swisher SG. Major pathologic response and RAD51 predict survival in lung cancer patients receiving neoadjuvant chemotherapy. Cancer Med. 2018 06; 7(6):2405-2414. PMID: 29673125.
      View in: PubMed
    58. Cascone T, McKenzie JA, Mbofung RM, Punt S, Wang Z, Xu C, Williams LJ, Wang Z, Bristow CA, Carugo A, Peoples MD, Li L, Karpinets T, Huang L, Malu S, Creasy C, Leahey SE, Chen J, Chen Y, Pelicano H, Bernatchez C, Gopal YNV, Heffernan TP, Hu J, Wang J, Amaria RN, Garraway LA, Huang P, Yang P, Wistuba II, Woodman SE, Roszik J, Davis RE, Davies MA, Heymach JV, Hwu P, Peng W. Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy. Cell Metab. 2018 May 01; 27(5):977-987.e4. PMID: 29628419.
      View in: PubMed
    59. Parra ER, Villalobos P, Zhang J, Behrens C, Mino B, Swisher S, Sepesi B, Weissferdt A, Kalhor N, Heymach JV, Moran C, Zhang J, Lee J, Rodriguez-Canales J, Gibbons D, Wistuba II. Immunohistochemical and Image Analysis-Based Study Shows That Several Immune Checkpoints are Co-expressed in Non-Small Cell Lung Carcinoma Tumors. J Thorac Oncol. 2018 06; 13(6):779-791. PMID: 29526824.
      View in: PubMed
    60. Yu-Lee LY, Yu G, Lee YC, Lin SC, Pan J, Pan T, Yu KJ, Liu B, Creighton CJ, Rodriguez-Canales J, Villalobos PA, Wistuba II, de Nadal E, Posas F, Gallick GE, Lin SH. Osteoblast-Secreted Factors Mediate Dormancy of Metastatic Prostate Cancer in the Bone via Activation of the TGFßRIII-p38MAPK-pS249/T252RB Pathway. Cancer Res. 2018 06 01; 78(11):2911-2924. PMID: 29514796.
      View in: PubMed
    61. Tan X, Banerjee P, Liu X, Yu J, Gibbons DL, Wu P, Scott KL, Diao L, Zheng X, Wang J, Jalali A, Suraokar M, Fujimoto J, Behrens C, Liu X, Liu CG, Creighton CJ, Wistuba II, Kurie JM. The epithelial-to-mesenchymal transition activator ZEB1 initiates a prometastatic competing endogenous RNA network. J Clin Invest. 2018 04 02; 128(4):1267-1282. PMID: 29324442.
      View in: PubMed
    62. Roy-Chowdhuri S, Mehrotra M, Bolivar AM, Kanagal-Shamanna R, Barkoh BA, Hannigan B, Zalles S, Ye W, Duose D, Broaddus R, Staerkel G, Wistuba I, Medeiros LJ, Luthra R. Salvaging the supernatant: next generation cytopathology for solid tumor mutation profiling. Mod Pathol. 2018 07; 31(7):1036-1045. PMID: 29463880.
      View in: PubMed
    63. Wolff RA, Wang-Gillam A, Alvarez H, Tiriac H, Engle D, Hou S, Groff AF, San Lucas A, Bernard V, Allenson K, Castillo J, Kim D, Mulu F, Huang J, Stephens B, Wistuba II, Katz M, Varadhachary G, Park Y, Hicks J, Chinnaiyan A, Scampavia L, Spicer T, Gerhardinger C, Maitra A, Tuveson D, Rinn J, Lizee G, Yee C, Levine AJ. Dynamic changes during the treatment of pancreatic cancer. Oncotarget. 2018 Mar 13; 9(19):14764-14790. PMID: 29599906.
      View in: PubMed
    64. Lang FF, Conrad C, Gomez-Manzano C, Yung WKA, Sawaya R, Weinberg JS, Prabhu SS, Rao G, Fuller GN, Aldape KD, Gumin J, Vence LM, Wistuba I, Rodriguez-Canales J, Villalobos PA, Dirven CMF, Tejada S, Valle RD, Alonso MM, Ewald B, Peterkin JJ, Tufaro F, Fueyo J. Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma. J Clin Oncol. 2018 05 10; 36(14):1419-1427. PMID: 29432077.
      View in: PubMed
    65. Lee WC, Diao L, Wang J, Zhang J, Roarty EB, Varghese S, Chow CW, Fujimoto J, Behrens C, Cascone T, Peng W, Kalhor N, Moran CA, Weissferdt A, Johnson FM, William WN, Swisher SG, Lee JJ, Hong WK, Heymach JV, Wistuba II, Futreal PA, Zhang J. Multiregion gene expression profiling reveals heterogeneity in molecular subtypes and immunotherapy response signatures in lung cancer. Mod Pathol. 2018 06; 31(6):947-955. PMID: 29410488.
      View in: PubMed
    66. Kawakami M, Mustachio LM, Zheng L, Chen Y, Rodriguez-Canales J, Mino B, Kurie JM, Roszik J, Villalobos PA, Thu KL, Silvester J, Cescon DW, Wistuba II, Mak TW, Liu X, Dmitrovsky E. Polo-like kinase 4 inhibition produces polyploidy and apoptotic death of lung cancers. Proc Natl Acad Sci U S A. 2018 02 20; 115(8):1913-1918. PMID: 29434041.
      View in: PubMed
    67. Barua S, Fang P, Sharma A, Fujimoto J, Wistuba I, Rao AUK, Lin SH. Spatial interaction of tumor cells and regulatory T cells correlates with survival in non-small cell lung cancer. Lung Cancer. 2018 03; 117:73-79. PMID: 29409671.
      View in: PubMed
    68. Tang C, Hobbs B, Amer A, Li X, Behrens C, Canales JR, Cuentas EP, Villalobos P, Fried D, Chang JY, Hong DS, Welsh JW, Sepesi B, Court L, Wistuba II, Koay EJ. Development of an Immune-Pathology Informed Radiomics Model for Non-Small Cell Lung Cancer. Sci Rep. 2018 01 31; 8(1):1922. PMID: 29386574.
      View in: PubMed
    69. Kantrowitz J, Sinjab A, Xu L, McDowell TL, Sivakumar S, Lang W, Nunomura-Nakamura S, Fukuoka J, Nemer G, Darwiche N, Chami H, Tfayli A, Wistuba II, Scheet P, Fujimoto J, Spira AE, Kadara H. Genome-Wide Gene Expression Changes in the Normal-Appearing Airway during the Evolution of Smoking-Associated Lung Adenocarcinoma. Cancer Prev Res (Phila). 2018 04; 11(4):237-248. PMID: 29382653.
      View in: PubMed
    70. Gomez DR, Byers LA, Nilsson M, Diao L, Wang J, Li L, Tong P, Hofstad M, Saigal B, Wistuba I, Kalhor N, Swisher S, Fan Y, Hong WK, Suraokar M, Behrens C, Moran C, Heymach JV. Integrative proteomic and transcriptomic analysis provides evidence for TrkB (NTRK2) as a therapeutic target in combination with tyrosine kinase inhibitors for non-small cell lung cancer. Oncotarget. 2018 Mar 06; 9(18):14268-14284. PMID: 29581842.
      View in: PubMed
    71. Jour G, Andeen NK, Al-Rohil R, Aung PP, Mehrotra M, Duose D, Hoch B, Argenyi Z, Luthra R, Wistuba II, Prieto VG. Novel enriched pathways in superficial malignant peripheral nerve sheath tumours and spindle/desmoplastic melanomas. J Pathol. 2018 01; 244(1):97-106. PMID: 28991373.
      View in: PubMed
    72. Unver N, Delgado O, Zeleke K, Cumpian A, Tang X, Caetano MS, Wang H, Katayama H, Yu H, Szabo E, Wistuba II, Moghaddam SJ, Hanash SM, Ostrin EJ. Reduced IL-6 levels and tumor-associated phospho-STAT3 are associated with reduced tumor development in a mouse model of lung cancer chemoprevention with myo-inositol. Int J Cancer. 2018 04 01; 142(7):1405-1417. PMID: 29134640.
      View in: PubMed
    73. Aisner DL, Sholl LM, Berry LD, Rossi MR, Chen H, Fujimoto J, Moreira AL, Ramalingam SS, Villaruz LC, Otterson GA, Haura E, Politi K, Glisson B, Cetnar J, Garon EB, Schiller J, Waqar SN, Sequist LV, Brahmer J, Shyr Y, Kugler K, Wistuba II, Johnson BE, Minna JD, Kris MG, Bunn PA, Kwiatkowski DJ. The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2). Clin Cancer Res. 2018 03 01; 24(5):1038-1047. PMID: 29217530.
      View in: PubMed
    74. Cascone T, Gold KA, Swisher SG, Liu DD, Fossella FV, Sepesi B, Pataer A, Weissferdt A, Kalhor N, Vaporciyan AA, Hofstetter WL, Wistuba II, Heymach JV, Kim ES, William WN. Induction Cisplatin Docetaxel Followed by Surgery and Erlotinib in Non-Small Cell Lung Cancer. Ann Thorac Surg. 2018 Feb; 105(2):418-424. PMID: 29217088.
      View in: PubMed
    75. Tsao AS, Lin H, Carter BW, Lee JJ, Rice D, Vaporcyan A, Swisher S, Mehran R, Heymach J, Nilsson M, Fan Y, Nunez M, Diao L, Wang J, Fujimoto J, Wistuba II, Hong WK. Biomarker-Integrated Neoadjuvant Dasatinib Trial in Resectable Malignant Pleural Mesothelioma. J Thorac Oncol. 2018 02; 13(2):246-257. PMID: 29313814.
      View in: PubMed
    76. Yu W, Tang C, Hobbs BP, Li X, Koay EJ, Wistuba II, Sepesi B, Behrens C, Rodriguez Canales J, Parra Cuentas ER, Erasmus JJ, Court LE, Chang JY. Development and Validation of a Predictive Radiomics Model for Clinical Outcomes in Stage I Non-small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2018 11 15; 102(4):1090-1097. PMID: 29246722.
      View in: PubMed
    77. Nilsson MB, Sun H, Diao L, Tong P, Liu D, Li L, Fan Y, Poteete A, Lim SO, Howells K, Haddad V, Gomez D, Tran H, Pena GA, Sequist LV, Yang JC, Wang J, Kim ES, Herbst R, Lee JJ, Hong WK, Wistuba I, Hung MC, Sood AK, Heymach JV. Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with ß-blockers. Sci Transl Med. 2017 Nov 08; 9(415). PMID: 29118262.
      View in: PubMed
    78. Nicholson AG, Torkko K, Viola P, Duhig E, Geisinger K, Borczuk AC, Hiroshima K, Tsao MS, Warth A, Lantuejoul S, Russell PA, Thunnissen E, Marchevsky A, Mino-Kenudson M, Beasley MB, Botling J, Dacic S, Yatabe Y, Noguchi M, Travis WD, Kerr K, Hirsch FR, Chirieac LR, Wistuba II, Moreira A, Chung JH, Chou TY, Bubendorf L, Chen G, Pelosi G, Poleri C, Detterbeck FC, Franklin WA. Interobserver Variation among Pathologists and Refinement of Criteria in Distinguishing Separate Primary Tumors from Intrapulmonary Metastases in Lung. J Thorac Oncol. 2018 02; 13(2):205-217. PMID: 29127023.
      View in: PubMed
    79. Mehrotra M, Singh RR, Loghavi S, Duose DY, Barkoh BA, Behrens C, Patel KP, Routbort MJ, Kopetz S, Broaddus RR, Medeiros LJ, Wistuba II, Luthra R. Detection of somatic mutations in cell-free DNA in plasma and correlation with overall survival in patients with solid tumors. Oncotarget. 2018 02 13; 9(12):10259-10271. PMID: 29535804.
      View in: PubMed
    80. Parra ER, Uraoka N, Jiang M, Cook P, Gibbons D, Forget MA, Bernatchez C, Haymaker C, Wistuba II, Rodriguez-Canales J. Validation of multiplex immunofluorescence panels using multispectral microscopy for immune-profiling of formalin-fixed and paraffin-embedded human tumor tissues. Sci Rep. 2017 10 17; 7(1):13380. PMID: 29042640.
      View in: PubMed
    81. Zhang L, Lin J, Ye Y, Oba T, Gentile E, Lian J, Wang J, Zhao Y, Gu J, Wistuba II, Roth JA, Ji L, Wu X. Serum MicroRNA-150 Predicts Prognosis for Early-Stage Non-Small Cell Lung Cancer and Promotes Tumor Cell Proliferation by Targeting Tumor Suppressor Gene SRCIN1. Clin Pharmacol Ther. 2018 06; 103(6):1061-1073. PMID: 28891208.
      View in: PubMed
    82. Wang Y, Gudikote J, Giri U, Yan J, Deng W, Ye R, Jiang W, Li N, Hobbs BP, Wang J, Swisher SG, Fujimoto J, Wistuba II, Komaki R, Heymach JV, Lin SH. RAD50 Expression Is Associated with Poor Clinical Outcomes after Radiotherapy for Resected Non-small Cell Lung Cancer. Clin Cancer Res. 2018 01 15; 24(2):341-350. PMID: 29030353.
      View in: PubMed
    83. Tawbi HA, Burgess M, Bolejack V, Van Tine BA, Schuetze SM, Hu J, D'Angelo S, Attia S, Riedel RF, Priebat DA, Movva S, Davis LE, Okuno SH, Reed DR, Crowley J, Butterfield LH, Salazar R, Rodriguez-Canales J, Lazar AJ, Wistuba II, Baker LH, Maki RG, Reinke D, Patel S. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017 11; 18(11):1493-1501. PMID: 28988646.
      View in: PubMed
    84. Nejati R, Goldstein JB, Halperin DM, Wang H, Hejazi N, Rashid A, Katz MH, Lee JE, Fleming JB, Rodriguez-Canales J, Blando J, Wistuba II, Maitra A, Wolff RA, Varadhachary GR, Wang H. Prognostic Significance of Tumor-Infiltrating Lymphocytes in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Chemotherapy. Pancreas. 2017 10; 46(9):1180-1187. PMID: 28902789.
      View in: PubMed
    85. Sivakumar S, Lucas FAS, McDowell TL, Lang W, Xu L, Fujimoto J, Zhang J, Futreal PA, Fukuoka J, Yatabe Y, Dubinett SM, Spira AE, Fowler J, Hawk ET, Wistuba II, Scheet P, Kadara H. Genomic Landscape of Atypical Adenomatous Hyperplasia Reveals Divergent Modes to Lung Adenocarcinoma. Cancer Res. 2017 11 15; 77(22):6119-6130. PMID: 28951454.
      View in: PubMed
    86. Vykoukal J, Sun N, Aguilar-Bonavides C, Katayama H, Tanaka I, Fahrmann JF, Capello M, Fujimoto J, Aguilar M, Wistuba II, Taguchi A, Ostrin EJ, Hanash SM. Plasma-derived extracellular vesicle proteins as a source of biomarkers for lung adenocarcinoma. Oncotarget. 2017 Nov 10; 8(56):95466-95480. PMID: 29221141.
      View in: PubMed
    87. Cardnell RJ, Li L, Sen T, Bara R, Tong P, Fujimoto J, Ireland AS, Guthrie MR, Bheddah S, Banerjee U, Kalu NN, Fan YH, Dylla SJ, Johnson FM, Wistuba II, Oliver TG, Heymach JV, Glisson BS, Wang J, Byers LA. Protein expression of TTF1 and cMYC define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and other targeted therapies. Oncotarget. 2017 Sep 26; 8(43):73419-73432. PMID: 29088717.
      View in: PubMed
    88. Kawakami F, Sircar K, Rodriguez-Canales J, Fellman BM, Urbauer DL, Tamboli P, Tannir NM, Jonasch E, Wistuba II, Wood CG, Karam JA. Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation. Cancer. 2017 Dec 15; 123(24):4823-4831. PMID: 28832979.
      View in: PubMed
    89. Lin J, Zandi R, Shao R, Gu J, Ye Y, Wang J, Zhao Y, Pertsemlidis A, Wistuba II, Wu X, Roth JA, Ji L. A miR-SNP biomarker linked to an increased lung cancer survival by miRNA-mediated down-regulation of FZD4 expression and Wnt signaling. Sci Rep. 2017 08 22; 7(1):9029. PMID: 28831115.
      View in: PubMed
    90. Kim E, Feldman R, Wistuba II. Update on EGFR Mutational Testing and the Potential of Noninvasive Liquid Biopsy in Non-Small-cell Lung Cancer. Clin Lung Cancer. 2018 03; 19(2):105-114. PMID: 28935493.
      View in: PubMed
    91. Mehrotra M, Duose DY, Singh RR, Barkoh BA, Manekia J, Harmon MA, Patel KP, Routbort MJ, Medeiros LJ, Wistuba II, Luthra R. Versatile ion S5XL sequencer for targeted next generation sequencing of solid tumors in a clinical laboratory. PLoS One. 2017; 12(8):e0181968. PMID: 28767674.
      View in: PubMed
    92. Rimm DL, Han G, Taube JM, Yi ES, Bridge JA, Flieder DB, Homer R, West WW, Wu H, Roden AC, Fujimoto J, Yu H, Anders R, Kowalewski A, Rivard C, Rehman J, Batenchuk C, Burns V, Hirsch FR, Wistuba II. A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer. JAMA Oncol. 2017 Aug 01; 3(8):1051-1058. PMID: 28278348.
      View in: PubMed
    93. Schliekelman MJ, Creighton CJ, Baird BN, Chen Y, Banerjee P, Bota-Rabassedas N, Ahn YH, Roybal JD, Chen F, Zhang Y, Mishra DK, Kim MP, Liu X, Mino B, Villalobos P, Rodriguez-Canales J, Behrens C, Wistuba II, Hanash SM, Kurie JM. Thy-1+ Cancer-associated Fibroblasts Adversely Impact Lung Cancer Prognosis. Sci Rep. 2017 07 25; 7(1):6478. PMID: 28744021.
      View in: PubMed
    94. Reuben A, Gittelman R, Gao J, Zhang J, Yusko EC, Wu CJ, Emerson R, Zhang J, Tipton C, Li J, Quek K, Gopalakrishnan V, Chen R, Vence LM, Cascone T, Vignali M, Fujimoto J, Rodriguez-Canales J, Parra ER, Little LD, Gumbs C, Forget MA, Federico L, Haymaker C, Behrens C, Benzeno S, Bernatchez C, Sepesi B, Gibbons DL, Wargo JA, William WN, Swisher S, Heymach JV, Robins H, Lee JJ, Sharma P, Allison JP, Futreal PA, Wistuba II, Zhang J. TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence. Cancer Discov. 2017 10; 7(10):1088-1097. PMID: 28733428.
      View in: PubMed
    95. Shien K, Papadimitrakopoulou VA, Ruder D, Behrens C, Shen L, Kalhor N, Song J, Lee JJ, Wang J, Tang X, Herbst RS, Toyooka S, Girard L, Minna JD, Kurie JM, Wistuba II, Izzo JG. JAK1/STAT3 Activation through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Non-Small Cell Lung Cancer. Mol Cancer Ther. 2017 10; 16(10):2234-2245. PMID: 28729401.
      View in: PubMed
    96. Fujimoto J, Nunomura-Nakamura S, Liu Y, Lang W, McDowell T, Jakubek Y, Ezzeddine D, Kapere Ochieng J, Petersen J, Davies G, Fukuoka J, Wistuba II, Ehli E, Fowler J, Scheet P, Kadara H. Development of Kras mutant lung adenocarcinoma in mice with knockout of the airway lineage-specific gene Gprc5a. Int J Cancer. 2017 10 15; 141(8):1589-1599. PMID: 28653505.
      View in: PubMed
    97. Wang Z, Kim TB, Peng B, Karam J, Creighton C, Joon A, Kawakami F, Trevisan P, Jonasch E, Chow CW, Canales JR, Tamboli P, Tannir N, Wood C, Monzon F, Baggerly K, Varella-Garcia M, Czerniak B, Wistuba I, Mills G, Shaw K, Chen K, Sircar K. Sarcomatoid Renal Cell Carcinoma Has a Distinct Molecular Pathogenesis, Driver Mutation Profile, and Transcriptional Landscape. Clin Cancer Res. 2017 Nov 01; 23(21):6686-6696. PMID: 28710314.
      View in: PubMed
    98. Kasiri S, Shao C, Chen B, Wilson AN, Yenerall P, Timmons BC, Girard L, Tian H, Behrens C, Wistuba II, Gazdar AF, Kim J. GLI1 Blockade Potentiates the Antitumor Activity of PI3K Antagonists in Lung Squamous Cell Carcinoma. Cancer Res. 2017 08 15; 77(16):4448-4459. PMID: 28652248.
      View in: PubMed
    99. Tsao AS, Moon J, Wistuba II, Vogelzang NJ, Kalemkerian GP, Redman MW, Gandara DR, Kelly K. Phase I Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma (SWOG S0905). J Thorac Oncol. 2017 08; 12(8):1299-1308. PMID: 28599887.
      View in: PubMed
    100. Kawakami M, Mustachio LM, Rodriguez-Canales J, Mino B, Roszik J, Tong P, Wang J, Lee JJ, Myung JH, Heymach JV, Johnson FM, Hong S, Zheng L, Hu S, Villalobos PA, Behrens C, Wistuba I, Freemantle S, Liu X, Dmitrovsky E. Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung Cancer. J Natl Cancer Inst. 2017 06 01; 109(6). PMID: 28376145.
      View in: PubMed
    101. Cascone T, Xu L, Lin HY, Liu W, Tran HT, Liu Y, Howells K, Haddad V, Hanrahan E, Nilsson MB, Cortez MA, Giri U, Kadara H, Saigal B, Park YY, Peng W, Lee JS, Ryan AJ, Jüergensmeier JM, Herbst RS, Wang J, Langley RR, Wistuba II, Lee JJ, Heymach JV. The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non-Small Cell Lung Cancer. Clin Cancer Res. 2017 Sep 15; 23(18):5489-5501. PMID: 28559461.
      View in: PubMed
    102. Sepesi B, Cuentas EP, Canales JR, Behrens C, Correa AM, Vaporciyan A, Weissferdt A, Kalhor N, Moran C, Swisher S, Wistuba I. Programmed Death Cell Ligand 1 (PD-L1) Is Associated With Survival in Stage I Non-Small Cell Lung Cancer. Semin Thorac Cardiovasc Surg. 2017 Autumn; 29(3):408-415. PMID: 29195578.
      View in: PubMed
    103. Dalvi MP, Wang L, Zhong R, Kollipara RK, Park H, Bayo J, Yenerall P, Zhou Y, Timmons BC, Rodriguez-Canales J, Behrens C, Mino B, Villalobos P, Parra ER, Suraokar M, Pataer A, Swisher SG, Kalhor N, Bhanu NV, Garcia BA, Heymach JV, Coombes K, Xie Y, Girard L, Gazdar AF, Kittler R, Wistuba II, Minna JD, Martinez ED. Taxane-Platin-Resistant Lung Cancers Co-develop Hypersensitivity to JumonjiC Demethylase Inhibitors. Cell Rep. 2017 05 23; 19(8):1669-1684. PMID: 28538184.
      View in: PubMed
    104. Mehrotra M, Singh RR, Chen W, Huang RSP, Almohammedsalim AA, Barkoh BA, Simien CM, Hernandez M, Behrens C, Patel KP, Routbort MJ, Broaddus RR, Medeiros LJ, Wistuba II, Kopetz S, Luthra R. Study of Preanalytic and Analytic Variables for Clinical Next-Generation Sequencing of Circulating Cell-Free Nucleic Acid. J Mol Diagn. 2017 07; 19(4):514-524. PMID: 28506684.
      View in: PubMed
    105. Allison Stewart C, Tong P, Cardnell RJ, Sen T, Li L, Gay CM, Masrorpour F, Fan Y, Bara RO, Feng Y, Ru Y, Fujimoto J, Kundu ST, Post LE, Yu K, Shen Y, Glisson BS, Wistuba I, Heymach JV, Gibbons DL, Wang J, Byers LA. Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer. Oncotarget. 2017 Apr 25; 8(17):28575-28587. PMID: 28212573.
      View in: PubMed
    106. Reuben A, Spencer CN, Prieto PA, Gopalakrishnan V, Reddy SM, Miller JP, Mao X, De Macedo MP, Chen J, Song X, Jiang H, Chen PL, Beird HC, Garber HR, Roh W, Wani K, Chen E, Haymaker C, Forget MA, Little LD, Gumbs C, Thornton RL, Hudgens CW, Chen WS, Austin-Breneman J, Sloane RS, Nezi L, Cogdill AP, Bernatchez C, Roszik J, Hwu P, Woodman SE, Chin L, Tawbi H, Davies MA, Gershenwald JE, Amaria RN, Glitza IC, Diab A, Patel SP, Hu J, Lee JE, Grimm EA, Tetzlaff MT, Lazar AJ, Wistuba II, Clise-Dwyer K, Carter BW, Zhang J, Futreal PA, Sharma P, Allison JP, Cooper ZA, Wargo JA. Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. NPJ Genom Med. 2017; 2. PMID: 28819565.
      View in: PubMed
    107. Quek K, Li J, Estecio M, Zhang J, Fujimoto J, Roarty E, Little L, Chow CW, Song X, Behrens C, Chen T, William WN, Swisher S, Heymach J, Wistuba I, Zhang J, Futreal A, Zhang J. DNA methylation intratumor heterogeneity in localized lung adenocarcinomas. Oncotarget. 2017 Mar 28; 8(13):21994-22002. PMID: 28423542.
      View in: PubMed
    108. Gao J, Ward JF, Pettaway CA, Shi LZ, Subudhi SK, Vence LM, Zhao H, Chen J, Chen H, Efstathiou E, Troncoso P, Allison JP, Logothetis CJ, Wistuba II, Sepulveda MA, Sun J, Wargo J, Blando J, Sharma P. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat Med. 2017 May; 23(5):551-555. PMID: 28346412.
      View in: PubMed
    109. Weissferdt A, Fujimoto J, Kalhor N, Rodriguez J, Bassett R, Wistuba II, Moran CA. Expression of PD-1 and PD-L1 in thymic epithelial neoplasms. Mod Pathol. 2017 06; 30(6):826-833. PMID: 28281549.
      View in: PubMed
    110. Villalobos P, Wistuba II. Lung Cancer Biomarkers. Hematol Oncol Clin North Am. 2017 02; 31(1):13-29. PMID: 27912828.
      View in: PubMed
    111. Miller AD, De Las Heras M, Yu J, Zhang F, Liu SL, Vaughan AE, Vaughan TL, Rosadio R, Rocca S, Palmieri G, Goedert JJ, Fujimoto J, Wistuba II. Evidence against a role for jaagsiekte sheep retrovirus in human lung cancer. Retrovirology. 2017 01 20; 14(1):3. PMID: 28107820.
      View in: PubMed
    112. Van Roosbroeck K, Fanini F, Setoyama T, Ivan C, Rodriguez-Aguayo C, Fuentes-Mattei E, Xiao L, Vannini I, Redis RS, D'Abundo L, Zhang X, Nicoloso MS, Rossi S, Gonzalez-Villasana V, Rupaimoole R, Ferracin M, Morabito F, Neri A, Ruvolo PP, Ruvolo VR, Pecot CV, Amadori D, Abruzzo L, Calin S, Wang X, You MJ, Ferrajoli A, Orlowski R, Plunkett W, Lichtenberg TM, Davuluri RV, Berindan-Neagoe I, Negrini M, Wistuba II, Kantarjian HM, Sood AK, Lopez-Berestein G, Keating MJ, Fabbri M, Calin GA. Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers. Clin Cancer Res. 2017 06 01; 23(11):2891-2904. PMID: 27903673.
      View in: PubMed
    113. Zhou X, Updegraff BL, Guo Y, Peyton M, Girard L, Larsen JE, Xie XJ, Zhou Y, Hwang TH, Xie Y, Rodriguez-Canales J, Villalobos P, Behrens C, Wistuba II, Minna JD, O'Donnell KA. PROTOCADHERIN 7 Acts through SET and PP2A to Potentiate MAPK Signaling by EGFR and KRAS during Lung Tumorigenesis. Cancer Res. 2017 01 01; 77(1):187-197. PMID: 27821484.
      View in: PubMed
    114. Luo X, Zang X, Yang L, Huang J, Liang F, Rodriguez-Canales J, Wistuba II, Gazdar A, Xie Y, Xiao G. Comprehensive Computational Pathological Image Analysis Predicts Lung Cancer Prognosis. J Thorac Oncol. 2017 03; 12(3):501-509. PMID: 27826035.
      View in: PubMed
    115. Liu Y, Zhang J, Li L, Yin G, Zhang J, Zheng S, Cheung H, Wu N, Lu N, Mao X, Yang L, Zhang J, Zhang L, Seth S, Chen H, Song X, Liu K, Xie Y, Zhou L, Zhao C, Han N, Chen W, Zhang S, Chen L, Cai W, Li L, Shen M, Xu N, Cheng S, Yang H, Lee JJ, Correa A, Fujimoto J, Behrens C, Chow CW, William WN, Heymach JV, Hong WK, Swisher S, Wistuba II, Wang J, Lin D, Liu X, Futreal PA, Gao Y. Genomic heterogeneity of multiple synchronous lung cancer. Nat Commun. 2016 10 21; 7:13200. PMID: 27767028.
      View in: PubMed
    116. Papadimitrakopoulou V, Lee JJ, Wistuba II, Tsao AS, Fossella FV, Kalhor N, Gupta S, Byers LA, Izzo JG, Gettinger SN, Goldberg SB, Tang X, Miller VA, Skoulidis F, Gibbons DL, Shen L, Wei C, Diao L, Peng SA, Wang J, Tam AL, Coombes KR, Koo JS, Mauro DJ, Rubin EH, Heymach JV, Hong WK, Herbst RS. The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2016 Oct 20; 34(30):3638-3647. PMID: 27480147.
      View in: PubMed
    117. Kim J, McMillan E, Kim HS, Venkateswaran N, Makkar G, Rodriguez-Canales J, Villalobos P, Neggers JE, Mendiratta S, Wei S, Landesman Y, Senapedis W, Baloglu E, Chow CB, Frink RE, Gao B, Roth M, Minna JD, Daelemans D, Wistuba II, Posner BA, Scaglioni PP, White MA. XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer. Nature. 2016 Oct 06; 538(7623):114-117. PMID: 27680702.
      View in: PubMed
    118. Boo HJ, Min HY, Jang HJ, Yun HJ, Smith JK, Jin Q, Lee HJ, Liu D, Kweon HS, Behrens C, Lee JJ, Wistuba II, Lee E, Hong WK, Lee HY. The tobacco-specific carcinogen-operated calcium channel promotes lung tumorigenesis via IGF2 exocytosis in lung epithelial cells. Nat Commun. 2016 Sep 26; 7:12961. PMID: 27666821.
      View in: PubMed
    119. Weissferdt A, Kalhor N, Rodriguez Canales J, Fujimoto J, Wistuba II, Moran CA. Spindle cell and pleomorphic ("sarcomatoid") carcinomas of the lung: an immunohistochemical analysis of 86 cases. Hum Pathol. 2017 01; 59:1-9. PMID: 27569293.
      View in: PubMed
    120. Larsen JE, Nathan V, Osborne JK, Farrow RK, Deb D, Sullivan JP, Dospoy PD, Augustyn A, Hight SK, Sato M, Girard L, Behrens C, Wistuba II, Gazdar AF, Hayward NK, Minna JD. ZEB1 drives epithelial-to-mesenchymal transition in lung cancer. J Clin Invest. 2016 09 01; 126(9):3219-35. PMID: 27500490.
      View in: PubMed
    121. Padanad MS, Konstantinidou G, Venkateswaran N, Melegari M, Rindhe S, Mitsche M, Yang C, Batten K, Huffman KE, Liu J, Tang X, Rodriguez-Canales J, Kalhor N, Shay JW, Minna JD, McDonald J, Wistuba II, DeBerardinis RJ, Scaglioni PP. Fatty Acid Oxidation Mediated by Acyl-CoA Synthetase Long Chain 3 Is Required for Mutant KRAS Lung Tumorigenesis. Cell Rep. 2016 08 09; 16(6):1614-1628. PMID: 27477280.
      View in: PubMed
    122. Girard L, Rodriguez-Canales J, Behrens C, Thompson DM, Botros IW, Tang H, Xie Y, Rekhtman N, Travis WD, Wistuba II, Minna JD, Gazdar AF. An Expression Signature as an Aid to the Histologic Classification of Non-Small Cell Lung Cancer. Clin Cancer Res. 2016 Oct 01; 22(19):4880-4889. PMID: 27354471.
      View in: PubMed
    123. Shien K, Papadimitrakopoulou VA, Wistuba II. Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer. Lung Cancer. 2016 09; 99:79-87. PMID: 27565919.
      View in: PubMed
    124. Cardó-Vila M, Marchiò S, Sato M, Staquicini FI, Smith TL, Bronk JK, Yin G, Zurita AJ, Sun M, Behrens C, Sidman RL, Lee JJ, Hong WK, Wistuba II, Arap W, Pasqualini R. Interleukin-11 Receptor Is a Candidate Target for Ligand-Directed Therapy in Lung Cancer: Analysis of Clinical Samples and BMTP-11 Preclinical Activity. Am J Pathol. 2016 08; 186(8):2162-2170. PMID: 27317903.
      View in: PubMed
    125. Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, Miller JP, Bassett RL, Gopalakrishnan V, Wani K, De Macedo MP, Austin-Breneman JL, Jiang H, Chang Q, Reddy SM, Chen WS, Tetzlaff MT, Broaddus RJ, Davies MA, Gershenwald JE, Haydu L, Lazar AJ, Patel SP, Hwu P, Hwu WJ, Diab A, Glitza IC, Woodman SE, Vence LM, Wistuba II, Amaria RN, Kwong LN, Prieto V, Davis RE, Ma W, Overwijk WW, Sharpe AH, Hu J, Futreal PA, Blando J, Sharma P, Allison JP, Chin L, Wargo JA. Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discov. 2016 08; 6(8):827-37. PMID: 27301722.
      View in: PubMed
    126. Parra ER, Behrens C, Rodriguez-Canales J, Lin H, Mino B, Blando J, Zhang J, Gibbons DL, Heymach JV, Sepesi B, Swisher SG, Weissferdt A, Kalhor N, Izzo J, Kadara H, Moran C, Lee JJ, Wistuba II. Image Analysis-based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports Distinct Intratumoral Microenvironment Groups in Non-small Cell Lung Carcinoma Patients. Clin Cancer Res. 2016 Dec 15; 22(24):6278-6289. PMID: 27252415.
      View in: PubMed
    127. Tan DS, Yom SS, Tsao MS, Pass HI, Kelly K, Peled N, Yung RC, Wistuba II, Yatabe Y, Unger M, Mack PC, Wynes MW, Mitsudomi T, Weder W, Yankelevitz D, Herbst RS, Gandara DR, Carbone DP, Bunn PA, Mok TS, Hirsch FR. The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016. J Thorac Oncol. 2016 07; 11(7):946-63. PMID: 27229180.
      View in: PubMed
    128. Jakubek Y, Lang W, Vattathil S, Garcia M, Xu L, Huang L, Yoo SY, Shen L, Lu W, Chow CW, Weber Z, Davies G, Huang J, Behrens C, Kalhor N, Moran C, Fujimoto J, Mehran R, El-Zein R, Swisher SG, Wang J, Fowler J, Spira AE, Ehli EA, Wistuba II, Scheet P, Kadara H. Genomic Landscape Established by Allelic Imbalance in the Cancerization Field of a Normal Appearing Airway. Cancer Res. 2016 07 01; 76(13):3676-83. PMID: 27216194.
      View in: PubMed
    129. Feldmeyer L, Hudgens CW, Ray-Lyons G, Nagarajan P, Aung PP, Curry JL, Torres-Cabala CA, Mino B, Rodriguez-Canales J, Reuben A, Chen PL, Ko JS, Billings SD, Bassett RL, Wistuba II, Cooper ZA, Prieto VG, Wargo JA, Tetzlaff MT. Density, Distribution, and Composition of Immune Infiltrates Correlate with Survival in Merkel Cell Carcinoma. Clin Cancer Res. 2016 Nov 15; 22(22):5553-5563. PMID: 27166398.
      View in: PubMed
    130. Yabe M, Medeiros LJ, Tang G, Wang SA, Ahmed S, Nieto Y, Hu S, Bhagat G, Oki Y, Patel KP, Routbort M, Luthra R, Fanale MA, Bueso-Ramos CE, Jorgensen JL, Vega F, Chen W, Hoehn D, Konoplev S, Milton DR, Wistuba I, Li S, You MJ, Young KH, Miranda RN. Prognostic Factors of Hepatosplenic T-cell Lymphoma: Clinicopathologic Study of 28 Cases. Am J Surg Pathol. 2016 May; 40(5):676-88. PMID: 26872013.
      View in: PubMed
    131. Caetano MS, Zhang H, Cumpian AM, Gong L, Unver N, Ostrin EJ, Daliri S, Chang SH, Ochoa CE, Hanash S, Behrens C, Wistuba II, Sternberg C, Kadara H, Ferreira CG, Watowich SS, Moghaddam SJ. IL6 Blockade Reprograms the Lung Tumor Microenvironment to Limit the Development and Progression of K-ras-Mutant Lung Cancer. Cancer Res. 2016 06 01; 76(11):3189-99. PMID: 27197187.
      View in: PubMed
    132. DeNicola GM, Chen PH, Mullarky E, Sudderth JA, Hu Z, Wu D, Tang H, Xie Y, Asara JM, Huffman KE, Wistuba II, Minna JD, DeBerardinis RJ, Cantley LC. Erratum: NRF2 regulates serine biosynthesis in non-small cell lung cancer. Nat Genet. 2016 Apr; 48(4):473. PMID: 27023779.
      View in: PubMed
    133. Kadara H, Scheet P, Wistuba II, Spira AE. Early Events in the Molecular Pathogenesis of Lung Cancer. Cancer Prev Res (Phila). 2016 Jul; 9(7):518-27. PMID: 27006378.
      View in: PubMed
    134. Tripathi SC, Peters HL, Taguchi A, Katayama H, Wang H, Momin A, Jolly MK, Celiktas M, Rodriguez-Canales J, Liu H, Behrens C, Wistuba II, Ben-Jacob E, Levine H, Molldrem JJ, Hanash SM, Ostrin EJ. Immunoproteasome deficiency is a feature of non-small cell lung cancer with a mesenchymal phenotype and is associated with a poor outcome. Proc Natl Acad Sci U S A. 2016 Mar 15; 113(11):E1555-64. PMID: 26929325.
      View in: PubMed
    135. Lou Y, Diao L, Cuentas ER, Denning WL, Chen L, Fan YH, Byers LA, Wang J, Papadimitrakopoulou VA, Behrens C, Rodriguez JC, Hwu P, Wistuba II, Heymach JV, Gibbons DL. Epithelial-Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma. Clin Cancer Res. 2016 07 15; 22(14):3630-42. PMID: 26851185.
      View in: PubMed
    136. Cooper ZA, Reuben A, Spencer CN, Prieto PA, Austin-Breneman JL, Jiang H, Haymaker C, Gopalakrishnan V, Tetzlaff MT, Frederick DT, Sullivan RJ, Amaria RN, Patel SP, Hwu P, Woodman SE, Glitza IC, Diab A, Vence LM, Rodriguez-Canales J, Parra ER, Wistuba II, Coussens LM, Sharpe AH, Flaherty KT, Gershenwald JE, Chin L, Davies MA, Clise-Dwyer K, Allison JP, Sharma P, Wargo JA. Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. Oncoimmunology. 2016 Mar; 5(3):e1136044. PMID: 27141370.
      View in: PubMed
    137. William WN, Papadimitrakopoulou V, Lee JJ, Mao L, Cohen EE, Lin HY, Gillenwater AM, Martin JW, Lingen MW, Boyle JO, Shin DM, Vigneswaran N, Shinn N, Heymach JV, Wistuba II, Tang X, Kim ES, Saintigny P, Blair EA, Meiller T, Gutkind JS, Myers J, El-Naggar A, Lippman SM. Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial. JAMA Oncol. 2016 Feb; 2(2):209-16. PMID: 26540028.
      View in: PubMed
    138. Koyama S, Akbay EA, Li YY, Aref AR, Skoulidis F, Herter-Sprie GS, Buczkowski KA, Liu Y, Awad MM, Denning WL, Diao L, Wang J, Parra-Cuentas ER, Wistuba II, Soucheray M, Thai T, Asahina H, Kitajima S, Altabef A, Cavanaugh JD, Rhee K, Gao P, Zhang H, Fecci PE, Shimamura T, Hellmann MD, Heymach JV, Hodi FS, Freeman GJ, Barbie DA, Dranoff G, Hammerman PS, Wong KK. STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment. Cancer Res. 2016 Mar 01; 76(5):999-1008. PMID: 26833127.
      View in: PubMed
    139. Rodriguez-Canales J, Parra-Cuentas E, Wistuba II. Diagnosis and Molecular Classification of Lung Cancer. Cancer Treat Res. 2016; 170:25-46. PMID: 27535388.
      View in: PubMed
    140. Riquelme E, Behrens C, Lin HY, Simon G, Papadimitrakopoulou V, Izzo J, Moran C, Kalhor N, Lee JJ, Minna JD, Wistuba II. Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations. Cancer Res. 2016 Feb 01; 76(3):675-85. PMID: 26676756.
      View in: PubMed
    141. Pankova D, Chen Y, Terajima M, Schliekelman MJ, Baird BN, Fahrenholtz M, Sun L, Gill BJ, Vadakkan TJ, Kim MP, Ahn YH, Roybal JD, Liu X, Parra Cuentas ER, Rodriguez J, Wistuba II, Creighton CJ, Gibbons DL, Hicks JM, Dickinson ME, West JL, Grande-Allen KJ, Hanash SM, Yamauchi M, Kurie JM. Cancer-Associated Fibroblasts Induce a Collagen Cross-link Switch in Tumor Stroma. Mol Cancer Res. 2016 Mar; 14(3):287-95. PMID: 26631572.
      View in: PubMed
    142. Roy-Chowdhuri S, Chow CW, Kane MK, Yao H, Wistuba II, Krishnamurthy S, Stewart J, Staerkel G. Optimizing the DNA yield for molecular analysis from cytologic preparations. Cancer Cytopathol. 2016 Apr; 124(4):254-60. PMID: 26630358.
      View in: PubMed
    143. Weissferdt A, Tang X, Suster S, Wistuba II, Moran CA. Pleuropulmonary Meningothelial Proliferations: Evidence for a Common Histogenesis. Am J Surg Pathol. 2015 Dec; 39(12):1673-8. PMID: 26291511.
      View in: PubMed
    144. Tam AL, Lim HJ, Wistuba II, Tamrazi A, Kuo MD, Ziv E, Wong S, Shih AJ, Webster RJ, Fischer GS, Nagrath S, Davis SE, White SB, Ahrar K. Image-Guided Biopsy in the Era of Personalized Cancer Care: Proceedings from the Society of Interventional Radiology Research Consensus Panel. J Vasc Interv Radiol. 2016 Jan; 27(1):8-19. PMID: 26626860.
      View in: PubMed
    145. Nilsson MB, Giri U, Gudikote J, Tang X, Lu W, Tran H, Fan Y, Koo A, Diao L, Tong P, Wang J, Herbst R, Johnson BE, Ryan A, Webster A, Rowe P, Wistuba II, Heymach JV. KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib. Clin Cancer Res. 2016 Apr 15; 22(8):1940-50. PMID: 26578684.
      View in: PubMed
    146. Lou Y, Pecot CV, Tran HT, DeVito VJ, Tang XM, Heymach JV, Luthra R, Wistuba II, Zuo Z, Tsao AS. Germline Mutation of T790M and Dual/Multiple EGFR Mutations in Patients With Lung Adenocarcinoma. Clin Lung Cancer. 2016 Mar; 17(2):e5-11. PMID: 26700910.
      View in: PubMed
    147. DeNicola GM, Chen PH, Mullarky E, Sudderth JA, Hu Z, Wu D, Tang H, Xie Y, Asara JM, Huffman KE, Wistuba II, Minna JD, DeBerardinis RJ, Cantley LC. NRF2 regulates serine biosynthesis in non-small cell lung cancer. Nat Genet. 2015 Dec; 47(12):1475-81. PMID: 26482881.
      View in: PubMed
    148. Aramburu A, Zudaire I, Pajares MJ, Agorreta J, Orta A, Lozano MD, Gúrpide A, Gómez-Román J, Martinez-Climent JA, Jassem J, Skrzypski M, Suraokar M, Behrens C, Wistuba II, Pio R, Rubio A, Montuenga LM. Combined clinical and genomic signatures for the prognosis of early stage non-small cell lung cancer based on gene copy number alterations. BMC Genomics. 2015 Oct 06; 16:752. PMID: 26444668.
      View in: PubMed
    149. Mak MP, Tong P, Diao L, Cardnell RJ, Gibbons DL, William WN, Skoulidis F, Parra ER, Rodriguez-Canales J, Wistuba II, Heymach JV, Weinstein JN, Coombes KR, Wang J, Byers LA. A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition. Clin Cancer Res. 2016 Feb 01; 22(3):609-20. PMID: 26420858.
      View in: PubMed
    150. Timsah Z, Berrout J, Suraokar M, Behrens C, Song J, Lee JJ, Ivan C, Gagea M, Shires M, Hu X, Vallien C, Kingsley CV, Wistuba I, Ladbury JE. Expression pattern of FGFR2, Grb2 and Plc?1 acts as a novel prognostic marker of recurrence recurrence-free survival in lung adenocarcinoma. Am J Cancer Res. 2015; 5(10):3135-48. PMID: 26693065.
      View in: PubMed
    151. Maki Y, Fujimoto J, Lang W, Xu L, Behrens C, Wistuba II, Kadara H. LAPTM4B is associated with poor prognosis in NSCLC and promotes the NRF2-mediated stress response pathway in lung cancer cells. Sci Rep. 2015 Sep 07; 5:13846. PMID: 26343532.
      View in: PubMed
    152. Ileana EE, Wistuba II, Izzo JG. From Uniplex to Multiplex Molecular Profiling in Advanced Non-Small Cell Lung Carcinoma. Cancer J. 2015 Sep-Oct; 21(5):413-24. PMID: 26389767.
      View in: PubMed
    153. Levy BP, Chioda MD, Herndon D, Longshore JW, Mohamed M, Ou SH, Reynolds C, Singh J, Wistuba II, Bunn PA, Hirsch FR. Molecular Testing for Treatment of Metastatic Non-Small Cell Lung Cancer: How to Implement Evidence-Based Recommendations. Oncologist. 2015 Oct; 20(10):1175-81. PMID: 26330460.
      View in: PubMed
    154. Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, Chirieac LR, Dacic S, Duhig E, Flieder DB, Geisinger K, Hirsch FR, Ishikawa Y, Kerr KM, Noguchi M, Pelosi G, Powell CA, Tsao MS, Wistuba I. The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. J Thorac Oncol. 2015 Sep; 10(9):1243-1260. PMID: 26291008.
      View in: PubMed
    155. Kerr KM, Tsao MS, Nicholson AG, Yatabe Y, Wistuba II, Hirsch FR. Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art? J Thorac Oncol. 2015 Jul; 10(7):985-9. PMID: 26134220.
      View in: PubMed
    156. Kim JS, Kim ES, Liu D, Lee JJ, Behrens C, Lippman SM, Hong WK, Wistuba II, Lee E, Lee HY. Activation of insulin-like growth factor 1 receptor in patients with non-small cell lung cancer. Oncotarget. 2015 Jun 30; 6(18):16746-56. PMID: 25944691.
      View in: PubMed
    157. Soh J, Toyooka S, Matsuo K, Yamamoto H, Wistuba II, Lam S, Fong KM, Gazdar AF, Miyoshi S. Ethnicity affects EGFR and KRAS gene alterations of lung adenocarcinoma. Oncol Lett. 2015 Sep; 10(3):1775-1782. PMID: 26622749.
      View in: PubMed
    158. Skoulidis F, Byers LA, Diao L, Papadimitrakopoulou VA, Tong P, Izzo J, Behrens C, Kadara H, Parra ER, Canales JR, Zhang J, Giri U, Gudikote J, Cortez MA, Yang C, Fan Y, Peyton M, Girard L, Coombes KR, Toniatti C, Heffernan TP, Choi M, Frampton GM, Miller V, Weinstein JN, Herbst RS, Wong KK, Zhang J, Sharma P, Mills GB, Hong WK, Minna JD, Allison JP, Futreal A, Wang J, Wistuba II, Heymach JV. Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discov. 2015 Aug; 5(8):860-77. PMID: 26069186.
      View in: PubMed
    159. Zhu X, Xu Y, Solis LM, Tao W, Wang L, Behrens C, Xu X, Zhao L, Liu D, Wu J, Zhang N, Wistuba II, Farokhzad OC, Zetter BR, Shi J. Long-circulating siRNA nanoparticles for validating Prohibitin1-targeted non-small cell lung cancer treatment. Proc Natl Acad Sci U S A. 2015 Jun 23; 112(25):7779-84. PMID: 26056316.
      View in: PubMed
    160. Min HY, Yun HJ, Lee JS, Lee HJ, Cho J, Jang HJ, Park SH, Liu D, Oh SH, Lee JJ, Wistuba II, Lee HY. Targeting the insulin-like growth factor receptor and Src signaling network for the treatment of non-small cell lung cancer. Mol Cancer. 2015 Jun 04; 14:113. PMID: 26041671.
      View in: PubMed
    161. Komaki R, Allen PK, Wei X, Blumenschein GR, Tang X, Lee JJ, Welsh JW, Wistuba II, Liu DD, Hong WK. Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2015 Jun 01; 92(2):317-24. PMID: 25968826.
      View in: PubMed
    162. Guo C, Hao C, Shao R, Fang B, Correa AM, Hofstetter WL, Roth JA, Behrens C, Kalhor N, Wistuba II, Swisher SG, Pataer A. RNA-dependent protein kinase (PKR) depletes nutrients, inducing phosphorylation of AMP-activated kinase in lung cancer. Oncotarget. 2015 May 10; 6(13):11114-24. PMID: 25798539.
      View in: PubMed
    163. Sholl LM, Aisner DL, Varella-Garcia M, Berry LD, Dias-Santagata D, Wistuba II, Chen H, Fujimoto J, Kugler K, Franklin WA, Iafrate AJ, Ladanyi M, Kris MG, Johnson BE, Bunn PA, Minna JD, Kwiatkowski DJ. Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience. J Thorac Oncol. 2015 May; 10(5):768-777. PMID: 25738220.
      View in: PubMed
    164. Cardnell RJ, Behrens C, Diao L, Fan Y, Tang X, Tong P, Minna JD, Mills GB, Heymach JV, Wistuba II, Wang J, Byers LA. An Integrated Molecular Analysis of Lung Adenocarcinomas Identifies Potential Therapeutic Targets among TTF1-Negative Tumors, Including DNA Repair Proteins and Nrf2. Clin Cancer Res. 2015 Aug 01; 21(15):3480-91. PMID: 25878335.
      View in: PubMed
    165. Hu S, Danilov AV, Godek K, Orr B, Tafe LJ, Rodriguez-Canales J, Behrens C, Mino B, Moran CA, Memoli VA, Mustachio LM, Galimberti F, Ravi S, DeCastro A, Lu Y, Sekula D, Andrew AS, Wistuba II, Freemantle S, Compton DA, Dmitrovsky E. CDK2 Inhibition Causes Anaphase Catastrophe in Lung Cancer through the Centrosomal Protein CP110. Cancer Res. 2015 May 15; 75(10):2029-38. PMID: 25808870.
      View in: PubMed
    166. Tsimberidou AM, Said R, Culotta K, Wistuba I, Jelinek J, Fu S, Falchook G, Naing A, Piha-Paul S, Zinner R, Siddik ZH, He G, Hess K, Stewart DJ, Kurzrock R, Issa JP. Phase I study of azacitidine and oxaliplatin in patients with advanced cancers that have relapsed or are refractory to any platinum therapy. Clin Epigenetics. 2015; 7:29. PMID: 25806091.
      View in: PubMed
    167. Ilmer M, Boiles AR, Regel I, Yokoi K, Michalski CW, Wistuba II, Rodriguez J, Alt E, Vykoukal J. RSPO2 Enhances Canonical Wnt Signaling to Confer Stemness-Associated Traits to Susceptible Pancreatic Cancer Cells. Cancer Res. 2015 May 01; 75(9):1883-96. PMID: 25769727.
      View in: PubMed
    168. Schliekelman MJ, Taguchi A, Zhu J, Dai X, Rodriguez J, Celiktas M, Zhang Q, Chin A, Wong CH, Wang H, McFerrin L, Selamat SA, Yang C, Kroh EM, Garg KS, Behrens C, Gazdar AF, Laird-Offringa IA, Tewari M, Wistuba II, Thiery JP, Hanash SM. Molecular portraits of epithelial, mesenchymal, and hybrid States in lung adenocarcinoma and their relevance to survival. Cancer Res. 2015 May 01; 75(9):1789-800. PMID: 25744723.
      View in: PubMed
    169. Suzuki H, Roa JC, Kawamoto T, Ishige K, Wistuba II, Li D, Thomas MB, Shoda J. Expression of insulin-like growth factor I receptor as a biomarker for predicting prognosis in biliary tract cancer patients. Mol Clin Oncol. 2015 May; 3(3):464-470. PMID: 26137252.
      View in: PubMed
    170. Zenali MJ, Weissferdt A, Solis LM, Ali S, Tang X, Mehran RJ, Wistuba II, Moran CA, Kalhor N. An update on clinicopathological, immunohistochemical, and molecular profiles of colloid carcinoma of the lung. Hum Pathol. 2015 Jun; 46(6):836-42. PMID: 25776025.
      View in: PubMed
    171. Chen Y, Terajima M, Yang Y, Sun L, Ahn YH, Pankova D, Puperi DS, Watanabe T, Kim MP, Blackmon SH, Rodriguez J, Liu H, Behrens C, Wistuba II, Minelli R, Scott KL, Sanchez-Adams J, Guilak F, Pati D, Thilaganathan N, Burns AR, Creighton CJ, Martinez ED, Zal T, Grande-Allen KJ, Yamauchi M, Kurie JM. Lysyl hydroxylase 2 induces a collagen cross-link switch in tumor stroma. J Clin Invest. 2015 Mar 02; 125(3):1147-62. PMID: 25664850.
      View in: PubMed
    172. Staquicini FI, Qian MD, Salameh A, Dobroff AS, Edwards JK, Cimino DF, Moeller BJ, Kelly P, Nunez MI, Tang X, Liu DD, Lee JJ, Hong WK, Ferrara F, Bradbury AR, Lobb RR, Edelman MJ, Sidman RL, Wistuba II, Arap W, Pasqualini R. Receptor tyrosine kinase EphA5 is a functional molecular target in human lung cancer. J Biol Chem. 2015 Mar 20; 290(12):7345-59. PMID: 25623065.
      View in: PubMed
    173. Lam DC, Luo SY, Deng W, Kwan JSh, Rodriguez-Canales J, Cheung AL, Cheng GH, Lin CH, Wistuba II, Sham PC, Wan TS, Tsao SW. Oncogenic mutation profiling in new lung cancer and mesothelioma cell lines. Onco Targets Ther. 2015; 8:195-209. PMID: 25653542.
      View in: PubMed
    174. Tian H, Lu JY, Shao C, Huffman KE, Carstens RM, Larsen JE, Girard L, Liu H, Rodriguez-Canales J, Frenkel EP, Wistuba II, Minna JD, Hofmann SL. Systematic siRNA Screen Unmasks NSCLC Growth Dependence by Palmitoyltransferase DHHC5. Mol Cancer Res. 2015 Apr; 13(4):784-94. PMID: 25573953.
      View in: PubMed
    175. Bueno R, Hughes E, Wagner S, Gutin AS, Lanchbury JS, Zheng Y, Archer MA, Gustafson C, Jones JT, Rushton K, Saam J, Kim E, Barberis M, Wistuba I, Wenstrup RJ, Wallace WA, Hartman AR, Harrison DJ. Validation of a molecular and pathological model for five-year mortality risk in patients with early stage lung adenocarcinoma. J Thorac Oncol. 2015 Jan; 10(1):67-73. PMID: 25396679.
      View in: PubMed
    176. Borkowski R, Du L, Zhao Z, McMillan E, Kosti A, Yang CR, Suraokar M, Wistuba II, Gazdar AF, Minna JD, White MA, Pertsemlidis A. Genetic mutation of p53 and suppression of the miR-17~92 cluster are synthetic lethal in non-small cell lung cancer due to upregulation of vitamin D Signaling. Cancer Res. 2015 Feb 15; 75(4):666-75. PMID: 25519225.
      View in: PubMed
    177. Lin SH, Wang J, Saintigny P, Wu CC, Giri U, Zhang J, Menju T, Diao L, Byers L, Weinstein JN, Coombes KR, Girard L, Komaki R, Wistuba II, Date H, Minna JD, Heymach JV. Genes suppressed by DNA methylation in non-small cell lung cancer reveal the epigenetics of epithelial-mesenchymal transition. BMC Genomics. 2014 Dec 08; 15:1079. PMID: 25486910.
      View in: PubMed
    178. Weissferdt A, Rodriguez-Canales J, Liu H, Fujimoto J, Wistuba II, Moran CA. Primary mediastinal seminomas: a comprehensive immunohistochemical study with a focus on novel markers. Hum Pathol. 2015 Mar; 46(3):376-83. PMID: 25576290.
      View in: PubMed
    179. Chen L, Gibbons DL, Goswami S, Cortez MA, Ahn YH, Byers LA, Zhang X, Yi X, Dwyer D, Lin W, Diao L, Wang J, Roybal J, Patel M, Ungewiss C, Peng D, Antonia S, Mediavilla-Varela M, Robertson G, Suraokar M, Welsh JW, Erez B, Wistuba II, Chen L, Peng D, Wang S, Ullrich SE, Heymach JV, Kurie JM, Qin FX. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun. 2014 Oct 28; 5:5241. PMID: 25348003.
      View in: PubMed
    180. Zhang J, Fujimoto J, Zhang J, Wedge DC, Song X, Zhang J, Seth S, Chow CW, Cao Y, Gumbs C, Gold KA, Kalhor N, Little L, Mahadeshwar H, Moran C, Protopopov A, Sun H, Tang J, Wu X, Ye Y, William WN, Lee JJ, Heymach JV, Hong WK, Swisher S, Wistuba II, Futreal PA. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science. 2014 Oct 10; 346(6206):256-9. PMID: 25301631.
      View in: PubMed
    181. Augustyn A, Borromeo M, Wang T, Fujimoto J, Shao C, Dospoy PD, Lee V, Tan C, Sullivan JP, Larsen JE, Girard L, Behrens C, Wistuba II, Xie Y, Cobb MH, Gazdar AF, Johnson JE, Minna JD. ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers. Proc Natl Acad Sci U S A. 2014 Oct 14; 111(41):14788-93. PMID: 25267614.
      View in: PubMed
    182. Weissferdt A, Kalhor N, Liu H, Rodriguez J, Fujimoto J, Tang X, Wistuba II, Moran CA. Thymic neuroendocrine tumors (paraganglioma and carcinoid tumors): a comparative immunohistochemical study of 46 cases. Hum Pathol. 2014 Dec; 45(12):2463-70. PMID: 25294372.
      View in: PubMed
    183. Thunnissen E, Noguchi M, Aisner S, Beasley MB, Brambilla E, Chirieac LR, Chung JH, Dacic S, Geisinger KR, Hirsch FR, Ishikawa Y, Kerr KM, Lantejoul S, Matsuno Y, Minami Y, Moreira AL, Pelosi G, Petersen I, Roggli V, Travis WD, Wistuba I, Yatabe Y, Dziadziuszko R, Witte B, Tsao MS, Nicholson AG. Reproducibility of histopathological diagnosis in poorly differentiated NSCLC: an international multiobserver study. J Thorac Oncol. 2014 Sep; 9(9):1354-62. PMID: 25122431.
      View in: PubMed
    184. Gold KA, Lee JJ, Harun N, Tang X, Price J, Kawedia JD, Tran HT, Erasmus JJ, Blumenschein GR, William WN, Wistuba II, Johnson FM. A phase I/II study combining erlotinib and dasatinib for non-small cell lung cancer. Oncologist. 2014 Oct; 19(10):1040-1. PMID: 25170013.
      View in: PubMed
    185. Quintás-Cardama A, Post SM, Solis LM, Xiong S, Yang P, Chen N, Wistuba II, Killary AM, Lozano G. Loss of the novel tumour suppressor and polarity gene Trim62 (Dear1) synergizes with oncogenic Ras in invasive lung cancer. J Pathol. 2014 Sep; 234(1):108-19. PMID: 24890125.
      View in: PubMed
    186. Stewart DJ, Nunez MI, Jelinek J, Hong D, Gupta S, Aldaz M, Issa JP, Kurzrock R, Wistuba II. Impact of decitabine on immunohistochemistry expression of the putative tumor suppressor genes FHIT, WWOX, FUS1 and PTEN in clinical tumor samples. Clin Epigenetics. 2014; 6(1):13. PMID: 25024751.
      View in: PubMed
    187. Riquelme E, Suraokar MB, Rodriguez J, Mino B, Lin HY, Rice DC, Tsao A, Wistuba II. Frequent coamplification and cooperation between C-MYC and PVT1 oncogenes promote malignant pleural mesothelioma. J Thorac Oncol. 2014 Jul; 9(7):998-1007. PMID: 24926545.
      View in: PubMed
    188. Taguchi A, Taylor AD, Rodriguez J, Celiktas M, Liu H, Ma X, Zhang Q, Wong CH, Chin A, Girard L, Behrens C, Lam WL, Lam S, Minna JD, Wistuba II, Gazdar AF, Hanash SM. A search for novel cancer/testis antigens in lung cancer identifies VCX/Y genes, expanding the repertoire of potential immunotherapeutic targets. Cancer Res. 2014 Sep 01; 74(17):4694-705. PMID: 24970476.
      View in: PubMed
    189. Luo SY, Sit KY, Sihoe AD, Suen WS, Au WK, Tang X, Ma ES, Chan WK, Wistuba II, Minna JD, Tsao GS, Lam DC. Aberrant large tumor suppressor 2 (LATS2) gene expression correlates with EGFR mutation and survival in lung adenocarcinomas. Lung Cancer. 2014 Aug; 85(2):282-92. PMID: 24976335.
      View in: PubMed
    190. Fujimoto J, Wistuba II. Current concepts on the molecular pathology of non-small cell lung carcinoma. Semin Diagn Pathol. 2014 Jul; 31(4):306-13. PMID: 25239274.
      View in: PubMed
    191. Shao C, Sullivan JP, Girard L, Augustyn A, Yenerall P, Rodriguez-Canales J, Liu H, Behrens C, Shay JW, Wistuba II, Minna JD. Essential role of aldehyde dehydrogenase 1A3 for the maintenance of non-small cell lung cancer stem cells is associated with the STAT3 pathway. Clin Cancer Res. 2014 Aug 01; 20(15):4154-66. PMID: 24907115.
      View in: PubMed
    192. Riquelme E, Suraokar M, Behrens C, Lin HY, Girard L, Nilsson MB, Simon G, Wang J, Coombes KR, Lee JJ, Hong WK, Heymach J, Minna JD, Wistuba II. VEGF/VEGFR-2 upregulates EZH2 expression in lung adenocarcinoma cells and EZH2 depletion enhances the response to platinum-based and VEGFR-2-targeted therapy. Clin Cancer Res. 2014 Jul 15; 20(14):3849-61. PMID: 24850841.
      View in: PubMed
    193. Kris MG, Johnson BE, Berry LD, Kwiatkowski DJ, Iafrate AJ, Wistuba II, Varella-Garcia M, Franklin WA, Aronson SL, Su PF, Shyr Y, Camidge DR, Sequist LV, Glisson BS, Khuri FR, Garon EB, Pao W, Rudin C, Schiller J, Haura EB, Socinski M, Shirai K, Chen H, Giaccone G, Ladanyi M, Kugler K, Minna JD, Bunn PA. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014 May 21; 311(19):1998-2006. PMID: 24846037.
      View in: PubMed
    194. Massarelli E, Onn A, Marom EM, Alden CM, Liu DD, Tran HT, Mino B, Wistuba II, Faiz SA, Bashoura L, Eapen GA, Morice RC, Jack Lee J, Hong WK, Herbst RS, Jimenez CA. Vandetanib and indwelling pleural catheter for non-small-cell lung cancer with recurrent malignant pleural effusion. Clin Lung Cancer. 2014 Sep; 15(5):379-86. PMID: 24913066.
      View in: PubMed
    195. Stewart DJ, Nunez MI, Behrens C, Liu D, Lin YH, Lee JJ, Roth J, Heymach J, Swisher SG, Hong WK, Wistuba II. Membrane carbonic anhydrase IX expression and relapse risk in resected stage I-II non-small-cell lung cancer. J Thorac Oncol. 2014 May; 9(5):675-84. PMID: 24662455.
      View in: PubMed
    196. Yang Y, Ahn YH, Chen Y, Tan X, Guo L, Gibbons DL, Ungewiss C, Peng DH, Liu X, Lin SH, Thilaganathan N, Wistuba II, Rodriguez-Canales J, McLendon G, Creighton CJ, Kurie JM. ZEB1 sensitizes lung adenocarcinoma to metastasis suppression by PI3K antagonism. J Clin Invest. 2014 Jun; 124(6):2696-708. PMID: 24762440.
      View in: PubMed
    197. Kim ES, Tang X, Peterson DR, Kilari D, Chow CW, Fujimoto J, Kalhor N, Swisher SG, Stewart DJ, Wistuba II, Siddik ZH. Copper transporter CTR1 expression and tissue platinum concentration in non-small cell lung cancer. Lung Cancer. 2014 Jul; 85(1):88-93. PMID: 24792335.
      View in: PubMed
    198. Seguin L, Kato S, Franovic A, Camargo MF, Lesperance J, Elliott KC, Yebra M, Mielgo A, Lowy AM, Husain H, Cascone T, Diao L, Wang J, Wistuba II, Heymach JV, Lippman SM, Desgrosellier JS, Anand S, Weis SM, Cheresh DA. An integrin ß3-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition. Nat Cell Biol. 2014 May; 16(5):457-68. PMID: 24747441.
      View in: PubMed
    199. Suraokar MB, Nunez MI, Diao L, Chow CW, Kim D, Behrens C, Lin H, Lee S, Raso G, Moran C, Rice D, Mehran R, Lee JJ, Pass HI, Wang J, Momin AA, James BP, Corvalan A, Coombes K, Tsao A, Wistuba II. Expression profiling stratifies mesothelioma tumors and signifies deregulation of spindle checkpoint pathway and microtubule network with therapeutic implications. Ann Oncol. 2014 Jun; 25(6):1184-92. PMID: 24669013.
      View in: PubMed
    200. Kadara H, Fujimoto J, Yoo SY, Maki Y, Gower AC, Kabbout M, Garcia MM, Chow CW, Chu Z, Mendoza G, Shen L, Kalhor N, Hong WK, Moran C, Wang J, Spira A, Coombes KR, Wistuba II. Transcriptomic architecture of the adjacent airway field cancerization in non-small cell lung cancer. J Natl Cancer Inst. 2014 Mar; 106(3):dju004. PMID: 24563515.
      View in: PubMed
    201. Tsao AS, Harun N, Fujimoto J, Devito V, Lee JJ, Kuhn E, Mehran R, Rice D, Moran C, Hong WK, Shen L, Suraokar M, Wistuba I. Elevated PDGFRB gene copy number gain is prognostic for improved survival outcomes in resected malignant pleural mesothelioma. Ann Diagn Pathol. 2014 Jun; 18(3):140-5. PMID: 24747001.
      View in: PubMed
    202. Delgado O, Batten KG, Richardson JA, Xie XJ, Gazdar AF, Kaisani AA, Girard L, Behrens C, Suraokar M, Fasciani G, Wright WE, Story MD, Wistuba II, Minna JD, Shay JW. Radiation-enhanced lung cancer progression in a transgenic mouse model of lung cancer is predictive of outcomes in human lung and breast cancer. Clin Cancer Res. 2014 Mar 15; 20(6):1610-22. PMID: 24486591.
      View in: PubMed
    203. Pajares MJ, Agorreta J, Salvo E, Behrens C, Wistuba II, Montuenga LM, Pio R, Rouzaut A. TGFBI expression is an independent predictor of survival in adjuvant-treated lung squamous cell carcinoma patients. Br J Cancer. 2014 Mar 18; 110(6):1545-51. PMID: 24481402.
      View in: PubMed
    204. Stewart DJ, Nunez MI, Jelinek J, Hong D, Gupta S, Issa JP, Wistuba II, Kurzrock R. Decitabine impact on the endocytosis regulator RhoA, the folate carriers RFC1 and FOLR1, and the glucose transporter GLUT4 in human tumors. Clin Epigenetics. 2014 Jan 09; 6(1):2. PMID: 24401732.
      View in: PubMed
    205. Sourisseau T, Hassan KA, Wistuba I, Penault-Llorca F, Adam J, Deutsch E, Soria JC. Lung cancer stem cell: fancy conceptual model of tumor biology or cornerstone of a forthcoming therapeutic breakthrough? J Thorac Oncol. 2014 Jan; 9(1):7-17. PMID: 24346089.
      View in: PubMed
    206. Kim JS, Kim ES, Liu D, Lee JJ, Solis L, Behrens C, Lippman SM, Hong WK, Wistuba II, Lee HY. Prognostic implications of tumoral expression of insulin like growth factors 1 and 2 in patients with non-small-cell lung cancer. Clin Lung Cancer. 2014 May; 15(3):213-21. PMID: 24485233.
      View in: PubMed
    207. Pop LM, Barman S, Shao C, Poe JC, Venturi GM, Shelton JM, Pop IV, Gerber DE, Girard L, Liu XY, Behrens C, Rodriguez-Canales J, Liu H, Wistuba II, Richardson JA, Minna JD, Tedder TF, Vitetta ES. A reevaluation of CD22 expression in human lung cancer. Cancer Res. 2014 Jan 01; 74(1):263-71. PMID: 24395821.
      View in: PubMed
    208. Shames DS, Wistuba II. The evolving genomic classification of lung cancer. J Pathol. 2014 Jan; 232(2):121-33. PMID: 24114583.
      View in: PubMed
    209. Tsao AS, Harun N, Lee JJ, Heymach J, Pisters K, Hong WK, Fujimoto J, Wistuba I. Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemonaive patients with unresectable malignant pleural mesothelioma. Clin Lung Cancer. 2014 May; 15(3):197-201. PMID: 24492162.
      View in: PubMed
    210. Gold KA, Kim ES, Liu DD, Yuan P, Behrens C, Solis LM, Kadara H, Rice DC, Wistuba II, Swisher SG, Hofstetter WL, Lee JJ, Hong WK. Prediction of survival in resected non-small cell lung cancer using a protein expression-based risk model: implications for personalized chemoprevention and therapy. Clin Cancer Res. 2014 Apr 01; 20(7):1946-54. PMID: 24366692.
      View in: PubMed
    211. Cumberbatch M, Tang X, Beran G, Eckersley S, Wang X, Ellston RP, Dearden S, Cosulich S, Smith PD, Behrens C, Kim ES, Su X, Fan S, Gray N, Blowers DP, Wistuba II, Womack C. Identification of a subset of human non-small cell lung cancer patients with high PI3Kß and low PTEN expression, more prevalent in squamous cell carcinoma. Clin Cancer Res. 2014 Feb 01; 20(3):595-603. PMID: 24284056.
      View in: PubMed
    212. Luis-Ravelo D, Antón I, Zandueta C, Valencia K, Pajares MJ, Agorreta J, Montuenga L, Vicent S, Wistuba II, De Las Rivas J, Lecanda F. RHOB influences lung adenocarcinoma metastasis and resistance in a host-sensitive manner. Mol Oncol. 2014 Mar; 8(2):196-206. PMID: 24321314.
      View in: PubMed
    213. Blumenschein GR, Saintigny P, Liu S, Kim ES, Tsao AS, Herbst RS, Alden C, Lee JJ, Tang X, Stewart DJ, Kies MS, Fossella FV, Tran HT, Mao L, Hicks ME, Erasmus J, Gupta S, Girard L, Peyton M, Diao L, Wang J, Davis SE, Minna JD, Wistuba I, Hong WK, Heymach JV, Lippman SM. Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial. Clin Cancer Res. 2013 Dec 15; 19(24):6967-75. PMID: 24166906.
      View in: PubMed
    214. Behrens C, Solis LM, Lin H, Yuan P, Tang X, Kadara H, Riquelme E, Galindo H, Moran CA, Kalhor N, Swisher SG, Simon GR, Stewart DJ, Lee JJ, Wistuba II. EZH2 protein expression associates with the early pathogenesis, tumor progression, and prognosis of non-small cell lung carcinoma. Clin Cancer Res. 2013 Dec 01; 19(23):6556-65. PMID: 24097870.
      View in: PubMed
    215. Wistuba II, Behrens C, Lombardi F, Wagner S, Fujimoto J, Raso MG, Spaggiari L, Galetta D, Riley R, Hughes E, Reid J, Sangale Z, Swisher SG, Kalhor N, Moran CA, Gutin A, Lanchbury JS, Barberis M, Kim ES. Validation of a proliferation-based expression signature as prognostic marker in early stage lung adenocarcinoma. Clin Cancer Res. 2013 Nov 15; 19(22):6261-71. PMID: 24048333.
      View in: PubMed
    216. Du L, Zhao Z, Ma X, Hsiao TH, Chen Y, Young E, Suraokar M, Wistuba I, Minna JD, Pertsemlidis A. miR-93-directed downregulation of DAB2 defines a novel oncogenic pathway in lung cancer. Oncogene. 2014 Aug 21; 33(34):4307-15. PMID: 24037530.
      View in: PubMed
    217. Osborne JK, Larsen JE, Gonzales JX, Shames DS, Sato M, Wistuba II, Girard L, Minna JD, Cobb MH. NeuroD1 regulation of migration accompanies the differential sensitivity of neuroendocrine carcinomas to TrkB inhibition. Oncogenesis. 2013 Aug 19; 2:e63. PMID: 23958853.
      View in: PubMed
    218. Chang X, Izumchenko E, Solis LM, Kim MS, Chatterjee A, Ling S, Monitto CL, Harari PM, Hidalgo M, Goodman SN, Wistuba II, Bedi A, Sidransky D. The relative expression of Mig6 and EGFR is associated with resistance to EGFR kinase inhibitors. PLoS One. 2013; 8(7):e68966. PMID: 23935914.
      View in: PubMed
    219. Chen N, Balasenthil S, Reuther J, Frayna A, Wang Y, Chandler DS, Abruzzo LV, Rashid A, Rodriguez J, Lozano G, Cao Y, Lokken E, Chen J, Frazier ML, Sahin AA, Wistuba II, Sen S, Lott ST, Killary AM. DEAR1 is a chromosome 1p35 tumor suppressor and master regulator of TGF-ß-driven epithelial-mesenchymal transition. Cancer Discov. 2013 Oct; 3(10):1172-89. PMID: 23838884.
      View in: PubMed
    220. Weissferdt A, Tang X, Wistuba II, Moran CA. Comparative immunohistochemical analysis of pulmonary and thymic neuroendocrine carcinomas using PAX8 and TTF-1. Mod Pathol. 2013 Dec; 26(12):1554-60. PMID: 23787439.
      View in: PubMed
    221. Vanhecke E, Valent A, Tang X, Vielh P, Friboulet L, Tang T, Goubar A, Li Y, Robin A, Behrens C, Commo F, Validire P, André F, Wistuba II, Soria JC, Olaussen KA. 19q13-ERCC1 gene copy number increase in non--small-cell lung cancer. Clin Lung Cancer. 2013 Sep; 14(5):549-57. PMID: 23773262.
      View in: PubMed
    222. Baird BN, Schliekelman MJ, Ahn YH, Chen Y, Roybal JD, Gill BJ, Mishra DK, Erez B, O'Reilly M, Yang Y, Patel M, Liu X, Thilaganathan N, Larina IV, Dickinson ME, West JL, Gibbons DL, Liu DD, Kim MP, Hicks JM, Wistuba II, Hanash SM, Kurie JM. Fibulin-2 is a driver of malignant progression in lung adenocarcinoma. PLoS One. 2013; 8(6):e67054. PMID: 23785517.
      View in: PubMed
    223. Liu Y, Marks K, Cowley GS, Carretero J, Liu Q, Nieland TJ, Xu C, Cohoon TJ, Gao P, Zhang Y, Chen Z, Altabef AB, Tchaicha JH, Wang X, Choe S, Driggers EM, Zhang J, Bailey ST, Sharpless NE, Hayes DN, Patel NM, Janne PA, Bardeesy N, Engelman JA, Manning BD, Shaw RJ, Asara JM, Scully R, Kimmelman A, Byers LA, Gibbons DL, Wistuba II, Heymach JV, Kwiatkowski DJ, Kim WY, Kung AL, Gray NS, Root DE, Cantley LC, Wong KK. Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer. Cancer Discov. 2013 Aug; 3(8):870-9. PMID: 23715154.
      View in: PubMed
    224. Ahn J, Yuan Y, Parmigiani G, Suraokar MB, Diao L, Wistuba II, Wang W. DeMix: deconvolution for mixed cancer transcriptomes using raw measured data. Bioinformatics. 2013 Aug 01; 29(15):1865-71. PMID: 23712657.
      View in: PubMed
    225. Kabbout M, Garcia MM, Fujimoto J, Liu DD, Woods D, Chow CW, Mendoza G, Momin AA, James BP, Solis L, Behrens C, Lee JJ, Wistuba II, Kadara H. ETS2 mediated tumor suppressive function and MET oncogene inhibition in human non-small cell lung cancer. Clin Cancer Res. 2013 Jul 01; 19(13):3383-95. PMID: 23659968.
      View in: PubMed
    226. Tsao AS, Liu S, Lee JJ, Alden CM, Blumenschein GR, Herbst R, Davis SE, Kim E, Lippman S, Heymach J, Tran H, Tang X, Wistuba I, Hong WK. Clinical and biomarker outcomes of the phase II vandetanib study from the BATTLE trial. J Thorac Oncol. 2013 May; 8(5):658-61. PMID: 23584298.
      View in: PubMed
    227. Osborne JK, Larsen JE, Shields MD, Gonzales JX, Shames DS, Sato M, Kulkarni A, Wistuba II, Girard L, Minna JD, Cobb MH. NeuroD1 regulates survival and migration of neuroendocrine lung carcinomas via signaling molecules TrkB and NCAM. Proc Natl Acad Sci U S A. 2013 Apr 16; 110(16):6524-9. PMID: 23553831.
      View in: PubMed
    228. Tam AL, Kim ES, Lee JJ, Ensor JE, Hicks ME, Tang X, Blumenschein GR, Alden CM, Erasmus JJ, Tsao A, Lippman SM, Hong WK, Wistuba II, Gupta S. Feasibility of image-guided transthoracic core-needle biopsy in the BATTLE lung trial. J Thorac Oncol. 2013 Apr; 8(4):436-42. PMID: 23442309.
      View in: PubMed
    229. Guo C, Shao R, Correa AM, Behrens C, Johnson FM, Raso MG, Prudkin L, Solis LM, Nunez MI, Fang B, Roth JA, Wistuba II, Swisher SG, Lin T, Pataer A. Prognostic significance of combinations of RNA-dependent protein kinase and EphA2 biomarkers for NSCLC. J Thorac Oncol. 2013 Mar; 8(3):301-8. PMID: 23370317.
      View in: PubMed
    230. Kalhor N, Wistuba II. Perfecting the fine-needle aspirate cell block. Cancer Cytopathol. 2013 Mar; 121(3):109-10. PMID: 23614136.
      View in: PubMed
    231. Sato M, Larsen JE, Lee W, Sun H, Shames DS, Dalvi MP, Ramirez RD, Tang H, DiMaio JM, Gao B, Xie Y, Wistuba II, Gazdar AF, Shay JW, Minna JD. Human lung epithelial cells progressed to malignancy through specific oncogenic manipulations. Mol Cancer Res. 2013 Jun; 11(6):638-50. PMID: 23449933.
      View in: PubMed
    232. Massarelli E, Johnson FM, Erickson HS, Wistuba II, Papadimitrakopoulou V. Uncommon epidermal growth factor receptor mutations in non-small cell lung cancer and their mechanisms of EGFR tyrosine kinase inhibitors sensitivity and resistance. Lung Cancer. 2013 Jun; 80(3):235-41. PMID: 23485129.
      View in: PubMed
    233. William WN, Pataer A, Kalhor N, Correa AM, Rice DC, Wistuba II, Heymach J, Lee JJ, Kim ES, Munden R, Gold KA, Papadimitrakopoulou V, Swisher SG, Erasmus JJ. Computed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non-small-cell lung cancer after neoadjuvant chemotherapy. J Thorac Oncol. 2013 Feb; 8(2):222-8. PMID: 23287849.
      View in: PubMed
    234. Tang H, Xiao G, Behrens C, Schiller J, Allen J, Chow CW, Suraokar M, Corvalan A, Mao J, White MA, Wistuba II, Minna JD, Xie Y. A 12-gene set predicts survival benefits from adjuvant chemotherapy in non-small cell lung cancer patients. Clin Cancer Res. 2013 Mar 15; 19(6):1577-86. PMID: 23357979.
      View in: PubMed
    235. Konstantinidou G, Ramadori G, Torti F, Kangasniemi K, Ramirez RE, Cai Y, Behrens C, Dellinger MT, Brekken RA, Wistuba II, Heguy A, Teruya-Feldstein J, Scaglioni PP. RHOA-FAK is a required signaling axis for the maintenance of KRAS-driven lung adenocarcinomas. Cancer Discov. 2013 Apr; 3(4):444-57. PMID: 23358651.
      View in: PubMed
    236. Galluzzi L, Goubar A, Olaussen KA, Vitale I, Senovilla L, Michels J, Robin A, Dorvault N, Besse B, Validire P, Fouret P, Behrens C, Wistuba II, Soria JC, Kroemer G. Prognostic value of LIPC in non-small cell lung carcinoma. Cell Cycle. 2013 Feb 15; 12(4):647-54. PMID: 23343765.
      View in: PubMed
    237. Gold KA, Kim ES, Wistuba II, Hong WK. Personalizing lung cancer prevention through a reverse migration strategy. Top Curr Chem. 2013; 329:221-40. PMID: 22752582.
      View in: PubMed
    238. Mao M, Tian F, Mariadason JM, Tsao CC, Lemos R, Dayyani F, Gopal YN, Jiang ZQ, Wistuba II, Tang XM, Bornman WG, Bollag G, Mills GB, Powis G, Desai J, Gallick GE, Davies MA, Kopetz S. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin Cancer Res. 2013 Feb 01; 19(3):657-67. PMID: 23251002.
      View in: PubMed
    239. Yan W, Shih J, Rodriguez-Canales J, Tangrea MA, Player A, Diao L, Hu N, Goldstein AM, Wang J, Taylor PR, Lippman SM, Wistuba II, Emmert-Buck MR, Erickson HS. Three-dimensional mRNA measurements reveal minimal regional heterogeneity in esophageal squamous cell carcinoma. Am J Pathol. 2013 Feb; 182(2):529-39. PMID: 23219752.
      View in: PubMed
    240. Fujimoto J, Kadara H, Garcia MM, Kabbout M, Behrens C, Liu DD, Lee JJ, Solis LM, Kim ES, Kalhor N, Moran C, Sharafkhaneh A, Lotan R, Wistuba II. G-protein coupled receptor family C, group 5, member A (GPRC5A) expression is decreased in the adjacent field and normal bronchial epithelia of patients with chronic obstructive pulmonary disease and non-small-cell lung cancer. J Thorac Oncol. 2012 Dec; 7(12):1747-1754. PMID: 23154545.
      View in: PubMed
    241. Saintigny P, Massarelli E, Lin S, Ahn YH, Chen Y, Goswami S, Erez B, O'Reilly MS, Liu D, Lee JJ, Zhang L, Ping Y, Behrens C, Solis Soto LM, Heymach JV, Kim ES, Herbst RS, Lippman SM, Wistuba II, Hong WK, Kurie JM, Koo JS. CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma. Cancer Res. 2013 Jan 15; 73(2):571-82. PMID: 23204236.
      View in: PubMed
    242. Tsao AS, Liu S, Lee JJ, Alden C, Blumenschein G, Herbst R, Davis SE, Kim E, Lippman S, Stewart D, Tang XM, Wistuba I, Hong WK. Clinical outcomes and biomarker profiles of elderly pretreated NSCLC patients from the BATTLE trial. J Thorac Oncol. 2012 Nov; 7(11):1645-52. PMID: 23059780.
      View in: PubMed
    243. Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, Shen L, Fan Y, Giri U, Tumula PK, Nilsson MB, Gudikote J, Tran H, Cardnell RJ, Bearss DJ, Warner SL, Foulks JM, Kanner SB, Gandhi V, Krett N, Rosen ST, Kim ES, Herbst RS, Blumenschein GR, Lee JJ, Lippman SM, Ang KK, Mills GB, Hong WK, Weinstein JN, Wistuba II, Coombes KR, Minna JD, Heymach JV. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res. 2013 Jan 01; 19(1):279-90. PMID: 23091115.
      View in: PubMed
    244. Kadara H, Shen L, Fujimoto J, Saintigny P, Chow CW, Lang W, Chu Z, Garcia M, Kabbout M, Fan YH, Behrens C, Liu DA, Mao L, Lee JJ, Gold KA, Wang J, Coombes KR, Kim ES, Hong WK, Wistuba II. Characterizing the molecular spatial and temporal field of injury in early-stage smoker non-small cell lung cancer patients after definitive surgery by expression profiling. Cancer Prev Res (Phila). 2013 Jan; 6(1):8-17. PMID: 23087048.
      View in: PubMed
    245. Yang P, Cartwright C, Efuet E, Hamilton SR, Wistuba II, Menter D, Addington C, Shureiqi I, Newman RA. Cellular location and expression of Na+, K+ -ATPase a subunits affect the anti-proliferative activity of oleandrin. Mol Carcinog. 2014 Apr; 53(4):253-63. PMID: 23073998.
      View in: PubMed
    246. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger K, Yatabe Y, Ishikawa Y, Wistuba I, Flieder DB, Franklin W, Gazdar A, Hasleton PS, Henderson DW, Kerr KM, Nakatani Y, Petersen I, Roggli V, Thunnissen E, Tsao M. Diagnosis of lung adenocarcinoma in resected specimens: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification. Arch Pathol Lab Med. 2013 May; 137(5):685-705. PMID: 22913371.
      View in: PubMed
    247. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger K, Yatabe Y, Ishikawa Y, Wistuba I, Flieder DB, Franklin W, Gazdar A, Hasleton PS, Henderson DW, Kerr KM, Petersen I, Roggli V, Thunnissen E, Tsao M. Diagnosis of lung cancer in small biopsies and cytology: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification. Arch Pathol Lab Med. 2013 May; 137(5):668-84. PMID: 22970842.
      View in: PubMed
    248. Byers LA, Wang J, Nilsson MB, Fujimoto J, Saintigny P, Yordy J, Giri U, Peyton M, Fan YH, Diao L, Masrorpour F, Shen L, Liu W, Duchemann B, Tumula P, Bhardwaj V, Welsh J, Weber S, Glisson BS, Kalhor N, Wistuba II, Girard L, Lippman SM, Mills GB, Coombes KR, Weinstein JN, Minna JD, Heymach JV. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov. 2012 Sep; 2(9):798-811. PMID: 22961666.
      View in: PubMed
    249. Weissferdt A, Wistuba II, Moran CA. Molecular aspects of thymic carcinoma. Lung Cancer. 2012 Nov; 78(2):127-32. PMID: 22921473.
      View in: PubMed
    250. Kim ES, Lee JJ, He G, Chow CW, Fujimoto J, Kalhor N, Swisher SG, Wistuba II, Stewart DJ, Siddik ZH. Tissue platinum concentration and tumor response in non-small-cell lung cancer. J Clin Oncol. 2012 Sep 20; 30(27):3345-52. PMID: 22891266.
      View in: PubMed
    251. Galluzzi L, Vitale I, Senovilla L, Olaussen KA, Pinna G, Eisenberg T, Goubar A, Martins I, Michels J, Kratassiouk G, Carmona-Gutierrez D, Scoazec M, Vacchelli E, Schlemmer F, Kepp O, Shen S, Tailler M, Niso-Santano M, Morselli E, Criollo A, Adjemian S, Jemaà M, Chaba K, Pailleret C, Michaud M, Pietrocola F, Tajeddine N, de La Motte Rouge T, Araujo N, Morozova N, Robert T, Ripoche H, Commo F, Besse B, Validire P, Fouret P, Robin A, Dorvault N, Girard P, Gouy S, Pautier P, Jägemann N, Nickel AC, Marsili S, Paccard C, Servant N, Hupé P, Behrens C, Behnam-Motlagh P, Kohno K, Cremer I, Damotte D, Alifano M, Midttun O, Ueland PM, Lazar V, Dessen P, Zischka H, Chatelut E, Castedo M, Madeo F, Barillot E, Thomale J, Wistuba II, Sautès-Fridman C, Zitvogel L, Soria JC, Harel-Bellan A, Kroemer G. Prognostic impact of vitamin B6 metabolism in lung cancer. Cell Rep. 2012 Aug 30; 2(2):257-69. PMID: 22854025.
      View in: PubMed
    252. Thunnissen E, Beasley MB, Borczuk AC, Brambilla E, Chirieac LR, Dacic S, Flieder D, Gazdar A, Geisinger K, Hasleton P, Ishikawa Y, Kerr KM, Lantejoul S, Matsuno Y, Minami Y, Moreira AL, Motoi N, Nicholson AG, Noguchi M, Nonaka D, Pelosi G, Petersen I, Rekhtman N, Roggli V, Travis WD, Tsao MS, Wistuba I, Xu H, Yatabe Y, Zakowski M, Witte B, Kuik DJ. Reproducibility of histopathological subtypes and invasion in pulmonary adenocarcinoma. An international interobserver study. Mod Pathol. 2012 Dec; 25(12):1574-83. PMID: 22814311.
      View in: PubMed
    253. Saintigny P, Peng S, Zhang L, Sen B, Wistuba II, Lippman SM, Girard L, Minna JD, Heymach JV, Johnson FM. Global evaluation of Eph receptors and ephrins in lung adenocarcinomas identifies EphA4 as an inhibitor of cell migration and invasion. Mol Cancer Ther. 2012 Sep; 11(9):2021-32. PMID: 22807579.
      View in: PubMed
    254. Tsuta K, Wistuba II, Moran CA. Differential expression of somatostatin receptors 1-5 in neuroendocrine carcinoma of the lung. Pathol Res Pract. 2012 Aug 15; 208(8):470-4. PMID: 22770972.
      View in: PubMed
    255. Weissferdt A, Lin H, Woods D, Tang X, Fujimoto J, Wistuba II, Moran CA. HER family receptor and ligand status in thymic carcinoma. Lung Cancer. 2012 Sep; 77(3):515-21. PMID: 22726920.
      View in: PubMed
    256. Du L, Subauste MC, DeSevo C, Zhao Z, Baker M, Borkowski R, Schageman JJ, Greer R, Yang CR, Suraokar M, Wistuba II, Gazdar AF, Minna JD, Pertsemlidis A. miR-337-3p and its targets STAT3 and RAP1A modulate taxane sensitivity in non-small cell lung cancers. PLoS One. 2012; 7(6):e39167. PMID: 22723956.
      View in: PubMed
    257. Jeong Y, Xie Y, Lee W, Bookout AL, Girard L, Raso G, Behrens C, Wistuba II, Gadzar AF, Minna JD, Mangelsdorf DJ. Research resource: Diagnostic and therapeutic potential of nuclear receptor expression in lung cancer. Mol Endocrinol. 2012 Aug; 26(8):1443-54. PMID: 22700587.
      View in: PubMed
    258. Sen B, Peng S, Tang X, Erickson HS, Galindo H, Mazumdar T, Stewart DJ, Wistuba I, Johnson FM. Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib. Sci Transl Med. 2012 May 30; 4(136):136ra70. PMID: 22649091.
      View in: PubMed
    259. Lockwood WW, Wilson IM, Coe BP, Chari R, Pikor LA, Thu KL, Solis LM, Nunez MI, Behrens C, Yee J, English J, Murray N, Tsao MS, Minna JD, Gazdar AF, Wistuba II, MacAulay CE, Lam S, Lam WL. Divergent genomic and epigenomic landscapes of lung cancer subtypes underscore the selection of different oncogenic pathways during tumor development. PLoS One. 2012; 7(5):e37775. PMID: 22629454.
      View in: PubMed
    260. Pataer A, Kalhor N, Correa AM, Raso MG, Erasmus JJ, Kim ES, Behrens C, Lee JJ, Roth JA, Stewart DJ, Vaporciyan AA, Wistuba II, Swisher SG. Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy. J Thorac Oncol. 2012 May; 7(5):825-32. PMID: 22481232.
      View in: PubMed
    261. Kadara H, Wistuba II. Field cancerization in non-small cell lung cancer: implications in disease pathogenesis. Proc Am Thorac Soc. 2012 May; 9(2):38-42. PMID: 22550239.
      View in: PubMed
    262. Nunez MI, Behrens C, Woods DM, Lin H, Suraokar M, Kadara H, Hofstetter W, Kalhor N, Lee JJ, Franklin W, Stewart DJ, Wistuba II. High expression of folate receptor alpha in lung cancer correlates with adenocarcinoma histology and EGFR [corrected] mutation. J Thorac Oncol. 2012 May; 7(5):833-40. PMID: 22729036.
      View in: PubMed
    263. Lu C, Stewart DJ, Lee JJ, Ji L, Ramesh R, Jayachandran G, Nunez MI, Wistuba II, Erasmus JJ, Hicks ME, Grimm EA, Reuben JM, Baladandayuthapani V, Templeton NS, McMannis JD, Roth JA. Phase I clinical trial of systemically administered TUSC2(FUS1)-nanoparticles mediating functional gene transfer in humans. PLoS One. 2012; 7(4):e34833. PMID: 22558101.
      View in: PubMed
    264. Long W, Foulds CE, Qin J, Liu J, Ding C, Lonard DM, Solis LM, Wistuba II, Qin J, Tsai SY, Tsai MJ, O'Malley BW. ERK3 signals through SRC-3 coactivator to promote human lung cancer cell invasion. J Clin Invest. 2012 May; 122(5):1869-80. PMID: 22505454.
      View in: PubMed
    265. Gold KA, Wistuba II, Kim ES. New strategies in squamous cell carcinoma of the lung: identification of tumor drivers to personalize therapy. Clin Cancer Res. 2012 Jun 01; 18(11):3002-7. PMID: 22461458.
      View in: PubMed
    266. Antón I, Molina E, Luis-Ravelo D, Zandueta C, Valencia K, Ormazabal C, Martínez-Canarias S, Perurena N, Pajares MJ, Agorreta J, Montuenga LM, Segura V, Wistuba II, De Las Rivas J, Hermida J, Lecanda F. Receptor of activated protein C promotes metastasis and correlates with clinical outcome in lung adenocarcinoma. Am J Respir Crit Care Med. 2012 Jul 01; 186(1):96-105. PMID: 22461368.
      View in: PubMed
    267. Vishwamitra D, Li Y, Wilson D, Manshouri R, Curry CV, Shi B, Tang XM, Sheehan AM, Wistuba II, Shi P, Amin HM. MicroRNA 96 is a post-transcriptional suppressor of anaplastic lymphoma kinase expression. Am J Pathol. 2012 May; 180(5):1772-80. PMID: 22414602.
      View in: PubMed
    268. Moran CA, Weissferdt A, Kalhor N, Solis LM, Behrens C, Wistuba II, Suster S. Thymomas I: a clinicopathologic correlation of 250 cases with emphasis on the World Health Organization schema. Am J Clin Pathol. 2012 Mar; 137(3):444-50. PMID: 22338057.
      View in: PubMed
    269. Kim WY, Prudkin L, Feng L, Kim ES, Hennessy B, Lee JS, Lee JJ, Glisson B, Lippman SM, Wistuba II, Hong WK, Lee HY. Epidermal growth factor receptor and K-Ras mutations and resistance of lung cancer to insulin-like growth factor 1 receptor tyrosine kinase inhibitors. Cancer. 2012 Aug 15; 118(16):3993-4003. PMID: 22359227.
      View in: PubMed
    270. Pajares MJ, Agorreta J, Larrayoz M, Vesin A, Ezponda T, Zudaire I, Torre W, Lozano MD, Brambilla E, Brambilla C, Wistuba II, Behrens C, Timsit JF, Pio R, Field JK, Montuenga LM. Expression of tumor-derived vascular endothelial growth factor and its receptors is associated with outcome in early squamous cell carcinoma of the lung. J Clin Oncol. 2012 Apr 01; 30(10):1129-36. PMID: 22355056.
      View in: PubMed
    271. He Y, Zhou Z, Hofstetter WL, Zhou Y, Hu W, Guo C, Wang L, Guo W, Pataer A, Correa AM, Lu Y, Wang J, Diao L, Byers LA, Wistuba II, Roth JA, Swisher SG, Heymach JV, Fang B. Aberrant expression of proteins involved in signal transduction and DNA repair pathways in lung cancer and their association with clinical parameters. PLoS One. 2012; 7(2):e31087. PMID: 22348039.
      View in: PubMed
    272. Takahashi O, Komaki R, Smith PD, Jürgensmeier JM, Ryan A, Bekele BN, Wistuba II, Jacoby JJ, Korshunova MV, Biernacka A, Erez B, Hosho K, Herbst RS, O'Reilly MS. Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis. Clin Cancer Res. 2012 Mar 15; 18(6):1641-54. PMID: 22275507.
      View in: PubMed
    273. Lewis CM, Glisson BS, Feng L, Wan F, Tang X, Wistuba II, El-Naggar AK, Rosenthal DI, Chambers MS, Lustig RA, Weber RS. A phase II study of gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck. Clin Cancer Res. 2012 Mar 01; 18(5):1435-46. PMID: 22261807.
      View in: PubMed
    274. Ihle NT, Byers LA, Kim ES, Saintigny P, Lee JJ, Blumenschein GR, Tsao A, Liu S, Larsen JE, Wang J, Diao L, Coombes KR, Chen L, Zhang S, Abdelmelek MF, Tang X, Papadimitrakopoulou V, Minna JD, Lippman SM, Hong WK, Herbst RS, Wistuba II, Heymach JV, Powis G. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst. 2012 Feb 08; 104(3):228-39. PMID: 22247021.
      View in: PubMed
    275. Kadara H, Kabbout M, Wistuba II. Pulmonary adenocarcinoma: a renewed entity in 2011. Respirology. 2012 Jan; 17(1):50-65. PMID: 22040022.
      View in: PubMed
    276. Wistuba II. Molecular testing of non-small cell lung carcinoma biopsy and cytology specimens. Am Soc Clin Oncol Educ Book. 2012; 459-64. PMID: 24451780.
      View in: PubMed
    277. Tsao AS, Liu S, Fujimoto J, Wistuba II, Lee JJ, Marom EM, Charnsangavej C, Fossella FV, Tran HT, Blumenschein GR, Papadimitrakopoulou V, Kies MS, Hong WK, Stewart DJ. Phase II trials of imatinib mesylate and docetaxel in patients with metastatic non-small cell lung cancer and head and neck squamous cell carcinoma. J Thorac Oncol. 2011 Dec; 6(12):2104-11. PMID: 21892101.
      View in: PubMed
    278. Sen B, Peng S, Woods DM, Wistuba I, Bell D, El-Naggar AK, Lai SY, Johnson FM. STAT5A-mediated SOCS2 expression regulates Jak2 and STAT3 activity following c-Src inhibition in head and neck squamous carcinoma. Clin Cancer Res. 2012 Jan 01; 18(1):127-39. PMID: 22090359.
      View in: PubMed
    279. He Y, Correa AM, Raso MG, Hofstetter WL, Fang B, Behrens C, Roth JA, Zhou Y, Yu L, Wistuba II, Swisher SG, Pataer A. The role of PKR/eIF2a signaling pathway in prognosis of non-small cell lung cancer. PLoS One. 2011; 6(11):e24855. PMID: 22102852.
      View in: PubMed
    280. Solis LM, Behrens C, Raso MG, Lin HY, Kadara H, Yuan P, Galindo H, Tang X, Lee JJ, Kalhor N, Wistuba II, Moran CA. Histologic patterns and molecular characteristics of lung adenocarcinoma associated with clinical outcome. Cancer. 2012 Jun 01; 118(11):2889-99. PMID: 22020674.
      View in: PubMed
    281. Zhang YA, Maitra A, Hsieh JT, Rudin CM, Peacock CD, Karikari C, Brekken RA, Stastny V, Gao B, Girard L, Wistuba I, Frenkel E, Minna JD, Gazdar AF. Frequent detection of infectious xenotropic murine leukemia virus (XMLV) in human cultures established from mouse xenografts. Cancer Biol Ther. 2011 Oct 01; 12(7):617-28. PMID: 21750403.
      View in: PubMed
    282. Kim JS, Kim ES, Liu D, Lee JJ, Solis L, Behrens C, Lippman SM, Hong WK, Wistuba II, Lee HY. Prognostic impact of insulin receptor expression on survival of patients with nonsmall cell lung cancer. Cancer. 2012 May 01; 118(9):2454-65. PMID: 21952750.
      View in: PubMed
    283. Ahn YH, Yang Y, Gibbons DL, Creighton CJ, Yang F, Wistuba II, Lin W, Thilaganathan N, Alvarez CA, Roybal J, Goldsmith EJ, Tournier C, Kurie JM. Map2k4 functions as a tumor suppressor in lung adenocarcinoma and inhibits tumor cell invasion by decreasing peroxisome proliferator-activated receptor ?2 expression. Mol Cell Biol. 2011 Nov; 31(21):4270-85. PMID: 21896780.
      View in: PubMed
    284. Kim MP, Chen Y, Bekele BN, Lopez A, Khanna A, Chen JQ, Spitz MR, Behrens C, Solis L, Wismach M, Ji L, Wistuba II, Roth JA, Katz RL. Activating enhancer-binding protein-2ß nucleolar localization predicts poor survival after stage I non-small cell lung cancer resection. Ann Thorac Surg. 2011 Sep; 92(3):1044-50. PMID: 21871297.
      View in: PubMed
    285. Tsuta K, Kalhor N, Wistuba II, Moran CA. Clinicopathological and immunohistochemical analysis of spindle-cell carcinoid tumour of the lung. Histopathology. 2011 Sep; 59(3):526-36. PMID: 22034892.
      View in: PubMed
    286. Moussalli MJ, Wu Y, Zuo X, Yang XL, Wistuba II, Raso MG, Morris JS, Bowser JL, Minna JD, Lotan R, Shureiqi I. Mechanistic contribution of ubiquitous 15-lipoxygenase-1 expression loss in cancer cells to terminal cell differentiation evasion. Cancer Prev Res (Phila). 2011 Dec; 4(12):1961-72. PMID: 21881028.
      View in: PubMed
    287. Tsuta K, Liu DC, Kalhor N, Wistuba II, Moran CA. Using the mitosis-specific marker anti-phosphohistone H3 to assess mitosis in pulmonary neuroendocrine carcinomas. Am J Clin Pathol. 2011 Aug; 136(2):252-9. PMID: 21757598.
      View in: PubMed
    288. Xie Y, Xiao G, Coombes KR, Behrens C, Solis LM, Raso G, Girard L, Erickson HS, Roth J, Heymach JV, Moran C, Danenberg K, Minna JD, Wistuba II. Robust gene expression signature from formalin-fixed paraffin-embedded samples predicts prognosis of non-small-cell lung cancer patients. Clin Cancer Res. 2011 Sep 01; 17(17):5705-14. PMID: 21742808.
      View in: PubMed
    289. Gold KA, Kim ES, Lee JJ, Wistuba II, Farhangfar CJ, Hong WK. The BATTLE to personalize lung cancer prevention through reverse migration. Cancer Prev Res (Phila). 2011 Jul; 4(7):962-72. PMID: 21733820.
      View in: PubMed
    290. Yang F, Tang X, Riquelme E, Behrens C, Nilsson MB, Giri U, Varella-Garcia M, Byers LA, Lin HY, Wang J, Raso MG, Girard L, Coombes K, Lee JJ, Herbst RS, Minna JD, Heymach JV, Wistuba II. Increased VEGFR-2 gene copy is associated with chemoresistance and shorter survival in patients with non-small-cell lung carcinoma who receive adjuvant chemotherapy. Cancer Res. 2011 Aug 15; 71(16):5512-21. PMID: 21724587.
      View in: PubMed
    291. Chen YJ, Huang WC, Wei YL, Hsu SC, Yuan P, Lin HY, Wistuba II, Lee JJ, Yen CJ, Su WC, Chang KY, Chang WC, Chou TC, Chou CK, Tsai CH, Hung MC. Elevated BCRP/ABCG2 expression confers acquired resistance to gefitinib in wild-type EGFR-expressing cells. PLoS One. 2011; 6(6):e21428. PMID: 21731744.
      View in: PubMed
    292. Kim ES, Lee JJ, Wistuba II. Cotargeting cyclin D1 starts a new chapter in lung cancer prevention and therapy. Cancer Prev Res (Phila). 2011 Jun; 4(6):779-82. PMID: 21636543.
      View in: PubMed
    293. Kim ES, Herbst RS, Wistuba II, Lee JJ, Blumenschein GR, Tsao A, Stewart DJ, Hicks ME, Erasmus J, Gupta S, Alden CM, Liu S, Tang X, Khuri FR, Tran HT, Johnson BE, Heymach JV, Mao L, Fossella F, Kies MS, Papadimitrakopoulou V, Davis SE, Lippman SM, Hong WK. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov. 2011 Jun; 1(1):44-53. PMID: 22586319.
      View in: PubMed
    294. Tsao AS, Wei W, Kuhn E, Spencer L, Solis LM, Suraokar M, Lee JJ, Hong WK, Wistuba II. Immunohistochemical overexpression of platelet-derived growth factor receptor-beta (PDGFR-ß) is associated with PDGFRB gene copy number gain in sarcomatoid non-small-cell lung cancer. Clin Lung Cancer. 2011 Nov; 12(6):369-74. PMID: 21729646.
      View in: PubMed
    295. Damelin M, Geles KG, Follettie MT, Yuan P, Baxter M, Golas J, DiJoseph JF, Karnoub M, Huang S, Diesl V, Behrens C, Choe SE, Rios C, Gruzas J, Sridharan L, Dougher M, Kunz A, Hamann PR, Evans D, Armellino D, Khandke K, Marquette K, Tchistiakova L, Boghaert ER, Abraham RT, Wistuba II, Zhou BB. Delineation of a cellular hierarchy in lung cancer reveals an oncofetal antigen expressed on tumor-initiating cells. Cancer Res. 2011 Jun 15; 71(12):4236-46. PMID: 21540235.
      View in: PubMed
    296. Ponz-Sarvisé M, Nguewa PA, Pajares MJ, Agorreta J, Lozano MD, Redrado M, Pio R, Behrens C, Wistuba II, García-Franco CE, García-Foncillas J, Montuenga LM, Calvo A, Gil-Bazo I. Inhibitor of differentiation-1 as a novel prognostic factor in NSCLC patients with adenocarcinoma histology and its potential contribution to therapy resistance. Clin Cancer Res. 2011 Jun 15; 17(12):4155-66. PMID: 21540238.
      View in: PubMed
    297. Gomperts BN, Spira A, Massion PP, Walser TC, Wistuba II, Minna JD, Dubinett SM. Evolving concepts in lung carcinogenesis. Semin Respir Crit Care Med. 2011 Feb; 32(1):32-43. PMID: 21500122.
      View in: PubMed
    298. Kim WY, Kim MJ, Moon H, Yuan P, Kim JS, Woo JK, Zhang G, Suh YA, Feng L, Behrens C, Van Pelt CS, Kang H, Lee JJ, Hong WK, Wistuba II, Lee HY. Differential impacts of insulin-like growth factor-binding protein-3 (IGFBP-3) in epithelial IGF-induced lung cancer development. Endocrinology. 2011 Jun; 152(6):2164-73. PMID: 21447628.
      View in: PubMed
    299. William WN, Kim JS, Liu DD, Solis L, Behrens C, Lee JJ, Lippman SM, Kim ES, Hong WK, Wistuba II, Lee HY. The impact of phosphorylated AMP-activated protein kinase expression on lung cancer survival. Ann Oncol. 2012 Jan; 23(1):78-85. PMID: 21430184.
      View in: PubMed
    300. Wistuba II, Gelovani JG, Jacoby JJ, Davis SE, Herbst RS. Methodological and practical challenges for personalized cancer therapies. Nat Rev Clin Oncol. 2011 Mar; 8(3):135-41. PMID: 21364686.
      View in: PubMed
    301. Tsuta K, Kalhor N, Raso MG, Wistuba II, Moran CA. Oncocytic neuroendocrine tumors of the lung: histopathologic spectrum and immunohistochemical analysis of 15 cases. Hum Pathol. 2011 Apr; 42(4):578-85. PMID: 21329962.
      View in: PubMed
    302. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ, Van Schil PE, Garg K, Austin JH, Asamura H, Rusch VW, Hirsch FR, Scagliotti G, Mitsudomi T, Huber RM, Ishikawa Y, Jett J, Sanchez-Cespedes M, Sculier JP, Takahashi T, Tsuboi M, Vansteenkiste J, Wistuba I, Yang PC, Aberle D, Brambilla C, Flieder D, Franklin W, Gazdar A, Gould M, Hasleton P, Henderson D, Johnson B, Johnson D, Kerr K, Kuriyama K, Lee JS, Miller VA, Petersen I, Roggli V, Rosell R, Saijo N, Thunnissen E, Tsao M, Yankelewitz D. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011 Feb; 6(2):244-85. PMID: 21252716.
      View in: PubMed
    303. Stewart DJ, Behrens C, Roth J, Wistuba II. Exponential decay nonlinear regression analysis of patient survival curves: preliminary assessment in non-small cell lung cancer. Lung Cancer. 2011 Feb; 71(2):217-23. PMID: 20627364.
      View in: PubMed
    304. Tang X, Kadara H, Behrens C, Liu DD, Xiao Y, Rice D, Gazdar AF, Fujimoto J, Moran C, Varella-Garcia M, Lee JJ, Hong WK, Wistuba II. Abnormalities of the TITF-1 lineage-specific oncogene in NSCLC: implications in lung cancer pathogenesis and prognosis. Clin Cancer Res. 2011 Apr 15; 17(8):2434-43. PMID: 21257719.
      View in: PubMed
    305. Tsuta K, Raso MG, Kalhor N, Liu DC, Wistuba II, Moran CA. Sox10-positive sustentacular cells in neuroendocrine carcinoma of the lung. Histopathology. 2011 Jan; 58(2):276-85. PMID: 21323953.
      View in: PubMed
    306. Yan W, Wistuba II, Emmert-Buck MR, Erickson HS. Squamous Cell Carcinoma - Similarities and Differences among Anatomical Sites. Am J Cancer Res. 2011 Jan 01; 1(3):275-300. PMID: 21938273.
      View in: PubMed
    307. Kadara H, Behrens C, Yuan P, Solis L, Liu D, Gu X, Minna JD, Lee JJ, Kim E, Hong WK, Wistuba II, Lotan R. A five-gene and corresponding protein signature for stage-I lung adenocarcinoma prognosis. Clin Cancer Res. 2011 Mar 15; 17(6):1490-501. PMID: 21163870.
      View in: PubMed
    308. Jeong Y, Xie Y, Xiao G, Behrens C, Girard L, Wistuba II, Minna JD, Mangelsdorf DJ. Nuclear receptor expression defines a set of prognostic biomarkers for lung cancer. PLoS Med. 2010 Dec 14; 7(12):e1000378. PMID: 21179495.
      View in: PubMed
    309. Singh SP, Han L, Murali R, Solis L, Roth J, Ji L, Wistuba I, Kundra V. SSTR2-based reporters for assessing gene transfer into non-small cell lung cancer: evaluation using an intrathoracic mouse model. Hum Gene Ther. 2011 Jan; 22(1):55-64. PMID: 20653396.
      View in: PubMed
    310. Nanjundan M, Byers LA, Carey MS, Siwak DR, Raso MG, Diao L, Wang J, Coombes KR, Roth JA, Mills GB, Wistuba II, Minna JD, Heymach JV. Proteomic profiling identifies pathways dysregulated in non-small cell lung cancer and an inverse association of AMPK and adhesion pathways with recurrence. J Thorac Oncol. 2010 Dec; 5(12):1894-904. PMID: 21124077.
      View in: PubMed
    311. Sullivan JP, Spinola M, Dodge M, Raso MG, Behrens C, Gao B, Schuster K, Shao C, Larsen JE, Sullivan LA, Honorio S, Xie Y, Scaglioni PP, DiMaio JM, Gazdar AF, Shay JW, Wistuba II, Minna JD. Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling. Cancer Res. 2010 Dec 01; 70(23):9937-48. PMID: 21118965.
      View in: PubMed
    312. Su X, Chakravarti D, Cho MS, Liu L, Gi YJ, Lin YL, Leung ML, El-Naggar A, Creighton CJ, Suraokar MB, Wistuba I, Flores ER. TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs. Nature. 2010 Oct 21; 467(7318):986-90. PMID: 20962848.
      View in: PubMed
    313. Richards KL, Zhang B, Sun M, Dong W, Churchill J, Bachinski LL, Wilson CD, Baggerly KA, Yin G, Hayes DN, Wistuba II, Krahe R. Methylation of the candidate biomarker TCF21 is very frequent across a spectrum of early-stage nonsmall cell lung cancers. Cancer. 2011 Feb 01; 117(3):606-17. PMID: 20945327.
      View in: PubMed
    314. Pataer A, Raso MG, Correa AM, Behrens C, Tsuta K, Solis L, Fang B, Roth JA, Wistuba II, Swisher SG. Prognostic significance of RNA-dependent protein kinase on non-small cell lung cancer patients. Clin Cancer Res. 2010 Nov 15; 16(22):5522-8. PMID: 20930042.
      View in: PubMed
    315. Chau NG, Kim ES, Wistuba I. The multidisciplinary approach to thymoma: combining molecular and clinical approaches. J Thorac Oncol. 2010 Oct; 5(10 Suppl 4):S313-7. PMID: 20859125.
      View in: PubMed
    316. Johnson FM, Bekele BN, Feng L, Wistuba I, Tang XM, Tran HT, Erasmus JJ, Hwang LL, Takebe N, Blumenschein GR, Lippman SM, Stewart DJ. Phase II study of dasatinib in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2010 Oct 20; 28(30):4609-15. PMID: 20855820.
      View in: PubMed
    317. Saintigny P, Wistuba II, Kim ES. Bronchioloalveolar carcinoma: a translational perspective. Oncology (Williston Park). 2010 Sep; 24(10):907-8, 914. PMID: 21138171.
      View in: PubMed
    318. Ooi AT, Mah V, Nickerson DW, Gilbert JL, Ha VL, Hegab AE, Horvath S, Alavi M, Maresh EL, Chia D, Gower AC, Lenburg ME, Spira A, Solis LM, Wistuba II, Walser TC, Wallace WD, Dubinett SM, Goodglick L, Gomperts BN. Presence of a putative tumor-initiating progenitor cell population predicts poor prognosis in smokers with non-small cell lung cancer. Cancer Res. 2010 Aug 15; 70(16):6639-48. PMID: 20710044.
      View in: PubMed
    319. Cai D, Shames DS, Raso MG, Xie Y, Kim YH, Pollack JR, Girard L, Sullivan JP, Gao B, Peyton M, Nanjundan M, Byers L, Heymach J, Mills G, Gazdar AF, Wistuba I, Kodadek T, Minna JD. Steroid receptor coactivator-3 expression in lung cancer and its role in the regulation of cancer cell survival and proliferation. Cancer Res. 2010 Aug 15; 70(16):6477-85. PMID: 20663904.
      View in: PubMed
    320. Solis LM, Behrens C, Dong W, Suraokar M, Ozburn NC, Moran CA, Corvalan AH, Biswal S, Swisher SG, Bekele BN, Minna JD, Stewart DJ, Wistuba II. Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features. Clin Cancer Res. 2010 Jul 15; 16(14):3743-53. PMID: 20534738.
      View in: PubMed
    321. Byers LA, Holsinger FC, Kies MS, William WN, El-Naggar AK, Lee JJ, Hu J, Lopez A, Tran HT, Yan S, Du Z, Ang KK, Glisson BS, Raso MG, Wistuba II, Myers JN, Hong WK, Papadimitrakopoulou V, Lippman SM, Heymach JV. Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer. Mol Cancer Ther. 2010 Jun; 9(6):1755-63. PMID: 20530716.
      View in: PubMed
    322. Lee JJ, Feng L, Reshef DS, Sabichi AL, Williams B, Rinsurongkawong W, Wistuba II, Lotan R, Lippman SM. Mortality in the randomized, controlled lung intergroup trial of isotretinoin. Cancer Prev Res (Phila). 2010 Jun; 3(6):738-44. PMID: 20501862.
      View in: PubMed
    323. Tsuta K, Raso MG, Kalhor N, Liu DD, Wistuba II, Moran CA. Histologic features of low- and intermediate-grade neuroendocrine carcinoma (typical and atypical carcinoid tumors) of the lung. Lung Cancer. 2011 Jan; 71(1):34-41. PMID: 20462655.
      View in: PubMed
    324. Spivey KA, Banyard J, Solis LM, Wistuba II, Barletta JA, Gandhi L, Feldman HA, Rodig SJ, Chirieac LR, Zetter BR. Collagen XXIII: a potential biomarker for the detection of primary and recurrent non-small cell lung cancer. Cancer Epidemiol Biomarkers Prev. 2010 May; 19(5):1362-72. PMID: 20447926.
      View in: PubMed
    325. Xu L, Nilsson MB, Saintigny P, Cascone T, Herynk MH, Du Z, Nikolinakos PG, Yang Y, Prudkin L, Liu D, Lee JJ, Johnson FM, Wong KK, Girard L, Gazdar AF, Minna JD, Kurie JM, Wistuba II, Heymach JV. Epidermal growth factor receptor regulates MET levels and invasiveness through hypoxia-inducible factor-1alpha in non-small cell lung cancer cells. Oncogene. 2010 May 06; 29(18):2616-27. PMID: 20154724.
      View in: PubMed
    326. Yuan P, Kadara H, Behrens C, Tang X, Woods D, Solis LM, Huang J, Spinola M, Dong W, Yin G, Fujimoto J, Kim E, Xie Y, Girard L, Moran C, Hong WK, Minna JD, Wistuba II. Sex determining region Y-Box 2 (SOX2) is a potential cell-lineage gene highly expressed in the pathogenesis of squamous cell carcinomas of the lung. PLoS One. 2010 Feb 09; 5(2):e9112. PMID: 20161759.
      View in: PubMed
    327. Kim ES, Hong WK, Lee JJ, Mao L, Morice RC, Liu DD, Jimenez CA, Eapen GA, Lotan R, Tang X, Newman RA, Wistuba II, Kurie JM. Biological activity of celecoxib in the bronchial epithelium of current and former smokers. Cancer Prev Res (Phila). 2010 Feb; 3(2):148-59. PMID: 20103722.
      View in: PubMed
    328. Solis LM, Raso MG, Kalhor N, Behrens C, Wistuba II, Moran CA. Primary oncocytic adenocarcinomas of the lung: a clinicopathologic, immunohistochemical, and molecular biologic analysis of 16 cases. Am J Clin Pathol. 2010 Jan; 133(1):133-40. PMID: 20023269.
      View in: PubMed
    329. Behrens C, Feng L, Kadara H, Kim HJ, Lee JJ, Mehran R, Hong WK, Lotan R, Wistuba II. Expression of interleukin-1 receptor-associated kinase-1 in non-small cell lung carcinoma and preneoplastic lesions. Clin Cancer Res. 2010 Jan 01; 16(1):34-44. PMID: 20028769.
      View in: PubMed
    330. Brannan JM, Sen B, Saigal B, Prudkin L, Behrens C, Solis L, Dong W, Bekele BN, Wistuba I, Johnson FM. EphA2 in the early pathogenesis and progression of non-small cell lung cancer. Cancer Prev Res (Phila). 2009 Dec; 2(12):1039-49. PMID: 19934338.
      View in: PubMed
    331. Ramos AH, Dutt A, Mermel C, Perner S, Cho J, Lafargue CJ, Johnson LA, Stiedl AC, Tanaka KE, Bass AJ, Barretina J, Weir BA, Beroukhim R, Thomas RK, Minna JD, Chirieac LR, Lindeman NI, Giordano T, Beer DG, Wagner P, Wistuba II, Rubin MA, Meyerson M. Amplification of chromosomal segment 4q12 in non-small cell lung cancer. Cancer Biol Ther. 2009 Nov; 8(21):2042-50. PMID: 19755855.
      View in: PubMed
    332. Tsao AS, Liu D, Martin J, Tang XM, Lee JJ, El-Naggar AK, Wistuba I, Culotta KS, Mao L, Gillenwater A, Sagesaka YM, Hong WK, Papadimitrakopoulou V. Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions. Cancer Prev Res (Phila). 2009 Nov; 2(11):931-41. PMID: 19892663.
      View in: PubMed
    333. Ivanova AV, Ivanov SV, Prudkin L, Nonaka D, Liu Z, Tsao A, Wistuba I, Roth J, Pass HI. Mechanisms of FUS1/TUSC2 deficiency in mesothelioma and its tumorigenic transcriptional effects. Mol Cancer. 2009 Oct 24; 8:91. PMID: 19852844.
      View in: PubMed
    334. Soh J, Okumura N, Lockwood WW, Yamamoto H, Shigematsu H, Zhang W, Chari R, Shames DS, Tang X, MacAulay C, Varella-Garcia M, Vooder T, Wistuba II, Lam S, Brekken R, Toyooka S, Minna JD, Lam WL, Gazdar AF. Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells. PLoS One. 2009 Oct 14; 4(10):e7464. PMID: 19826477.
      View in: PubMed
    335. Kim WY, Jin Q, Oh SH, Kim ES, Yang YJ, Lee DH, Feng L, Behrens C, Prudkin L, Miller YE, Lee JJ, Lippman SM, Hong WK, Wistuba II, Lee HY. Elevated epithelial insulin-like growth factor expression is a risk factor for lung cancer development. Cancer Res. 2009 Sep 15; 69(18):7439-48. PMID: 19738076.
      View in: PubMed
    336. Jin N, Cho SN, Raso MG, Wistuba I, Smith Y, Yang Y, Kurie JM, Yen R, Evans CM, Ludwig T, Jeong JW, DeMayo FJ. Mig-6 is required for appropriate lung development and to ensure normal adult lung homeostasis. Development. 2009 Oct; 136(19):3347-56. PMID: 19710174.
      View in: PubMed
    337. Raso MG, Behrens C, Herynk MH, Liu S, Prudkin L, Ozburn NC, Woods DM, Tang X, Mehran RJ, Moran C, Lee JJ, Wistuba II. Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation. Clin Cancer Res. 2009 Sep 01; 15(17):5359-68. PMID: 19706809.
      View in: PubMed
    338. Pao W, Kris MG, Iafrate AJ, Ladanyi M, Jänne PA, Wistuba II, Miake-Lye R, Herbst RS, Carbone DP, Johnson BE, Lynch TJ. Integration of molecular profiling into the lung cancer clinic. Clin Cancer Res. 2009 Sep 01; 15(17):5317-22. PMID: 19706816.
      View in: PubMed
    339. Du L, Schageman JJ, Subauste MC, Saber B, Hammond SM, Prudkin L, Wistuba II, Ji L, Roth JA, Minna JD, Pertsemlidis A. miR-93, miR-98, and miR-197 regulate expression of tumor suppressor gene FUS1. Mol Cancer Res. 2009 Aug; 7(8):1234-43. PMID: 19671678.
      View in: PubMed
    340. Kadara H, Lacroix L, Behrens C, Solis L, Gu X, Lee JJ, Tahara E, Lotan D, Hong WK, Wistuba II, Lotan R. Identification of gene signatures and molecular markers for human lung cancer prognosis using an in vitro lung carcinogenesis system. Cancer Prev Res (Phila). 2009 Aug; 2(8):702-11. PMID: 19638491.
      View in: PubMed
    341. Sun M, Behrens C, Feng L, Ozburn N, Tang X, Yin G, Komaki R, Varella-Garcia M, Hong WK, Aldape KD, Wistuba II. HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumors. Clin Cancer Res. 2009 Aug 01; 15(15):4829-37. PMID: 19622585.
      View in: PubMed
    342. Ivan D, Prieto VG, Esmaeli B, Wistuba II, Tang X, Lazar AJ. Epidermal growth factor receptor (EGFR) expression in periocular and extraocular sebaceous carcinoma. J Cutan Pathol. 2010 Feb; 37(2):231-6. PMID: 19614729.
      View in: PubMed
    343. Brannan JM, Dong W, Prudkin L, Behrens C, Lotan R, Bekele BN, Wistuba I, Johnson FM. Expression of the receptor tyrosine kinase EphA2 is increased in smokers and predicts poor survival in non-small cell lung cancer. Clin Cancer Res. 2009 Jul 01; 15(13):4423-30. PMID: 19531623.
      View in: PubMed
    344. Uribe P, Wistuba II, Gonzalez S. Allelotyping, microsatellite instability, and BRAF mutation analyses in common and atypical melanocytic nevi and primary cutaneous melanomas. Am J Dermatopathol. 2009 Jun; 31(4):354-63. PMID: 19461239.
      View in: PubMed
    345. Stewart DJ, Issa JP, Kurzrock R, Nunez MI, Jelinek J, Hong D, Oki Y, Guo Z, Gupta S, Wistuba II. Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas. Clin Cancer Res. 2009 Jun 01; 15(11):3881-8. PMID: 19470736.
      View in: PubMed
    346. Gibbons DL, Lin W, Creighton CJ, Zheng S, Berel D, Yang Y, Raso MG, Liu DD, Wistuba II, Lozano G, Kurie JM. Expression signatures of metastatic capacity in a genetic mouse model of lung adenocarcinoma. PLoS One. 2009; 4(4):e5401. PMID: 19404390.
      View in: PubMed
    347. Prudkin L, Liu DD, Ozburn NC, Sun M, Behrens C, Tang X, Brown KC, Bekele BN, Moran C, Wistuba II. Epithelial-to-mesenchymal transition in the development and progression of adenocarcinoma and squamous cell carcinoma of the lung. Mod Pathol. 2009 May; 22(5):668-78. PMID: 19270647.
      View in: PubMed
    348. Tsao AS, Wistuba I, Roth JA, Kindler HL. Malignant pleural mesothelioma. J Clin Oncol. 2009 Apr 20; 27(12):2081-90. PMID: 19255316.
      View in: PubMed
    349. Perera SA, Li D, Shimamura T, Raso MG, Ji H, Chen L, Borgman CL, Zaghlul S, Brandstetter KA, Kubo S, Takahashi M, Chirieac LR, Padera RF, Bronson RT, Shapiro GI, Greulich H, Meyerson M, Guertler U, Chesa PG, Solca F, Wistuba II, Wong KK. HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy. Proc Natl Acad Sci U S A. 2009 Jan 13; 106(2):474-9. PMID: 19122144.
      View in: PubMed
    350. Prudkin L, Tang X, Wistuba II. Germ-line and somatic presentations of the EGFR T790M mutation in lung cancer. J Thorac Oncol. 2009 Jan; 4(1):139-41. PMID: 19096324.
      View in: PubMed
    351. McDonald JM, Pelloski CE, Ledoux A, Sun M, Raso G, Komaki R, Wistuba II, Bekele BN, Aldape K. Elevated phospho-S6 expression is associated with metastasis in adenocarcinoma of the lung. Clin Cancer Res. 2008 Dec 01; 14(23):7832-7. PMID: 19047111.
      View in: PubMed
    352. Deus HF, Stanislaus R, Behrens C, Wistuba II, Minna JD, Garner HR, Swisher SG, Roth JA, Correa AM, Broom B, Coombes K, Almeida JS. Data driven semantic integration of translational lung cancer research at MDAnderson Cancer Center. AMIA Annu Symp Proc. 2008 Nov 06; 927. PMID: 18999102.
      View in: PubMed
    353. Wistuba II, Meyerson M. Chromosomal deletions and progression of premalignant lesions: less is more. Cancer Prev Res (Phila). 2008 Nov; 1(6):404-8. PMID: 19138986.
      View in: PubMed
    354. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, Sougnez C, Greulich H, Muzny DM, Morgan MB, Fulton L, Fulton RS, Zhang Q, Wendl MC, Lawrence MS, Larson DE, Chen K, Dooling DJ, Sabo A, Hawes AC, Shen H, Jhangiani SN, Lewis LR, Hall O, Zhu Y, Mathew T, Ren Y, Yao J, Scherer SE, Clerc K, Metcalf GA, Ng B, Milosavljevic A, Gonzalez-Garay ML, Osborne JR, Meyer R, Shi X, Tang Y, Koboldt DC, Lin L, Abbott R, Miner TL, Pohl C, Fewell G, Haipek C, Schmidt H, Dunford-Shore BH, Kraja A, Crosby SD, Sawyer CS, Vickery T, Sander S, Robinson J, Winckler W, Baldwin J, Chirieac LR, Dutt A, Fennell T, Hanna M, Johnson BE, Onofrio RC, Thomas RK, Tonon G, Weir BA, Zhao X, Ziaugra L, Zody MC, Giordano T, Orringer MB, Roth JA, Spitz MR, Wistuba II, Ozenberger B, Good PJ, Chang AC, Beer DG, Watson MA, Ladanyi M, Broderick S, Yoshizawa A, Travis WD, Pao W, Province MA, Weinstock GM, Varmus HE, Gabriel SB, Lander ES, Gibbs RA, Meyerson M, Wilson RK. Somatic mutations affect key pathways in lung adenocarcinoma. Nature. 2008 Oct 23; 455(7216):1069-75. PMID: 18948947.
      View in: PubMed
    355. Moghaddam SJ, Li H, Cho SN, Dishop MK, Wistuba II, Ji L, Kurie JM, Dickey BF, Demayo FJ. Promotion of lung carcinogenesis by chronic obstructive pulmonary disease-like airway inflammation in a K-ras-induced mouse model. Am J Respir Cell Mol Biol. 2009 Apr; 40(4):443-53. PMID: 18927348.
      View in: PubMed
    356. Behrens C, Lin HY, Lee JJ, Raso MG, Hong WK, Wistuba II, Lotan R. Immunohistochemical expression of basic fibroblast growth factor and fibroblast growth factor receptors 1 and 2 in the pathogenesis of lung cancer. Clin Cancer Res. 2008 Oct 01; 14(19):6014-22. PMID: 18829480.
      View in: PubMed
    357. Shivapurkar N, Stastny V, Okumura N, Girard L, Xie Y, Prinsen C, Thunnissen FB, Wistuba II, Czerniak B, Frenkel E, Roth JA, Liloglou T, Xinarianos G, Field JK, Minna JD, Gazdar AF. Cytoglobin, the newest member of the globin family, functions as a tumor suppressor gene. Cancer Res. 2008 Sep 15; 68(18):7448-56. PMID: 18794132.
      View in: PubMed
    358. Massion PP, Zou Y, Chen H, Jiang A, Coulson P, Amos CI, Wu X, Wistuba I, Wei Q, Shyr Y, Spitz MR. Smoking-related genomic signatures in non-small cell lung cancer. Am J Respir Crit Care Med. 2008 Dec 01; 178(11):1164-72. PMID: 18776155.
      View in: PubMed
    359. Yamamoto H, Shigematsu H, Nomura M, Lockwood WW, Sato M, Okumura N, Soh J, Suzuki M, Wistuba II, Fong KM, Lee H, Toyooka S, Date H, Lam WL, Minna JD, Gazdar AF. PIK3CA mutations and copy number gains in human lung cancers. Cancer Res. 2008 Sep 01; 68(17):6913-21. PMID: 18757405.
      View in: PubMed
    360. Borghero Y, Crane CH, Szklaruk J, Oyarzo M, Curley S, Pisters PW, Evans D, Abdalla EK, Thomas MB, Das P, Wistuba II, Krishnan S, Vauthey JN. Extrahepatic bile duct adenocarcinoma: patients at high-risk for local recurrence treated with surgery and adjuvant chemoradiation have an equivalent overall survival to patients with standard-risk treated with surgery alone. Ann Surg Oncol. 2008 Nov; 15(11):3147-56. PMID: 18754070.
      View in: PubMed
    361. Deus HF, Stanislaus R, Veiga DF, Behrens C, Wistuba II, Minna JD, Garner HR, Swisher SG, Roth JA, Correa AM, Broom B, Coombes K, Chang A, Vogel LH, Almeida JS. A Semantic Web management model for integrative biomedical informatics. PLoS One. 2008 Aug 13; 3(8):e2946. PMID: 18698353.
      View in: PubMed
    362. Tang X, Varella-Garcia M, Xavier AC, Massarelli E, Ozburn N, Moran C, Wistuba II. Epidermal growth factor receptor abnormalities in the pathogenesis and progression of lung adenocarcinomas. Cancer Prev Res (Phila). 2008 Aug; 1(3):192-200. PMID: 19138956.
      View in: PubMed
    363. Seo HS, Liu DD, Bekele BN, Kim MK, Pisters K, Lippman SM, Wistuba II, Koo JS. Cyclic AMP response element-binding protein overexpression: a feature associated with negative prognosis in never smokers with non-small cell lung cancer. Cancer Res. 2008 Aug 01; 68(15):6065-73. PMID: 18676828.
      View in: PubMed
    364. Kuhn E, Wistuba II. Molecular pathology of thymic epithelial neoplasms. Hematol Oncol Clin North Am. 2008 Jun; 22(3):443-55. PMID: 18514126.
      View in: PubMed
    365. Yang Y, Iwanaga K, Raso MG, Wislez M, Hanna AE, Wieder ED, Molldrem JJ, Wistuba II, Powis G, Demayo FJ, Kim CF, Kurie JM. Phosphatidylinositol 3-kinase mediates bronchioalveolar stem cell expansion in mouse models of oncogenic K-ras-induced lung cancer. PLoS One. 2008 May 21; 3(5):e2220. PMID: 18493606.
      View in: PubMed
    366. Velasco A, Corvalan A, Wistuba II, Riquelme E, Chuaqui R, Majerson A, Leach FS. Mismatch repair expression in testicular cancer predicts recurrence and survival. Int J Cancer. 2008 Apr 15; 122(8):1774-7. PMID: 18076065.
      View in: PubMed
    367. Yang Y, Wislez M, Fujimoto N, Prudkin L, Izzo JG, Uno F, Ji L, Hanna AE, Langley RR, Liu D, Johnson FM, Wistuba I, Kurie JM. A selective small molecule inhibitor of c-Met, PHA-665752, reverses lung premalignancy induced by mutant K-ras. Mol Cancer Ther. 2008 Apr; 7(4):952-60. PMID: 18413809.
      View in: PubMed
    368. Zhang J, Iwanaga K, Choi KC, Wislez M, Raso MG, Wei W, Wistuba II, Kurie JM. Intratumoral epiregulin is a marker of advanced disease in non-small cell lung cancer patients and confers invasive properties on EGFR-mutant cells. Cancer Prev Res (Phila). 2008 Aug; 1(3):201-7. PMID: 19138957.
      View in: PubMed
    369. Iwanaga K, Yang Y, Raso MG, Ma L, Hanna AE, Thilaganathan N, Moghaddam S, Evans CM, Li H, Cai WW, Sato M, Minna JD, Wu H, Creighton CJ, Demayo FJ, Wistuba II, Kurie JM. Pten inactivation accelerates oncogenic K-ras-initiated tumorigenesis in a mouse model of lung cancer. Cancer Res. 2008 Feb 15; 68(4):1119-27. PMID: 18281487.
      View in: PubMed
    370. Prudkin L, Behrens C, Liu DD, Zhou X, Ozburn NC, Bekele BN, Minna JD, Moran C, Roth JA, Ji L, Wistuba II. Loss and reduction of FUS1 protein expression is a frequent phenomenon in the pathogenesis of lung cancer. Clin Cancer Res. 2008 Jan 01; 14(1):41-7. PMID: 18172250.
      View in: PubMed
    371. Jin Q, Feng L, Behrens C, Bekele BN, Wistuba II, Hong WK, Lee HY. Implication of AMP-activated protein kinase and Akt-regulated survivin in lung cancer chemopreventive activities of deguelin. Cancer Res. 2007 Dec 15; 67(24):11630-9. PMID: 18089792.
      View in: PubMed
    372. Weir BA, Woo MS, Getz G, Perner S, Ding L, Beroukhim R, Lin WM, Province MA, Kraja A, Johnson LA, Shah K, Sato M, Thomas RK, Barletta JA, Borecki IB, Broderick S, Chang AC, Chiang DY, Chirieac LR, Cho J, Fujii Y, Gazdar AF, Giordano T, Greulich H, Hanna M, Johnson BE, Kris MG, Lash A, Lin L, Lindeman N, Mardis ER, McPherson JD, Minna JD, Morgan MB, Nadel M, Orringer MB, Osborne JR, Ozenberger B, Ramos AH, Robinson J, Roth JA, Rusch V, Sasaki H, Shepherd F, Sougnez C, Spitz MR, Tsao MS, Twomey D, Verhaak RG, Weinstock GM, Wheeler DA, Winckler W, Yoshizawa A, Yu S, Zakowski MF, Zhang Q, Beer DG, Wistuba II, Watson MA, Garraway LA, Ladanyi M, Travis WD, Pao W, Rubin MA, Gabriel SB, Gibbs RA, Varmus HE, Wilson RK, Lander ES, Meyerson M. Characterizing the cancer genome in lung adenocarcinoma. Nature. 2007 Dec 06; 450(7171):893-8. PMID: 17982442.
      View in: PubMed
    373. Mah V, Seligson DB, Li A, Márquez DC, Wistuba II, Elshimali Y, Fishbein MC, Chia D, Pietras RJ, Goodglick L. Aromatase expression predicts survival in women with early-stage non small cell lung cancer. Cancer Res. 2007 Nov 01; 67(21):10484-90. PMID: 17974992.
      View in: PubMed
    374. Kawamoto T, Krishnamurthy S, Tarco E, Trivedi S, Wistuba II, Li D, Roa I, Roa JC, Thomas MB. HER Receptor Family: Novel Candidate for Targeted Therapy for Gallbladder and Extrahepatic Bile Duct Cancer. Gastrointest Cancer Res. 2007 Nov; 1(6):221-7. PMID: 19262900.
      View in: PubMed
    375. Toyooka S, Matsuo K, Shigematsu H, Kosaka T, Tokumo M, Yatabe Y, Ichihara S, Inukai M, Suehisa H, Soh J, Kiura K, Fong KM, Lee H, Wistuba II, Gazdar AF, Mitsudomi T, Date H. The impact of sex and smoking status on the mutational spectrum of epidermal growth factor receptor gene in non small cell lung cancer. Clin Cancer Res. 2007 Oct 01; 13(19):5763-8. PMID: 17908966.
      View in: PubMed
    376. Kim SW, Cheon K, Kim CH, Yoon JH, Hawke DH, Kobayashi R, Prudkin L, Wistuba II, Lotan R, Hong WK, Koo JS. Proteomics-based identification of proteins secreted in apical surface fluid of squamous metaplastic human tracheobronchial epithelial cells cultured by three-dimensional organotypic air-liquid interface method. Cancer Res. 2007 Jul 15; 67(14):6565-73. PMID: 17638865.
      View in: PubMed
    377. Raso MG, Wistuba II. Molecular pathogenesis of early-stage non-small cell lung cancer and a proposal for tissue banking to facilitate identification of new biomarkers. J Thorac Oncol. 2007 Jul; 2(7 Suppl 3):S128-35. PMID: 17603309.
      View in: PubMed
    378. Tsao AS, He D, Saigal B, Liu S, Lee JJ, Bakkannagari S, Ordonez NG, Hong WK, Wistuba I, Johnson FM. Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion. Mol Cancer Ther. 2007 Jul; 6(7):1962-72. PMID: 17620427.
      View in: PubMed
    379. Elayadi AN, Samli KN, Prudkin L, Liu YH, Bian A, Xie XJ, Wistuba II, Roth JA, McGuire MJ, Brown KC. A peptide selected by biopanning identifies the integrin alphavbeta6 as a prognostic biomarker for nonsmall cell lung cancer. Cancer Res. 2007 Jun 15; 67(12):5889-95. PMID: 17575158.
      View in: PubMed
    380. Massarelli E, Varella-Garcia M, Tang X, Xavier AC, Ozburn NC, Liu DD, Bekele BN, Herbst RS, Wistuba II. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res. 2007 May 15; 13(10):2890-6. PMID: 17504988.
      View in: PubMed
    381. Wu Q, Kiguchi K, Kawamoto T, Ajiki T, Traag J, Carbajal S, Ruffino L, Thames H, Wistuba I, Thomas M, Vasquez KM, DiGiovanni J. Therapeutic effect of rapamycin on gallbladder cancer in a transgenic mouse model. Cancer Res. 2007 Apr 15; 67(8):3794-800. PMID: 17440093.
      View in: PubMed
    382. Nomura M, Shigematsu H, Li L, Suzuki M, Takahashi T, Estess P, Siegelman M, Feng Z, Kato H, Marchetti A, Shay JW, Spitz MR, Wistuba II, Minna JD, Gazdar AF. Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers. PLoS Med. 2007 Apr; 4(4):e125. PMID: 17455987.
      View in: PubMed
    383. Haigis KM, Wistuba II, Kurie JM. Lung premalignancy induced by mutant B-Raf, what is thy fate? To senesce or not to senesce, that is the question. Genes Dev. 2007 Feb 15; 21(4):361-6. PMID: 17322395.
      View in: PubMed
    384. Wistuba II. Genetics of preneoplasia: lessons from lung cancer. Curr Mol Med. 2007 Feb; 7(1):3-14. PMID: 17311529.
      View in: PubMed
    385. Zhang J, Kalyankrishna S, Wislez M, Thilaganathan N, Saigal B, Wei W, Ma L, Wistuba II, Johnson FM, Kurie JM. SRC-family kinases are activated in non-small cell lung cancer and promote the survival of epidermal growth factor receptor-dependent cell lines. Am J Pathol. 2007 Jan; 170(1):366-76. PMID: 17200208.
      View in: PubMed
    386. Gu J, Berman D, Lu C, Wistuba II, Roth JA, Frazier M, Spitz MR, Wu X. Aberrant promoter methylation profile and association with survival in patients with non-small cell lung cancer. Clin Cancer Res. 2006 Dec 15; 12(24):7329-38. PMID: 17189404.
      View in: PubMed
    387. Xia D, Srinivas H, Ahn YH, Sethi G, Sheng X, Yung WK, Xia Q, Chiao PJ, Kim H, Brown PH, Wistuba II, Aggarwal BB, Kurie JM. Mitogen-activated protein kinase kinase-4 promotes cell survival by decreasing PTEN expression through an NF kappa B-dependent pathway. J Biol Chem. 2007 Feb 09; 282(6):3507-19. PMID: 17158870.
      View in: PubMed
    388. Tang X, Liu D, Shishodia S, Ozburn N, Behrens C, Lee JJ, Hong WK, Aggarwal BB, Wistuba II. Nuclear factor-kappaB (NF-kappaB) is frequently expressed in lung cancer and preneoplastic lesions. Cancer. 2006 Dec 01; 107(11):2637-46. PMID: 17078054.
      View in: PubMed
    389. Shen J, Behrens C, Wistuba II, Feng L, Lee JJ, Hong WK, Lotan R. Identification and validation of differences in protein levels in normal, premalignant, and malignant lung cells and tissues using high-throughput Western Array and immunohistochemistry. Cancer Res. 2006 Dec 01; 66(23):11194-206. PMID: 17145864.
      View in: PubMed
    390. Riquelme E, Tang M, Baez S, Diaz A, Pruyas M, Wistuba II, Corvalan A. Frequent epigenetic inactivation of chromosome 3p candidate tumor suppressor genes in gallbladder carcinoma. Cancer Lett. 2007 May 18; 250(1):100-6. PMID: 17084965.
      View in: PubMed
    391. Wislez M, Beer DG, Wistuba I, Cadranel J, Saijo N, Johnson BE. Molecular biology, genomics, and proteomics in bronchioloalveolar carcinoma. J Thorac Oncol. 2006 Nov; 1(9 Suppl):S8-12. PMID: 17410000.
      View in: PubMed
    392. Travis WD, Garg K, Franklin WA, Wistuba II, Sabloff B, Noguchi M, Kakinuma R, Zakowski M, Ginsberg M, Padera R, Jacobson F, Johnson BE, Hirsch F, Brambilla E, Flieder DB, Geisinger KR, Thunnissen F, Kerr K, Yankelevitz D, Franks TJ, Galvin JR, Henderson DW, Nicholson AG, Hasleton PS, Roggli V, Tsao MS, Cappuzzo F, Vazquez M. Bronchioloalveolar carcinoma and lung adenocarcinoma: the clinical importance and research relevance of the 2004 World Health Organization pathologic criteria. J Thorac Oncol. 2006 Nov; 1(9 Suppl):S13-9. PMID: 17409995.
      View in: PubMed
    393. Khatlani TS, Wislez M, Sun M, Srinivas H, Iwanaga K, Ma L, Hanna AE, Liu D, Girard L, Kim YH, Pollack JR, Minna JD, Wistuba II, Kurie JM. c-Jun N-terminal kinase is activated in non-small-cell lung cancer and promotes neoplastic transformation in human bronchial epithelial cells. Oncogene. 2007 Apr 19; 26(18):2658-66. PMID: 17057737.
      View in: PubMed
    394. Prudkin L, Wistuba II. Epidermal growth factor receptor abnormalities in lung cancer. Pathogenetic and clinical implications. Ann Diagn Pathol. 2006 Oct; 10(5):306-15. PMID: 16979526.
      View in: PubMed
    395. Castiblanco G A, Pires N Y, Wistuba O I, Riquelme S E, Andrade M L, Corvalán R A. [Pathogenic role of PTEN tumor suppressor gene in ovarian cancer associated to endometriosis]. Rev Med Chil. 2006 Mar; 134(3):271-8. PMID: 16676097.
      View in: PubMed
    396. Shivapurkar N, Stastny V, Suzuki M, Wistuba II, Li L, Zheng Y, Feng Z, Hol B, Prinsen C, Thunnissen FB, Gazdar AF. Application of a methylation gene panel by quantitative PCR for lung cancers. Cancer Lett. 2007 Mar 08; 247(1):56-71. PMID: 16644104.
      View in: PubMed
    397. Wislez M, Fujimoto N, Izzo JG, Hanna AE, Cody DD, Langley RR, Tang H, Burdick MD, Sato M, Minna JD, Mao L, Wistuba I, Strieter RM, Kurie JM. High expression of ligands for chemokine receptor CXCR2 in alveolar epithelial neoplasia induced by oncogenic kras. Cancer Res. 2006 Apr 15; 66(8):4198-207. PMID: 16618742.
      View in: PubMed
    398. Tsao AS, Tang XM, Sabloff B, Xiao L, Shigematsu H, Roth J, Spitz M, Hong WK, Gazdar A, Wistuba I. Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer. J Thorac Oncol. 2006 Mar; 1(3):231-9. PMID: 17409862.
      View in: PubMed
    399. Wistuba II, Gazdar AF. Lung cancer preneoplasia. Annu Rev Pathol. 2006; 1:331-48. PMID: 18039118.
      View in: PubMed
    400. Fujimoto N, Wislez M, Zhang J, Iwanaga K, Dackor J, Hanna AE, Kalyankrishna S, Cody DD, Price RE, Sato M, Shay JW, Minna JD, Peyton M, Tang X, Massarelli E, Herbst R, Threadgill DW, Wistuba II, Kurie JM. High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor. Cancer Res. 2005 Dec 15; 65(24):11478-85. PMID: 16357156.
      View in: PubMed
    401. Tang X, Shigematsu H, Bekele BN, Roth JA, Minna JD, Hong WK, Gazdar AF, Wistuba II. EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients. Cancer Res. 2005 Sep 01; 65(17):7568-72. PMID: 16140919.
      View in: PubMed
    402. Uribe P, Wistuba II, Solar A, Balestrini C, Perez-Cotapos ML, Gonzalez S. Comparative analysis of loss of heterozygosity and microsatellite instability in adult and pediatric melanoma. Am J Dermatopathol. 2005 Aug; 27(4):279-85. PMID: 16121045.
      View in: PubMed
    403. Moreno M, Pimentel F, Gazdar AF, Wistuba II, Miquel JF. TP53 abnormalities are frequent and early events in the sequential pathogenesis of gallbladder carcinoma. Ann Hepatol. 2005 Jul-Sep; 4(3):192-9. PMID: 16177659.
      View in: PubMed
    404. Takahashi T, Suzuki M, Shigematsu H, Shivapurkar N, Echebiri C, Nomura M, Stastny V, Augustus M, Wu CW, Wistuba II, Meltzer SJ, Gazdar AF. Aberrant methylation of Reprimo in human malignancies. Int J Cancer. 2005 Jul 01; 115(4):503-10. PMID: 15700311.
      View in: PubMed
    405. Travis WD, Garg K, Franklin WA, Wistuba II, Sabloff B, Noguchi M, Kakinuma R, Zakowski M, Ginsberg M, Padera R, Jacobson F, Johnson BE, Hirsch F, Brambilla E, Flieder DB, Geisinger KR, Thunnisen F, Kerr K, Yankelevitz D, Franks TJ, Galvin JR, Henderson DW, Nicholson AG, Hasleton PS, Roggli V, Tsao MS, Cappuzzo F, Vazquez M. Evolving concepts in the pathology and computed tomography imaging of lung adenocarcinoma and bronchioloalveolar carcinoma. J Clin Oncol. 2005 May 10; 23(14):3279-87. PMID: 15886315.
      View in: PubMed
    406. Sabloff BS, Wistuba II, Erasmus JJ. Cystic bronchioloalveolar cell carcinoma. J Thorac Imaging. 2005 May; 20(2):110-4. PMID: 15818211.
      View in: PubMed
    407. Wislez M, Spencer ML, Izzo JG, Juroske DM, Balhara K, Cody DD, Price RE, Hittelman WN, Wistuba II, Kurie JM. Inhibition of mammalian target of rapamycin reverses alveolar epithelial neoplasia induced by oncogenic K-ras. Cancer Res. 2005 Apr 15; 65(8):3226-35. PMID: 15833854.
      View in: PubMed
    408. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, Fong KM, Lee H, Toyooka S, Shimizu N, Fujisawa T, Feng Z, Roth JA, Herz J, Minna JD, Gazdar AF. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005 Mar 02; 97(5):339-46. PMID: 15741570.
      View in: PubMed
    409. Shigematsu H, Takahashi T, Nomura M, Majmudar K, Suzuki M, Lee H, Wistuba II, Fong KM, Toyooka S, Shimizu N, Fujisawa T, Minna JD, Gazdar AF. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res. 2005 Mar 01; 65(5):1642-6. PMID: 15753357.
      View in: PubMed
    410. Wistuba II. Histologic evaluation of bronchial squamous lesions: any role in lung cancer risk assessment? Clin Cancer Res. 2005 Feb 15; 11(4):1358-60. PMID: 15746032.
      View in: PubMed
    411. Guillaud M, le Riche JC, Dawe C, Korbelik J, Coldman A, Wistuba II, Park IW, Gazdar A, Lam S, MacAulay CE. Nuclear morphometry as a biomarker for bronchial intraepithelial neoplasia: correlation with genetic damage and cancer development. Cytometry A. 2005; 63(1):34-40. PMID: 15614828.
      View in: PubMed
    412. Tang X, Wu W, Sun SY, Wistuba II, Hong WK, Mao L. Hypermethylation of the death-associated protein kinase promoter attenuates the sensitivity to TRAIL-induced apoptosis in human non-small cell lung cancer cells. Mol Cancer Res. 2004 Dec; 2(12):685-91. PMID: 15634757.
      View in: PubMed
    413. Velasco A, Riquelme E, Schultz M, Wistuba II, Villarroel L, Koh MS, Leach FS. Microsatellite instability and loss of heterozygosity have distinct prognostic value for testicular germ cell tumor recurrence. Cancer Biol Ther. 2004 Nov; 3(11):1152-8; discussion 1159-61. PMID: 15492498.
      View in: PubMed
    414. Goldenberg D, Rosenbaum E, Argani P, Wistuba II, Sidransky D, Thuluvath PJ, Hidalgo M, Califano J, Maitra A. The V599E BRAF mutation is uncommon in biliary tract cancers. Mod Pathol. 2004 Nov; 17(11):1386-91. PMID: 15181454.
      View in: PubMed
    415. Velasco A, Riquelme E, Schultz M, Wistuba II, Villarroel L, Pizarro J, Berlin A, Ittmann M, Koh MS, Leach FS. Mismatch repair gene expression and genetic instability in testicular germ cell tumor. Cancer Biol Ther. 2004 Oct; 3(10):977-82. PMID: 15467433.
      View in: PubMed
    416. Takahashi T, Shivapurkar N, Riquelme E, Shigematsu H, Reddy J, Suzuki M, Miyajima K, Zhou X, Bekele BN, Gazdar AF, Wistuba II. Aberrant promoter hypermethylation of multiple genes in gallbladder carcinoma and chronic cholecystitis. Clin Cancer Res. 2004 Sep 15; 10(18 Pt 1):6126-33. PMID: 15447999.
      View in: PubMed
    417. Wistuba II, Gazdar AF. Gallbladder cancer: lessons from a rare tumour. Nat Rev Cancer. 2004 Sep; 4(9):695-706. PMID: 15343276.
      View in: PubMed
    418. Sabloff BS, Truong MT, Wistuba II, Erasmus JJ. Bronchioalveolar cell carcinoma: radiologic appearance and dilemmas in the assessment of response. Clin Lung Cancer. 2004 Sep; 6(2):108-12. PMID: 15476596.
      View in: PubMed
    419. Fullerton DA, López F, Avendaño R, Aparicio R, Wistuba I. [Atypical presentation of a colorectal carcinoma]. Rev Med Chil. 2004 Aug; 132(8):985-8. PMID: 15478301.
      View in: PubMed
    420. Kronberg U, López-Kostner F, Soto G, Zúñiga A, Wistuba I, Miranda V, Pinto E, Viviani P, Marshall G. Detection of lymphatic micrometastases in patients with stages I and II colorectal cancer: impact on five-year survival. Dis Colon Rectum. 2004 Jul; 47(7):1151-7. PMID: 15164250.
      View in: PubMed
    421. Tang M, Baez S, Pruyas M, Diaz A, Calvo A, Riquelme E, Wistuba II. Mitochondrial DNA mutation at the D310 (displacement loop) mononucleotide sequence in the pathogenesis of gallbladder carcinoma. Clin Cancer Res. 2004 Feb 01; 10(3):1041-6. PMID: 14871983.
      View in: PubMed
    422. Uribe P, Wistuba II, González S. BRAF mutation: a frequent event in benign, atypical, and malignant melanocytic lesions of the skin. Am J Dermatopathol. 2003 Oct; 25(5):365-70. PMID: 14501284.
      View in: PubMed
    423. House MG, Wistuba II, Argani P, Guo M, Schulick RD, Hruban RH, Herman JG, Maitra A. Progression of gene hypermethylation in gallstone disease leading to gallbladder cancer. Ann Surg Oncol. 2003 Oct; 10(8):882-9. PMID: 14527906.
      View in: PubMed
    424. Wistuba II, Behrens C, Albores-Saavedra J, Delgado R, Lopez F, Gazdar AF. Distinct K-ras mutation pattern characterizes signet ring cell colorectal carcinoma. Clin Cancer Res. 2003 Sep 01; 9(10 Pt 1):3615-9. PMID: 14506148.
      View in: PubMed
    425. Tang M, Pires Y, Schultz M, Duarte I, Gallegos M, Wistuba II. Microsatellite analysis of synchronous and metachronous tumors: a tool for double primary tumor and metastasis assessment. Diagn Mol Pathol. 2003 Sep; 12(3):151-9. PMID: 12960697.
      View in: PubMed
    426. Miquel JF, Moreno M, Amigo L, Molina H, Mardones P, Wistuba II, Rigotti A. Expression and regulation of scavenger receptor class B type I (SR-BI) in gall bladder epithelium. Gut. 2003 Jul; 52(7):1017-24. PMID: 12801960.
      View in: PubMed
    427. Hansel DE, Rahman A, Hidalgo M, Thuluvath PJ, Lillemoe KD, Schulick R, Ku JL, Park JG, Miyazaki K, Ashfaq R, Wistuba II, Varma R, Hawthorne L, Geradts J, Argani P, Maitra A. Identification of novel cellular targets in biliary tract cancers using global gene expression technology. Am J Pathol. 2003 07; 163(1):217-29. PMID: 12819026.
      View in: PubMed
    428. Wistuba II, Gazdar AF. Characteristic genetic alterations in lung cancer. Methods Mol Med. 2003; 74:3-28. PMID: 12415683.
      View in: PubMed
    429. Wistuba II, Mao L, Gazdar AF. Smoking molecular damage in bronchial epithelium. Oncogene. 2002 Oct 21; 21(48):7298-306. PMID: 12379874.
      View in: PubMed
    430. Wistuba II, Maitra A, Carrasco R, Tang M, Troncoso P, Minna JD, Gazdar AF. High resolution chromosome 3p, 8p, 9q and 22q allelotyping analysis in the pathogenesis of gallbladder carcinoma. Br J Cancer. 2002 Aug 12; 87(4):432-40. PMID: 12177780.
      View in: PubMed
    431. Field JK, Brambilla C, Caporaso N, Flahault A, Henschke C, Herman J, Hirsch F, Lachmann P, Lam S, Maier S, Montuenga LM, Mulshine J, Murphy M, Pullen J, Spitz M, Tockman M, Tyndale R, Wistuba I, Youngson J. Consensus statements from the Second International Lung Cancer Molecular Biomarkers Workshop: a European strategy for developing lung cancer molecular diagnostics in high risk populations. Int J Oncol. 2002 Aug; 21(2):369-73. PMID: 12118333.
      View in: PubMed
    432. Toyooka S, Fukuyama Y, Wistuba II, Tockman MS, Minna JD, Gazdar AF. Differential expression of FEZ1/LZTS1 gene in lung cancers and their cell cultures. Clin Cancer Res. 2002 Jul; 8(7):2292-7. PMID: 12114433.
      View in: PubMed
    433. Wistuba II, Ashfaq R, Maitra A, Alvarez H, Riquelme E, Gazdar AF. Fragile histidine triad gene abnormalities in the pathogenesis of gallbladder carcinoma. Am J Pathol. 2002 Jun; 160(6):2073-9. PMID: 12057912.
      View in: PubMed
    434. Huang J, Behrens C, Wistuba II, Gazdar AF, Jagirdar J. Clonality of combined tumors. Arch Pathol Lab Med. 2002 Apr; 126(4):437-41. PMID: 11900568.
      View in: PubMed
    435. Huang J, Behrens C, Wistuba I, Gazdar AF, Jagirdar J. Molecular analysis of synchronous and metachronous tumors of the lung: impact on management and prognosis. Ann Diagn Pathol. 2001 Dec; 5(6):321-9. PMID: 11745069.
      View in: PubMed
    436. Lazcano-Ponce EC, Miquel JF, Muñoz N, Herrero R, Ferrecio C, Wistuba II, Alonso de Ruiz P, Aristi Urista G, Nervi F. Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin. 2001 Nov-Dec; 51(6):349-64. PMID: 11760569.
      View in: PubMed
    437. Wistuba II. [Molecular pathology: applications of molecular biology in pathological anatomy]. Rev Med Chil. 2001 Jul; 129(7):791-804. PMID: 11552450.
      View in: PubMed
    438. Maitra A, Wistuba II, Washington C, Virmani AK, Ashfaq R, Milchgrub S, Gazdar AF, Minna JD. High-resolution chromosome 3p allelotyping of breast carcinomas and precursor lesions demonstrates frequent loss of heterozygosity and a discontinuous pattern of allele loss. Am J Pathol. 2001 Jul; 159(1):119-30. PMID: 11438460.
      View in: PubMed
    439. Wistuba II, Tang M, Maitra A, Alvarez H, Troncoso P, Pimentel F, Gazdar AF. Genome-wide allelotyping analysis reveals multiple sites of allelic loss in gallbladder carcinoma. Cancer Res. 2001 May 01; 61(9):3795-800. PMID: 11325854.
      View in: PubMed
    440. Wistuba II, Gazdar AF, Minna JD. Molecular genetics of small cell lung carcinoma. Semin Oncol. 2001 Apr; 28(2 Suppl 4):3-13. PMID: 11479891.
      View in: PubMed
    441. Maitra A, Wistuba II, Gazdar AF. Microdissection and the study of cancer pathways. Curr Mol Med. 2001 Mar; 1(1):153-62. PMID: 11899240.
      View in: PubMed
    442. Zöchbauer-Müller S, Wistuba II, Minna JD, Gazdar AF. Fragile histidine triad (FHIT) gene abnormalities in lung cancer. Clin Lung Cancer. 2000 Nov; 2(2):141-5. PMID: 14731325.
      View in: PubMed
    443. Behrens C, Travis LB, Wistuba II, Davis S, Maitra A, Clarke EA, Lynch CF, Glimelius B, Wiklund T, Tarone R, Gazdar AF. Molecular changes in second primary lung and breast cancers after therapy for Hodgkin's disease. Cancer Epidemiol Biomarkers Prev. 2000 Oct; 9(10):1027-35. PMID: 11045784.
      View in: PubMed
    444. Wistuba II, Tomlinson GE, Behrens C, Virmani A, Geradts J, Blum JL, Minna JD, Gazdar AF. Two identical triplet sisters carrying a germline BRCA1 gene mutation acquire very similar breast cancer somatic mutations at multiple other sites throughout the genome. Genes Chromosomes Cancer. 2000 Aug; 28(4):359-69. PMID: 10862044.
      View in: PubMed
    445. Wistuba II, Berry J, Behrens C, Maitra A, Shivapurkar N, Milchgrub S, Mackay B, Minna JD, Gazdar AF. Molecular changes in the bronchial epithelium of patients with small cell lung cancer. Clin Cancer Res. 2000 Jul; 6(7):2604-10. PMID: 10914700.
      View in: PubMed
    446. Larramendy ML, Lushnikova T, Björkqvist AM, Wistuba II, Virmani AK, Shivapurkar N, Gazdar AF, Knuutila S. Comparative genomic hybridization reveals complex genetic changes in primary breast cancer tumors and their cell lines. Cancer Genet Cytogenet. 2000 Jun; 119(2):132-8. PMID: 10867149.
      View in: PubMed
    447. Wistuba II, Behrens C, Virmani AK, Mele G, Milchgrub S, Girard L, Fondon JW, Garner HR, McKay B, Latif F, Lerman MI, Lam S, Gazdar AF, Minna JD. High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints. Cancer Res. 2000 Apr 01; 60(7):1949-60. PMID: 10766185.
      View in: PubMed
    448. Shivapurkar N, Wiethege T, Wistuba II, Milchgrub S, Muller KM, Gazdar AF. Presence of simian virus 40 sequences in malignant pleural, peritoneal and noninvasive mesotheliomas. Int J Cancer. 2000 Mar 01; 85(5):743-5. PMID: 10699959.
      View in: PubMed
    449. Milchgrub S, Wistuba II, Kim BK, Rutherford C, Urban J, Cruz PD, Gazdar AF. Molecular identification of metastatic cancer to the skin using laser capture microdissection: a case report. Cancer. 2000 Feb 15; 88(4):749-54. PMID: 10679642.
      View in: PubMed
    450. Wistuba II, Gazdar AF. Molecular pathology of lung cancer. Verh Dtsch Ges Pathol. 2000; 84:96-105. PMID: 11217455.
      View in: PubMed
    451. Euhus DM, Maitra A, Wistuba II, Ashfaq R, Alberts A, Gibbons D, Gazdar AF. Use of archival fine-needle aspirates for the allelotyping of tumors. Cancer. 1999 Dec 25; 87(6):372-9. PMID: 10603191.
      View in: PubMed
    452. Shivapurkar N, Wiethege T, Wistuba II, Salomon E, Milchgrub S, Muller KM, Churg A, Pass H, Gazdar AF. Presence of simian virus 40 sequences in malignant mesotheliomas and mesothelial cell proliferations. J Cell Biochem. 1999 Dec; 76(2):181-8. PMID: 10618635.
      View in: PubMed
    453. Maitra A, Tavassoli FA, Albores-Saavedra J, Behrens C, Wistuba II, Bryant D, Weinberg AG, Rogers BB, Saboorian MH, Gazdar AF. Molecular abnormalities associated with secretory carcinomas of the breast. Hum Pathol. 1999 Dec; 30(12):1435-40. PMID: 10667421.
      View in: PubMed
    454. Park IW, Wistuba II, Maitra A, Milchgrub S, Virmani AK, Minna JD, Gazdar AF. Multiple clonal abnormalities in the bronchial epithelium of patients with lung cancer. J Natl Cancer Inst. 1999 Nov 03; 91(21):1863-8. PMID: 10547393.
      View in: PubMed
    455. Wistuba II, Syed S, Behrens C, Duong M, Milchgrub S, Muller CY, Jagirdar J, Gazdar AF. Comparison of molecular changes in cervical intraepithelial neoplasia in HIV-positive and HIV-indeterminate subjects. Gynecol Oncol. 1999 Sep; 74(3):519-26. PMID: 10479524.
      View in: PubMed
    456. Maitra A, Wistuba II, Gibbons D, Gazdar AF, Albores-Saavedra J. Allelic losses at chromosome 3p are seen in human papilloma virus 16 associated transitional cell carcinoma of the cervix. Gynecol Oncol. 1999 Sep; 74(3):361-8. PMID: 10479494.
      View in: PubMed
    457. Shivapurkar N, Sood S, Wistuba II, Virmani AK, Maitra A, Milchgrub S, Minna JD, Gazdar AF. Multiple regions of chromosome 4 demonstrating allelic losses in breast carcinomas. Cancer Res. 1999 Aug 01; 59(15):3576-80. PMID: 10446964.
      View in: PubMed
    458. Ramnani DM, Wistuba II, Behrens C, Gazdar AF, Sobin LH, Albores-Saavedra J. K-ras and p53 mutations in the pathogenesis of classical and goblet cell carcinoids of the appendix. Cancer. 1999 Jul 01; 86(1):14-21. PMID: 10391558.
      View in: PubMed
    459. Wistuba II, Behrens C, Gazdar AF. Pathogenesis of non-AIDS-defining cancers: a review. AIDS Patient Care STDS. 1999 Jul; 13(7):415-26. PMID: 10870595.
      View in: PubMed
    460. Flowers LC, Wistuba II, Scurry J, Muller CY, Ashfaq R, Miller DS, Minna JD, Gazdar AF. Genetic changes during the multistage pathogenesis of human papillomavirus positive and negative vulvar carcinomas. J Soc Gynecol Investig. 1999 Jul-Aug; 6(4):213-21. PMID: 10486784.
      View in: PubMed
    461. Euhus DM, Maitra A, Wistuba II, Alberts A, Albores-Saavedra J, Gazdar AF. Loss of heterozygosity at 3p in benign lesions preceding invasive breast cancer. J Surg Res. 1999 May 01; 83(1):13-8. PMID: 10210636.
      View in: PubMed
    462. Wistuba II, Bryant D, Behrens C, Milchgrub S, Virmani AK, Ashfaq R, Minna JD, Gazdar AF. Comparison of features of human lung cancer cell lines and their corresponding tumors. Clin Cancer Res. 1999 May; 5(5):991-1000. PMID: 10353731.
      View in: PubMed
    463. Wistuba II, Behrens C, Virmani AK, Milchgrub S, Syed S, Lam S, Mackay B, Minna JD, Gazdar AF. Allelic losses at chromosome 8p21-23 are early and frequent events in the pathogenesis of lung cancer. Cancer Res. 1999 Apr 15; 59(8):1973-9. PMID: 10213509.
      View in: PubMed
    464. Maitra A, Wistuba II, Virmani AK, Sakaguchi M, Park I, Stucky A, Milchgrub S, Gibbons D, Minna JD, Gazdar AF. Enrichment of epithelial cells for molecular studies. Nat Med. 1999 Apr; 5(4):459-63. PMID: 10202940.
      View in: PubMed
    465. Onuki N, Wistuba II, Travis WD, Virmani AK, Yashima K, Brambilla E, Hasleton P, Gazdar AF. Genetic changes in the spectrum of neuroendocrine lung tumors. Cancer. 1999 Feb 01; 85(3):600-7. PMID: 10091733.
      View in: PubMed
    466. Wistuba II, Behrens C, Milchgrub S, Bryant D, Hung J, Minna JD, Gazdar AF. Sequential molecular abnormalities are involved in the multistage development of squamous cell lung carcinoma. Oncogene. 1999 Jan 21; 18(3):643-50. PMID: 9989814.
      View in: PubMed
    467. Shivapurkar N, Virmani AK, Wistuba II, Milchgrub S, Mackay B, Minna JD, Gazdar AF. Deletions of chromosome 4 at multiple sites are frequent in malignant mesothelioma and small cell lung carcinoma. Clin Cancer Res. 1999 Jan; 5(1):17-23. PMID: 9918198.
      View in: PubMed
    468. Wistuba II, Miquel JF, Gazdar AF, Albores-Saavedra J. Gallbladder adenomas have molecular abnormalities different from those present in gallbladder carcinomas. Hum Pathol. 1999 Jan; 30(1):21-5. PMID: 9923922.
      View in: PubMed
    469. Wistuba II, Thomas B, Behrens C, Onuki N, Lindberg G, Albores-Saavedra J, Gazdar AF. Molecular abnormalities associated with endocrine tumors of the uterine cervix. Gynecol Oncol. 1999 Jan; 72(1):3-9. PMID: 9889022.
      View in: PubMed
    470. Wistuba II, Albores-Saavedra J. Genetic abnormalities involved in the pathogenesis of gallbladder carcinoma. J Hepatobiliary Pancreat Surg. 1999; 6(3):237-44. PMID: 10526058.
      View in: PubMed
    471. Gazdar AF, Kurvari V, Virmani A, Gollahon L, Sakaguchi M, Westerfield M, Kodagoda D, Stasny V, Cunningham HT, Wistuba II, Tomlinson G, Tonk V, Ashfaq R, Leitch AM, Minna JD, Shay JW. Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int J Cancer. 1998 Dec 09; 78(6):766-74. PMID: 9833771.
      View in: PubMed
    472. Wistuba II, Behrens C, Milchgrub S, Syed S, Ahmadian M, Virmani AK, Kurvari V, Cunningham TH, Ashfaq R, Minna JD, Gazdar AF. Comparison of features of human breast cancer cell lines and their corresponding tumors. Clin Cancer Res. 1998 Dec; 4(12):2931-8. PMID: 9865903.
      View in: PubMed
    473. Forgacs E, Biesterveld EJ, Sekido Y, Fong K, Muneer S, Wistuba II, Milchgrub S, Brezinschek R, Virmani A, Gazdar AF, Minna JD. Mutation analysis of the PTEN/MMAC1 gene in lung cancer. Oncogene. 1998 Sep 24; 17(12):1557-65. PMID: 9794233.
      View in: PubMed
    474. Lininger RA, Wistuba I, Gazdar A, Koenig C, Tavassoli FA, Albores-Saavedra J. Human papillomavirus type 16 is detected in transitional cell carcinomas and squamotransitional cell carcinomas of the cervix and endometrium. Cancer. 1998 Aug 01; 83(3):521-7. PMID: 9690545.
      View in: PubMed
    475. Tomlinson GE, Chen TT, Stastny VA, Virmani AK, Spillman MA, Tonk V, Blum JL, Schneider NR, Wistuba II, Shay JW, Minna JD, Gazdar AF. Characterization of a breast cancer cell line derived from a germ-line BRCA1 mutation carrier. Cancer Res. 1998 Aug 01; 58(15):3237-42. PMID: 9699648.
      View in: PubMed
    476. Colby TV, Wistuba II, Gazdar A. Precursors to pulmonary neoplasia. Adv Anat Pathol. 1998 Jul; 5(4):205-15. PMID: 9859753.
      View in: PubMed
    477. Sekido Y, Ahmadian M, Wistuba II, Latif F, Bader S, Wei MH, Duh FM, Gazdar AF, Lerman MI, Minna JD. Cloning of a breast cancer homozygous deletion junction narrows the region of search for a 3p21.3 tumor suppressor gene. Oncogene. 1998 Jun 18; 16(24):3151-7. PMID: 9671394.
      View in: PubMed
    478. Wistuba II, Behrens C, Milchgrub S, Virmani AK, Jagirdar J, Thomas B, Ioachim HL, Litzky LA, Brambilla EM, Minna JD, Gazdar AF. Comparison of molecular changes in lung cancers in HIV-positive and HIV-indeterminate subjects. JAMA. 1998 May 20; 279(19):1554-9. PMID: 9605900.
      View in: PubMed
    479. Yamamoto Y, Wistuba II, Kishimoto Y, Virmani AK, Vuitch F, Albores-Saavedra J, Gazdar AF. DNA analysis at p53 locus in adenoid cystic carcinoma: comparison of molecular study and p53 immunostaining. Pathol Int. 1998 Apr; 48(4):273-80. PMID: 9648155.
      View in: PubMed
    480. Yamamoto Y, Kishimoto Y, Wistuba II, Virmani AK, Vuitch F, Gazdar AF, Albores-Saavedra J. DNA analysis at p53 locus in carcinomas arising from pleomorphic adenomas of salivary glands: comparison of molecular study and p53 immunostaining. Pathol Int. 1998 Apr; 48(4):265-72. PMID: 9648154.
      View in: PubMed
    481. Muller CY, O'Boyle JD, Fong KM, Wistuba II, Biesterveld E, Ahmadian M, Miller DS, Gazdar AF, Minna JD. Abnormalities of fragile histidine triad genomic and complementary DNAs in cervical cancer: association with human papillomavirus type. J Natl Cancer Inst. 1998 Mar 18; 90(6):433-9. PMID: 9521167.
      View in: PubMed
    482. Franklin WA, Gazdar AF, Haney J, Wistuba II, La Rosa FG, Kennedy T, Ritchey DM, Miller YE. Widely dispersed p53 mutation in respiratory epithelium. A novel mechanism for field carcinogenesis. J Clin Invest. 1997 Oct 15; 100(8):2133-7. PMID: 9329980.
      View in: PubMed
    483. Wistuba II, Lam S, Behrens C, Virmani AK, Fong KM, LeRiche J, Samet JM, Srivastava S, Minna JD, Gazdar AF. Molecular damage in the bronchial epithelium of current and former smokers. J Natl Cancer Inst. 1997 Sep 17; 89(18):1366-73. PMID: 9308707.
      View in: PubMed
    484. Ahmadian M, Wistuba II, Fong KM, Behrens C, Kodagoda DR, Saboorian MH, Shay J, Tomlinson GE, Blum J, Minna JD, Gazdar AF. Analysis of the FHIT gene and FRA3B region in sporadic breast cancer, preneoplastic lesions, and familial breast cancer probands. Cancer Res. 1997 Sep 01; 57(17):3664-8. PMID: 9288768.
      View in: PubMed
    485. Wistuba II, Montellano FD, Milchgrub S, Virmani AK, Behrens C, Chen H, Ahmadian M, Nowak JA, Muller C, Minna JD, Gazdar AF. Deletions of chromosome 3p are frequent and early events in the pathogenesis of uterine cervical carcinoma. Cancer Res. 1997 Aug 01; 57(15):3154-8. PMID: 9242443.
      View in: PubMed
    486. Yashima K, Litzky LA, Kaiser L, Rogers T, Lam S, Wistuba II, Milchgrub S, Srivastava S, Piatyszek MA, Shay JW, Gazdar AF. Telomerase expression in respiratory epithelium during the multistage pathogenesis of lung carcinomas. Cancer Res. 1997 Jun 15; 57(12):2373-7. PMID: 9192812.
      View in: PubMed
    487. Fong KM, Biesterveld EJ, Virmani A, Wistuba I, Sekido Y, Bader SA, Ahmadian M, Ong ST, Rassool FV, Zimmerman PV, Giaccone G, Gazdar AF, Minna JD. FHIT and FRA3B 3p14.2 allele loss are common in lung cancer and preneoplastic bronchial lesions and are associated with cancer-related FHIT cDNA splicing aberrations. Cancer Res. 1997 Jun 01; 57(11):2256-67. PMID: 9187130.
      View in: PubMed
    488. Ossa G, Wistuba I, Illesca V, Reydet P. [Invasive extrapulmonary infections due to Streptococcus pneumoniae. Report of three fatal cases and review]. Rev Med Chil. 1997 Feb; 125(2):200-8. PMID: 9430941.
      View in: PubMed
    489. Yamamoto Y, Virmani AK, Wistuba II, McIntire D, Vuitch F, Albores-Saavedra J, Gazdar AF. Loss of heterozygosity and microsatellite alterations in p53 and RB genes in adenoid cystic carcinoma of the salivary glands. Hum Pathol. 1996 Nov; 27(11):1204-10. PMID: 8912832.
      View in: PubMed
    490. Wistuba I, Capurro I. [Epidermoid carcinoma of the cervix uteri: molecular abnormalities of p53 and rb genes]. Rev Med Chil. 1996 May; 124(5):553-60. PMID: 9035506.
      View in: PubMed
    491. Wistuba II, Gazdar AF, Roa I, Albores-Saavedra J. p53 protein overexpression in gallbladder carcinoma and its precursor lesions: an immunohistochemical study. Hum Pathol. 1996 Apr; 27(4):360-5. PMID: 8617479.
      View in: PubMed
    492. Wistuba I, Roa I, Araya JC, Villaseca M, Capurro I, Chávez F. [Proliferating cell nuclear antigen in cervical cancer and precursor lesions]. Rev Med Chil. 1995 Sep; 123(9):1077-83. PMID: 8728730.
      View in: PubMed
    493. Wistuba II, Sugio K, Hung J, Kishimoto Y, Virmani AK, Roa I, Albores-Saavedra J, Gazdar AF. Allele-specific mutations involved in the pathogenesis of endemic gallbladder carcinoma in Chile. Cancer Res. 1995 Jun 15; 55(12):2511-5. PMID: 7780959.
      View in: PubMed
    494. Roa I, Araya JC, Wistuba I, Villaseca M, de Aretxabala X, Burgos L. [Gallbladder cancer in the IX Region of Chile. Impact of the anatomopathological study of 474 cases]. Rev Med Chil. 1994 Nov; 122(11):1248-56. PMID: 7659894.
      View in: PubMed
    495. Araya JC, Roa I, Hebel E, Wistuba I, Villaseca MA, Yañez M. [Proliferating cell nuclear antigen (PCNA) in patients with malabsorption syndrome: comparative study with morphometric parameters]. Rev Med Chil. 1994 Oct; 122(10):1134-9. PMID: 7659878.
      View in: PubMed
    496. Araya JC, Roa I, Wistuba I, Villaseca MA, Contreras E, Olcese A, Danton A. [Expression of p29, estrogen receptor related protein in primary breast carcinoma. Methodological, anatomoclinical, and DNA content analysis]. Rev Med Chil. 1994 Oct; 122(10):1140-6. PMID: 7659879.
      View in: PubMed
    497. Roa I, Araya JC, Wistuba I, Villaseca M, de Aretxabala X, Gómez A, Silva J. [Laparoscopic cholecystectomy makes difficult the analysis of gallbladder mucosa. Morphometric study]. Rev Med Chil. 1994 Sep; 122(9):1015-20. PMID: 7597331.
      View in: PubMed
    498. Roa I, Araya JC, Shiraishi T, Yatani R, Wistuba I, Villaseca M, de Aretxabala X. [Gallbladder carcinoma: expression of the c-myc and ras-p-21 oncogene products]. Rev Med Chil. 1994 Jul; 122(7):754-9. PMID: 7732224.
      View in: PubMed
    499. Araya JC, Roa I, Wistuba I, Villaseca MA, Contreras E, Olcese A, Danton A, Watanabe H. [Breast cancer and flow cytometry: comparative study of DNA ploidy pattern with clinicopathological parameters]. Rev Med Chil. 1994 Jun; 122(6):643-52. PMID: 7732208.
      View in: PubMed
    500. Roa I, Araya JC, Wistuba I, Villaseca M, de Aretxabala X, Ferreira A, Gómez A. [Determination of DNA content using cytophotometry in nuclear suspension conserved for prolonged periods (preliminary study)]. Rev Med Chil. 1994 Mar; 122(3):253-8. PMID: 7809514.
      View in: PubMed
    501. De Aretxabala X, Roa I, Araya JC, Burgos L, Flores P, Wistuba I, Villaseca MA, Sotomayor F, Roa JC. Gallbladder cancer in patients less than 40 years old. Br J Surg. 1994 Jan; 81(1):111. PMID: 8313082.
      View in: PubMed
    502. Wistuba I, Roa I, Araya J, Villaseca M, Chávez F, Capurro I. [Immunohistochemical expression of epidermal growth factor receptor (EGFR) in epidermoid carcinoma of the cervix uteri and its precursor lesions]. Rev Chil Obstet Ginecol. 1994; 59(2):116-22. PMID: 7659795.
      View in: PubMed
    503. Roa I, Araya JC, Shiraishi T, Yatani R, Wistuba I, Villaseca M, De Aretxabala X. DNA content in gallbladder carcinoma: a flow cytometric study of 96 cases. Histopathology. 1993 Nov; 23(5):459-64. PMID: 8314220.
      View in: PubMed
    504. Araya JC, Roa I, Mano H, Yamamoto M, Wistuba I, Villaseca MA, de Aretxabala X, Ohta T, Burgos L. [Mutagen extraction from bile of patients with inflammatory biliary pathology: Ames test using blue rayon]. Rev Med Chil. 1993 Nov; 121(11):1245-51. PMID: 8191130.
      View in: PubMed
    505. Wistuba I, Roa I, Araya JC, Villaseca M, Capurro I, Rojo J. [Nucleolar organizer regions in uterine cervical cancer and its precursor epithelial lesions]. Rev Med Chil. 1993 Oct; 121(10):1110-7. PMID: 8191113.
      View in: PubMed
    506. Roa I, Araya J, Shiraishi T, Yatani R, Villaseca M, Wistuba I, De-Aretxabala X. Proliferating cell nuclear antigen in gallbladder carcinoma. Histopathology. 1993 Aug; 23(2):179-83. PMID: 8104857.
      View in: PubMed
    507. Roa I, Araya JC, Shiraishi T, Yatani R, Wistuba I, Villaseca M, de Aretxabala X. [Stomach and gallbladder cancer. Analysis of cell cycle phases by means of flow cytometry]. Rev Med Chil. 1993 Aug; 121(8):881-8. PMID: 8296095.
      View in: PubMed
    508. Roa I, Villaseca M, Wistuba I, Araya JC, De Aretxabala X. [Determination of DNA content by means of cytophotometry. Technical and methodological considerations and its application in tumor pathology]. Rev Med Chil. 1993 Aug; 121(8):897-902. PMID: 8296097.
      View in: PubMed
    509. Wistuba I, Roa I, Villaseca MA, Araya JC, Capurro I. [Cervix uteri cancer: determination of DNA content by means of cytophotometry]. Rev Med Chil. 1993 Aug; 121(8):873-9. PMID: 8296094.
      View in: PubMed
    510. Wistuba I, Arcil G, Farrú O, Chuaqui B. [Idiopathic asymmetric heart hypertrophy in a newborn infant]. Pathologe. 1993 May; 14(3):127-30. PMID: 8516269.
      View in: PubMed
    511. Roa I, Araya JC, de Aretxabala X, Villaseca MA, Wistuba I, Burgos L. [Laparoscopic cholecystectomy makes the histopathological study of the gallbladder mucosa difficult]. Rev Med Chil. 1993 Apr; 121(4):458-9. PMID: 8272623.
      View in: PubMed
    512. Roa I, Araya JC, Wistuba I, Villaseca M, de Aretxabala X, Busel D, Burgos L. [Epithelial lesions associated with gallbladder carcinoma. A methodical study of 32 cases]. Rev Med Chil. 1993 Jan; 121(1):21-9. PMID: 8235160.
      View in: PubMed
    513. Roa I, Araya JC, Shiraishi T, Yatani R, Wistuba I, Villaseca M, de Aretxabala X. [Immunohistochemical demonstration of pepsinogens I and II in the gallbladder]. Rev Med Chil. 1992 Dec; 120(12):1351-8. PMID: 1343374.
      View in: PubMed
    514. Roa I, Araya JC, Shiraisch T, Yatani R, Wistuba I, Villaseca M, de Aretxabala X. [Gallbladder cancer: immunohistochemical expression of CA-19-9, epithelial membrane antigen, dupan-2 and carcinoembryonic antigen]. Rev Med Chil. 1992 Nov; 120(11):1218-26. PMID: 1340939.
      View in: PubMed
    515. de Aretxabala X, Araya JC, Flores P, Roa I, Fernández E, Wistuba I, Villaseca MA, Huenchullán I, Arredondo G, Flores M, et al. [Characteristics of gastric cancer in the IX region of Chile]. Rev Med Chil. 1992 Apr; 120(4):407-14. PMID: 1340570.
      View in: PubMed
    516. Capurro I, Jorquera J, Rojo JA, Wistuba I. [2 rare cases of a presentation of endometrial cancer]. Rev Chil Obstet Ginecol. 1992; 57(5):351-5. PMID: 1342466.
      View in: PubMed
    517. de Aretxabala X, Roa I, Burgos L, Araya JC, Fonseca L, Wistuba I, Flores P. Gallbladder cancer in Chile. A report on 54 potentially resectable tumors. Cancer. 1992 Jan 01; 69(1):60-5. PMID: 1727676.
      View in: PubMed
    518. Roa I, Araya JC, de Aretxabala X, Wistuba I, Villaseca M, Saito K, Nakamura K. [Gastric cancer: epidermal growth factor and epidermal growth factor receptor]. Rev Med Chil. 1992 Jan; 120(1):5-12. PMID: 1305311.
      View in: PubMed
    519. Roa I, Araya JC, Wistuba I, Villaseca M, de Aretxabala X. [Lithiasis of gallbladder in the IX region. Study of the autopsies in a zone with a high proportion of Mapuche population]. Rev Med Chil. 1991 Dec; 119(12):1367-71. PMID: 9723092.
      View in: PubMed
    520. de Aretxabala X, Roa I, Burgos L, Araya JC, Wistuba I, Villaseca MA, Fonseca L, Flores P, Sotomayor F. [Inapparent cancer of the gallbladder]. Rev Med Chil. 1991 Aug; 119(8):881-6. PMID: 1844768.
      View in: PubMed
    521. Roa I, Araya JC, de Aretxabala X, Wistuba I, Villaseca M, Saito K, Nakamura K. [Advanced stomach neoplasms: expression of the fixation index of bromodeoxyuridine in vivo]. Rev Med Chil. 1991 Jun; 119(6):637-46. PMID: 1844367.
      View in: PubMed
    522. Roa I, Araya JC, de Aretxabala X, Wistuba I, Villaseca M. [Nucleolus organizer regions and ploidy pattern of DNA in stomach neoplasms]. Rev Med Chil. 1991 Jun; 119(6):647-51. PMID: 1844368.
      View in: PubMed
    523. Araya JC, Roa I, Wistuba I, Villaseca M, de Aretxabala X. [Stomach neoplasms in the IX Region of Chile: comparison of the anatomo-pathological study of lymph node emptying in 2 periods]. Rev Med Chil. 1991 May; 119(5):546-52. PMID: 1844294.
      View in: PubMed
    524. Roa I, Araya JC, Wistuba I, De Aretxabala X, Salinas C, Mauriz A, Villaseca M. [Immunohistochemical expression of the carcinoembryonic antigen in gallbladder cancer]. Rev Med Chil. 1991 Feb; 119(2):129-36. PMID: 1824154.
      View in: PubMed
    525. de Aretxabala X, Wistuba I, Burgos L, Roa I, Araya JC, Fonseca L, Flores P. [Association of gallbladder and Vater's ampulla neoplasms. Report of a case]. Rev Med Chil. 1990 Jul; 118(7):783-6. PMID: 2131528.
      View in: PubMed
    526. Wistuba I, Gonzalez S. Eosinophilic globules in pigmented spindle cell nevus. Am J Dermatopathol. 1990 Jun; 12(3):268-71. PMID: 1693819.
      View in: PubMed
    527. Roa I, Araya JC, Wistuba I, de Aretxabala X. [Gallbladder cancer: anatomic and anatomo-pathologic considerations]. Rev Med Chil. 1990 May; 118(5):572-9. PMID: 2293279.
      View in: PubMed
    528. Araya JC, Roa I, Wistuba I, de Aretxabala X. [Neoplasms of Vater's papilla: study of nucleolar organizer regions]. Rev Med Chil. 1990 Apr; 118(4):373-81. PMID: 1723213.
      View in: PubMed
    529. Roa I, Araya JC, Wistuba I, De Aretxabala X, Mauriz A, Cea M. [In situ and invasive cancer of the gallbladder: nucleolar organizer regions]. Rev Med Chil. 1990 Apr; 118(4):369-72. PMID: 1723212.
      View in: PubMed
    530. Roa I, Aray JC, de Aretxabala X, Wistuba I, Burgos L. [The pathological findings in patients reoperated on for gallbladder cancer]. Rev Med Chil. 1990 Feb; 118(2):153-7. PMID: 2152714.
      View in: PubMed
    531. Roa I, Araya JC, de Aretxabala X, Salinas C, Wistuba I. [Gallbladder pathology in Temuco, IX Region]. Rev Med Chil. 1989 Aug; 117(8):889-94. PMID: 2519448.
      View in: PubMed
    532. Challenges in Facing the Lung Cancer Epidemic and Treating Advanced Disease in Latin America. Clinical Lung Cancer. 18:e71-e79.
    533. Minimally invasive genomic and transcriptomic profiling of visceral cancers by next-generation sequencing of circulating exosomes. Annals of Oncology. 27:635-641.
    534. Bronchioloalveolar carcinoma. Oncology. 24.
    535. Molecular testing for treatment of metastatic non-small cell lung cancer. Oncologist. 20:1175-1181.
    536. Ethnicity affects EGFR and KRAS gene alterations of lung adenocarcinoma. Oncology Letters. 10:1775-1782.
    537. Molecular biology of lung cancer. 67-80.
    538. An expression signature as an aid to the histologic classification of non-small cell lung cancer. Clinical Cancer Research. 22:4880-4889.
    539. KDR amplification is associated with VEGF-induced activation of the mTOR and invasion pathways but does not predict clinical benefit to the VEGFR TKI vandetanib. Clinical Cancer Research. 22:1940-1950.
    540. Regulation of AURKC expression by CpG island methylation in human cancer cells. Tumor Biology.
    541. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations. Oncotarget. 7:47998-48010.
    542. LAPTM4B is associated with poor prognosis in NSCLC and promotes the NRF2-mediated stress response pathway in lung cancer cells. Scientific Reports. 5.
    543. Phase i study of azacitidine and oxaliplatin in patients with advanced cancers that have relapsed or are refractory to any platinum therapy. Clinical Epigenetics. 7:1-11.
    544. Erlotinib and the risk of oral cancer the erlotinib Prevention of Oral Cancer (EPOC) randomized clinical trial. JAMA oncology. 2:209-216.
    545. Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. OncoImmunology. 5.
    546. Image-guided biopsy in the era of personalized cancer care. Journal of Vascular and Interventional Radiology. 27:8-19.
    547. Decitabine impact on the endocytosis regulator RhoA, the folate carriers RFC1 and FOLR1, and the glucose transporter GLUT4 in human tumors. Clinical Epigenetics. 6.
    548. The tobacco-specific carcinogen-operated calcium channel promotes lung tumorigenesis via IGF2 exocytosis in lung epithelial cells. Nature Communications. 7.
    549. Multi-institutional oncogenic driver mutation analysis in lung adenocarcinoma. Journal of Thoracic Oncology. 10:768-777.
    550. Pathology of lung cancer. 93-105.
    551. Human papillomavirus, lichen sclerosis and vulvar squamous cell carcinoma. International Journal of Gynecological Cancer. 8:298-306.
    552. The BATTLE-2 study. Journal of Clinical Oncology. 34:3638-3647.
    553. Inflammation and lung cancer. 69-93.
    554. Interleukin-11 Receptor Is a Candidate Target for Ligand-Directed Therapy in Lung Cancer. American Journal of Pathology. 186:2162-2170.
    555. Activation of insulin-like growth factor 1 receptor in patients with non-small cell lung cancer. Oncotarget. 6:16746-16756.
    556. Inhibition of FOXC2 restores epithelial phenotype and drug sensitivity in prostate cancer cells with stem-cell properties. Oncogene.
    557. Molecular Biology of Lung Preneoplasia. 110-128.
    558. Prognostic Impact of Vitamin B6 Metabolism in Lung Cancer. Cell Reports. 2:1472.
    559. Nicotinic acetylcholine receptor expression in human airway correlates with lung function. American Journal of Physiology - Lung Cellular and Molecular Physiology. 310:L232-L239.
    560. Early events in the molecular pathogenesis of lung cancer. Cancer Prevention Research. 9:518-527.
    561. Multiplatform-based molecular subtypes of non-small-cell lung cancer. Oncogene.
    562. Gas6/Axl is the sensor of arginine-auxotrophic response in targeted chemotherapy with arginine-depleting agents. Oncogene.
    563. Corrigendum to "PIAS1-FAK Interaction Promotes the Survival and Progression of Non-Small Cell Lung Cancer" [Neoplasia 18 (2016) 282-293]. Neoplasia (United States).
    564. Cancer-associated fibroblasts induce a collagen cross-link switch in tumor stroma. Molecular Cancer Research. 14:287-295.
    565. Fatty Acid Oxidation Mediated by Acyl-CoA Synthetase Long Chain 3 Is Required for Mutant KRAS Lung Tumorigenesis. Cell Reports.
    566. Human papillomavirus presence and survival (multiple letters). International Journal of Gynecological Cancer. 9:173-174.
    567. Modulation of EZH2 expression by MEK-ERK or PI3K-AKT signaling in lung cancer is dictated by different KRAS oncogene mutations. Cancer Research. 76:675-685.
    568. Targeting the insulin-like growth factor receptor and Src signaling network for the treatment of non-small cell lung cancer. Molecular Cancer. 14.
    569. A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition. Clinical Cancer Research. 22:609-620.
    570. Molecular pathology of lung cancer. 443-459.
    571. Validation of SCT methylation as a hallmark biomarker for lung cancers. Journal of Thoracic Oncology. 11:346-360.
    572. Combined clinical and genomic signatures for the prognosis of early stage non-small cell lung cancer based on gene copy number alterations. BMC Genomics. 16.
    573. ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers. Proceedings of the National Academy of Sciences of the United States of America. 111:14788-14793.
    574. Methodological and Practical Challenges for Personalized Therapies in Non-Small-Cell Lung Cancer. 480-485.
    575. Immunoproteasome deficiency is a feature of non-small cell lung cancer with a mesenchymal phenotype and is associated with a poor outcome. Proceedings of the National Academy of Sciences of the United States of America. 113:E1555-E1564.
    576. RNA-dependent protein kinase (PKR) depletes nutrients, inducing phosphorylation of AMP-activated kinase in lung cancer. Oncotarget. 6:11114-11124.
    577. PROTOCADHERIN 7 acts through SET and PP2A to potentiate MAPK signaling by EGFR and KRAS during lung tumorigenesis. Cancer Research. 77:187-197.
    578. Genes suppressed by DNA methylation in non-small cell lung cancer reveal the epigenetics of epithelial-mesenchymal transition. BMC Genomics. 15.
    579. An integrated molecular analysis of lung adenocarcinomas identifies potential therapeutic targets among TTF1-negative tumors, including DNA Repair Proteins and Nrf2. Clinical Cancer Research. 21:3480-3491.
    580. ZEB1 induces LOXL2-mediated collagen stabilization and deposition in the extracellular matrix to drive lung cancer invasion and metastasis. Oncogene.
    581. STK11/LKB1 deficiency promotes neutrophil recruitment and proinflammatory cytokine production to suppress T-cell activity in the lung tumor microenvironment. Cancer Research. 76:999-1008.
    582. Molecular changes in cervical endocrine tumors. Emergency Medicine. 45:25-36.
    583. Impact of decitabine on immunohistochemistry expression of the putative tumor suppressor genes FHIT, WWOX, FUS1 and PTEN in clinical tumor samples. Clinical Epigenetics. 6.
    584. Erratum. Nature Genetics. 48:473.
    585. Primary Mediastinal Yolk Sac Tumors. Applied Immunohistochemistry and Molecular Morphology.
    586. Density, distribution, and composition of immune infiltrates correlate with survival in Merkel cell carcinoma. Clinical Cancer Research. 22:5553-5563.
    587. The 2015 World Health Organization Classification of Lung Tumors. Journal of Thoracic Oncology. 10:1243-1260.
    588. Epithelial-mesenchymal transition is associated with a distinct tumor microenvironment including elevation of inflammatory signals and multiple immune checkpoints in lung adenocarcinoma. Clinical Cancer Research. 22:3630-3642.
    589. Lung Cancer. 99:79-87.
    590. LZTFL1 suppresses lung tumorigenesis by maintaining differentiation of lung epithelial cells. Oncogene.
    591. XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer. Nature. 538:114-117.
    592. ZEB1 drives epithelial-to-mesenchymal transition in lung cancer. Journal of Clinical Investigation. 126:3219-3235.
    593. The ISG15-specific protease USP18 regulates stability of PTEN. Oncotarget. 8:3-14.
    594. Molecular Biology of Preneoplastic Lesions of the Lung. 84-98.
    595. Lung Cancer Biomarkers. Hematology/Oncology Clinics of North America. 31:13-29.
    596. Oncogenic mutation profiling in new lung cancer and mesothelioma cell lines. OncoTargets and Therapy. 8:195-209.
    597. Image analysis-based assessment of PD-L1 and tumor-associated immune cells density supports distinct intratumoral microenvironment groups in non-small cell lung carcinoma patients. Clinical Cancer Research. 22:6278-6289.
    598. Germline Mutation of T790M and Dual/Multiple EGFR Mutations in Patients With Lung Adenocarcinoma. Clinical Lung Cancer.
    599. Erratum. Journal of Thoracic Oncology. 7:1065.
    600. Erratum. International Journal of Cancer. 132:498.
    601. Improvement of clinical response and biomarkers by Camellia sinensis (green tea) extract in patients with high-risk oral premalignant lesions. Focus on Alternative and Complementary Therapies. 15:122-123.
    602. Expression pattern of FGFR2, Grb2 and Plcγ1 acts as a novel prognostic marker of recurrence recurrence-free survival in lung adenocarcinoma. American Journal of Cancer Research. 5:3135-3148.
    603. Current concepts on the molecular pathology of non-small cell lung carcinoma. Seminars in Diagnostic Pathology. 31:306-313.
    604. NRF2 regulates serine biosynthesis in non-small cell lung cancer. Nature Genetics. 47:1475-1481.
    605. Molecular changes in cervical endocrine tumors. Contemporary Ob-Gyn. 45:25-36.
    606. IL6 blockade reprograms the lung tumor microenvironment to limit the development and progression of K-ras-mutant lung cancer. Cancer Research. 76:3189-3199.
    607. Genes suppressed by DNA methylation in non-small cell lung cancer reveal the epigenetics of epithelial-mesenchymal transition. BMC Genomics. 1-15.
    608. Erratum. Cancer. 118:6301.
    609. Genomic heterogeneity of multiple synchronous lung cancer. Nature Communications. 7.
    610. Genomic landscape established by allelic imbalance in the cancerization field of a normal appearing airway. Cancer Research. 76:3676-3683.
    611. Erratum. Journal of Clinical Investigation. 100:2639.
    612. Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discovery. 6:827-837.
    613. Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discovery. 5:861-878.
    614. Systematic siRNA screen unmasks NSCLC growth dependence by palmitoyltransferase DHHC5. Molecular Cancer Research. 13:784-794.
    615. Human Pathology. 59:1-9.
    616. The international association for the study of lung cancer consensus statement on optimizing management of EGFR mutation-positive non-small cell lung cancer. Journal of Thoracic Oncology. 11:946-963.
    617. Diagnosis and molecular classification of lung cancer. 25-46.
    WISTUBA's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description